<SEC-DOCUMENT>0000950170-25-055856.txt : 20250418
<SEC-HEADER>0000950170-25-055856.hdr.sgml : 20250418
<ACCEPTANCE-DATETIME>20250418160504
ACCESSION NUMBER:		0000950170-25-055856
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20250609
FILED AS OF DATE:		20250418
DATE AS OF CHANGE:		20250418

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SPRUCE BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001683553
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				812154263
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39594
		FILM NUMBER:		25850471

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BOULEVARD, SUITE 740
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(415) 655-4168

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BOULEVARD, SUITE 740
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>sprb-predef14a-2025.htm
<DESCRIPTION>PRE 14A
<TEXT>
<html>
 <head>
  <title>PRE 14A</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.25in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SCHEDULE 14A INFORMATION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proxy Statement Pursuant to Section 14(a) of the<br>Securities Exchange Act of 1934<br>(Amendment No.     )</font></p><p style="margin-left:36.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;border-bottom:0.5pt solid;margin-right:36.667%;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filed by the Registrant </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filed by a Party other than the Registrant &#9744;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Preliminary Proxy Statement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744; Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Definitive Proxy Statement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744; Definitive Additional Materials</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744; Soliciting Material Pursuant to &#167;240.14a-12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Spruce Biosciences, Inc.<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Name of Registrant as Specified In Its Charter)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N/A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of Filing Fee (Check the appropriate box):</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No fee required.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744; Fee paid previously with preliminary materials</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744; Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.25in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRELIMINARY PROXY STATEMENT &#x2013; SUBJECT TO COMPLETION DATED APRIL 18, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPRUCE BIOSCIENCES, INC.<br>611 Gateway Boulevard, Suite 740<br>South San Francisco, California 94080</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><img src="img191538130_0.jpg" alt="img191538130_0.jpg" style="width:174px;height:45px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To Be Held On June 9, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dear Stockholder:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the &#x201c;Annual Meeting&#x201d;) of Spruce Biosciences, Inc., a Delaware corporation (the &#x201c;Company&#x201d;). The Annual Meeting will be held on Monday, June 9, 2025, at 10:00 a.m. (Pacific Time). The Annual Meeting will be held through a live webcast at www.virtualshareholdermeeting.com/SPRB2025. You will not be able to attend the meeting in person. The Annual Meeting is being held for the following purposes:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To elect the three Class II directors named below to hold office until the Company&#x2019;s 2028 annual meeting of stockholders.</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominees:</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Percival-Baretto-Ko<br>Bali Muralidhar, M.D., Ph.D.<br>Daniel Spiegelman</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	To ratify the selection by the Audit Committee of the Board of Directors of BDO USA, P.C. as the independent registered public accounting firm of the Company for the Company&#x2019;s fiscal year ending December 31, 2025.</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of the Company's common stock by a ratio of between one-for-five and one-for-thirty, with the exact ratio to be determined by the Board in its sole discretion and with such Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion (&#x201c;Proposal 3&#x201d; or the &#x201c;Reverse Stock Split Proposal)&#x201d;;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. To approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3. (the &#x201c;Adjournment Proposal&#x201d;); and</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	To conduct any other business properly brought before the Annual Meeting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These items of business are more fully described in the Proxy Statement accompanying this Notice.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Annual Meeting will be held virtually through a live webcast. You will be able to attend the Annual Meeting, submit questions and vote during the live webcast by visiting www.virtualshareholdermeeting.com/SPRB2025 and entering the 16-digit Control Number included in your Notice of Internet Availability or in the instructions that you received via email. Please refer to the additional logistical details and recommendations in the accompanying proxy statement. You may log-in beginning at 9:45 a.m. (Pacific Time), on Monday, June 9, 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The record date for the Annual Meeting is April 10, 2025. Only stockholders of record at the close of business on that date may vote at the Annual Meeting or any adjournment thereof. The proxy materials, including this Proxy Statement and our 2024 Annual Report, are being distributed and made available on or about April 28, 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:1.62%;border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to Be Held on <br>June 9, 2025 at 10:00 a.m. (Pacific Time).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Proxy Statement and Annual Report to stockholders are available at www.proxyvote.com.</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.25in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By Order of the Board of Directors</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><img src="img191538130_1.jpg" alt="img191538130_1.jpg" style="width:147px;height:76px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH<br>Chief Executive Officer<br>South San Francisco, California<br>April 18, 2025</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.25in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRELIMINARY PROXY STATEMENT &#x2013; SUBJECT TO COMPLETION  DATED APRIL 18, 2025</font></p>
   <table style="margin-left:1.62%;border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">You are cordially invited to virtually attend the Annual Meeting online. Whether or not you expect to virtually attend the Annual Meeting, please complete, date, sign and return the proxy mailed to you, or vote over the telephone or the internet as instructed in these materials, as promptly as possible in order to ensure your representation at the Annual Meeting. Voting instructions are provided in the Notice of Internet Availability of Proxy Materials or, if you receive a paper proxy card by mail, the instructions are printed on your proxy card.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Even if you have voted by proxy, you may still vote online if you virtually attend the Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record holder.</font></p></td>
    </tr>
   </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.25in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.75in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:1.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:88%;box-sizing:content-box;"></td>
     <td style="width:12%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Page</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#questions"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Proposal 1  Election of Directors</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_info"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:21.6pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_indep"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Independence of the Board of Directors</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:21.6pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_structure"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Board Leadership Structure</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:21.6pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_role"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Role of the Board in Risk Oversight</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:21.6pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_mtg"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Meetings of the Board of Directors</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:21.6pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_comminfo"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Information Regarding Committees of the Board of Directors</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:43.2pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_ac"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Audit Committee</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:43.2pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_cc"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Compensation Committee</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:43.2pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_nom"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:21.6pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_stock"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Stockholder Communications With the Board</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:21.6pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p1_code"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Code of Conduct</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p2"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Proposal 2  Ratification of Selection of Independent Registered Public Accounting Firm</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p3"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Proposal 3  APPROVAL OF REVERSE STOCK SPLIT</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#p4"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PROPOSAL 4  APPROVAL OF ADJOURNMENT PROPOSAL</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#execo"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">EXECUTIVE OFFICERS</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#security"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#execcomp"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">EXECUTIVE COMPENSATION</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:21.6pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:4%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#dir"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Director Compensation</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#rp"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#house"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">HOUSEHOLDING OF PROXY MATERIALS</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#other"><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OTHER MATTERS</font></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</font></p></td>
    </tr>
   </table><p style="margin-left:1.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;margin-right:6.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPRUCE BIOSCIENCES, INC.<br>611 Gateway Boulevard, Suite 740<br>South San Francisco, California 94080</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PROXY STATEMENT<br>FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TO BE HELD ON JUNE 9, 2025</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="questions"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING</font></h1><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Why did I receive a notice regarding the availability of proxy materials on the internet?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to rules adopted by the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the &#x201c;Notice&#x201d;) because the Board of Directors (the &#x201c;Board&#x201d;) of Spruce Biosciences, Inc. (sometimes referred to as &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; or the &#x201c;Company&#x201d;) is soliciting your proxy to vote at the 2025 Annual Meeting of Stockholders (the &#x201c;Annual Meeting&#x201d;), including at any adjournments or postponements of the Annual Meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to first mail the Notice and make this proxy statement and the form of proxy available on or about April 28, 2025 to all stockholders of record entitled to vote at the Annual Meeting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Will I receive any other proxy materials by mail?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may send you a proxy card, along with a second Notice, ten calendar days after our first mailing of the Notice or thereafter.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Why are you holding a virtual Annual Meeting?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Annual Meeting will be held through a live webcast at www.virtualshareholdermeeting.com/SPRB2025. You will not be able to attend the Annual Meeting in person. If you attend the Annual Meeting online, you will be able to vote and submit questions, at www.virtualshareholdermeeting.com/SPRB2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">How do I attend the Annual Meeting?</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	You are entitled to attend the Annual Meeting if you were a stockholder as of the close of business on April 10, 2025, the record date (the &#x201c;Record Date&#x201d;). To be admitted to the Annual Meeting, you will need to visit www.virtualshareholdermeeting.com/SPRB2025 and enter the 16-digit Control Number found next to the label &#x201c;Control Number&#x201d; on your Notice of Internet Availability, proxy card or voting instruction form. Whether or not you participate in the Annual Meeting, it is important that you vote your shares. We encourage you to access the Annual Meeting before it begins. Online check-in will start approximately fifteen minutes before the meeting on June 9, 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What if I cannot find my Control Number?</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	If you encounter any difficulties while accessing the virtual meeting during the check-in or meeting time, a technical assistance phone number will be made available on the virtual meeting registration page 15 minutes prior to the start of the meeting.  You will be able to login as a guest. To view the meeting webcast visit www.virtualshareholdermeeting.com/SPRB2025 and register as a guest. If you login as a guest, you will not be able to vote your shares or ask questions during the meeting.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are a beneficial owner (that is, you hold your shares in an account at a bank, broker or other holder of record), and you lost your control number, you will need to contact that bank, broker or other holder of record to obtain your Control Number.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Annual Meeting, how do I ask questions of management and the board?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to have a Q&amp;A session at the Annual Meeting and will include as many stockholder questions as the allotted time permits. Questions may be submitted during the Annual Meeting through www.virtualshareholdermeeting.com/SPRB2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If I miss the Annual Meeting, will there be a copy posted online?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes, a replay of the Annual Meeting webcast will be available at our website at https://investors.sprucebio.com/ and remain for at least ninety days.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Who can vote at the Annual Meeting?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Only stockholders of record at the close of business on the Record Date will be entitled to vote at the Annual Meeting. On the Record Date, there were 42,231,285 shares of common stock outstanding and entitled to vote.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholder of Record: Shares Registered in Your Name</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If on the Record Date your shares were registered directly in your name with our transfer agent, Computershare Trust Company, N.A., then you are a stockholder of record. We urge you to fill out and return the proxy card that may be mailed to you or vote by proxy over the telephone or on the internet as instructed below to ensure your vote is counted.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Beneficial Owner: Shares Registered in the Name of a Broker or Bank</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If on the Record Date your shares were held, not in your name, but rather in an account at a brokerage firm, bank or other similar organization, then you are the beneficial owner of shares held in &#x201c;street name&#x201d; and the Notice is being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker, bank or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting. You may vote prior to the Annual Meeting by logging in with the Control Number on your voting instruction form at www.proxyvote.com. You may access the meeting and vote by logging in with your Control Number at www.virtualshareholdermeeting.com/2025.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What am I voting on?</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are four matters scheduled for a vote:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proposal 1: To elect the three Class II directors named below to hold office until the Company&#x2019;s 2028 annual meeting of stockholders.</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominees:</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Percival-Baretto-Ko<br>Bali Muralidhar, M.D., Ph.D.<br>Daniel Spiegelman</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proposal 2: To ratify the selection by the Audit Committee of the Board (the &#x201c;Audit Committee&#x201d;) of BDO USA, P.C. as the independent registered public accounting firm of the Company for the Company&#x2019;s fiscal year ending December 31, 2025;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proposal 3: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a the Reverse Stock Split of the Company's common stock by a ratio of between one-for-five and one-for-thirty, with the exact ratio to be determined by the Board in its sole discretion and with such Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proposal 4: To approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What if another matter is properly brought before the meeting?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">How do I vote?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may either vote &#x201c;For&#x201d; all the nominees to the Board or you may &#x201c;Withhold&#x201d; your vote for any nominee you specify. For each of the other matters to be voted on, you may vote &#x201c;For&#x201d; or &#x201c;Against&#x201d; or abstain from voting.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The procedures for voting are fairly simple:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholder of Record: Shares Registered in Your Name</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are a stockholder of record, you may vote using the following mechanisms:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To vote using the proxy card, simply complete, sign and date the proxy card that may be delivered and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To vote over the telephone, dial toll-free 1-800-690-6903 using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the Notice. Your telephone vote must be received by 11:59 p.m. (Eastern Time) on June 8, 2025 to be counted.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To vote through the internet, go to www.proxyvote.com to complete an electronic proxy card. You will be asked to provide the company number and control number from the Notice. Your internet vote must be received by 11:59 p.m. (Eastern Time) on June 8, 2025 to be counted.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Beneficial Owner: Shares Registered in the Name of Broker or Bank</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a Notice containing voting instructions from that organization rather than from the Company. Simply follow the voting instructions in the Notice to ensure that your vote is counted.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Internet proxy voting may be provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access.</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">How many votes do I have?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On each matter to be voted upon, you have one vote for each share of common stock you own as of the Record Date.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If I am a stockholder of record and I do not vote, or if I return a proxy card or otherwise vote without giving specific voting instructions, what happens?</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are a stockholder of record and do not vote by completing your proxy card, by telephone, through the internet or online at the Annual Meeting, your shares will not be voted.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#x201c;For&#x201d; the election of both nominees for director, &#x201c;For&#x201d; the ratification of the selection by the Audit Committee of BDO USA, P.C. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025, &#x201c;For&#x201d; the approval of the Reverse Stock Split Proposal, and &#x201c;For&#x201d; the Adjournment Proposal. If any other matter is properly presented at the Annual Meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with voting instructions, what happens?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion. In this regard, under the rules of the New York Stock Exchange (&#x201c;NYSE&#x201d;), brokers, banks and other securities intermediaries that are subject to NYSE rules may use their discretion to vote your &#x201c;uninstructed&#x201d; shares with respect to matters considered to be &#x201c;routine&#x201d; under NYSE rules, but not with respect to &#x201c;non-routine&#x201d; matters. Although our shares are not listed with NYSE, NYSE regulates broker-dealers and their discretion to vote on stockholder proposals. In this regard, Proposal 1 is considered to be &#x201c;non-routine&#x201d; under NYSE rules, meaning that your broker may not vote your shares on Proposal 1 in the absence of your voting instructions. However, Proposals 2, 3 and 4 are considered to be &#x201c;routine&#x201d; matters under NYSE rules, meaning that if you do not return voting instructions to your broker by its deadline, your shares may be voted by your broker in its discretion on Proposal 2, Proposal 3 and Proposal 4.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you must provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Who is paying for this proxy solicitation?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What does it mean if I receive more than one Notice?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on the Notices to ensure that all of your shares are voted.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Can I change my vote after submitting my proxy?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stockholder of Record: Shares Registered in Your Name.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may submit another properly completed proxy card with a later date.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may grant a subsequent proxy through the internet.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may virtually attend the Annual Meeting and vote online. Simply attending the Annual Meeting will not, by itself, revoke your proxy.</font></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your most current proxy card or telephone or internet proxy is the one that is counted.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Beneficial Owner: Shares Registered in the Name of Broker or Bank.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If your shares are held by your broker, bank or other agent, you should follow the instructions provided by your broker, bank or other agent.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Will a list of record stockholders as of the record date be available?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the ten days ending the day prior to the Annual Meeting, a list of our record stockholders as of the close of business on the Record Date will be available for examination by any stockholder of record for a legally valid purpose at our corporate headquarters during regular business hours. To access the list of record stockholders beginning May 19, 2025 and until the meeting, stockholders should email investors@sprucebio.com.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When are stockholder proposals and director nominations due for next year&#x2019;s annual meeting?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To be considered for inclusion in next year&#x2019;s proxy materials, your proposal must be submitted in writing by December 16, 2025, to 611 Gateway Boulevard, Suite 740, South San Francisco, California 94080, Attention: Corporate Secretary. If you wish to submit a proposal (including a director nomination) at the meeting that is not to be included in next year&#x2019;s proxy materials, you must do so between February 9, 2026 and March 11, 2026. In addition, stockholders who intend to solicit proxies in support of director nominees other than the Company&#x2019;s nominees must also comply with the additional requirements of Rule 14a-19(b). You are also advised to review the Company&#x2019;s amended and restated bylaws, which contain additional requirements relating to advance notice of stockholder proposals and director nominations. The timely submission of a proposal (including a director nomination) does not guarantee its inclusion in the Company&#x2019;s proxy materials.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Who will count the votes?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Votes will be counted by the inspector of election appointed for the Annual Meeting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What are </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">broker non-votes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed above, when a beneficial owner of shares held in street name does not give voting instructions to his or her broker, bank or other securities intermediary holding his or her shares as to how to vote on matters deemed to be &#x201c;non-routine&#x201d; under NYSE rules, the broker, bank or other such agent cannot vote the shares. When there is at least one &#x201c;routine&#x201d; matter that the broker, bank or other securities intermediary votes on, the shares that are un-voted on &#x201c;non-routine&#x201d; matters are counted as &#x201c;broker non-votes.&#x201d; Proposal 1 is considered to be &#x201c;non-routine&#x201d; under NYSE rules and we therefore expect broker non-votes to exist in connection with this proposal. Proposal 2 and Proposal 3 are &#x201c;routine&#x201d; matters and therefore we expect brokers, banks or other securities intermediaries to vote on these proposals.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">As a reminder, if you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you must provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">How many votes are needed to adopt or approve each proposal and how will votes be counted?</font></p><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the minimum vote needed to approve each proposal and the effect of abstentions and broker non-votes.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:7.421%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:15.223%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:37.888%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12.743%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:10.682%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:10.042%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.083in;vertical-align:bottom;padding-bottom:0.045in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Proposal</font></p><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</font></p></td>
     <td style="padding-top:0.083in;vertical-align:bottom;padding-bottom:0.045in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.083in;vertical-align:bottom;padding-bottom:0.045in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Proposal Description</font></p></td>
     <td style="padding-top:0.083in;vertical-align:bottom;padding-bottom:0.045in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.083in;vertical-align:bottom;padding-bottom:0.045in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vote Required for Approval</font></p></td>
     <td style="padding-top:0.083in;vertical-align:bottom;padding-bottom:0.045in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting Options</font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:4pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.083in;vertical-align:bottom;padding-bottom:0.045in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Effect of</font></p><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Abstentions or Withhold Votes, as applicable</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.083in;vertical-align:bottom;padding-bottom:0.045in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.083in;vertical-align:bottom;padding-bottom:0.045in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Effect of</font></p><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Broker Non-</font></p><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Votes</font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.045in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
     <td style="padding-top:0.045in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.045in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director Election Proposal</font></p></td>
     <td style="padding-top:0.045in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.045in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the election of director.</font></p></td>
     <td style="padding-top:0.045in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FOR or WITHHOLD with respect to each of the two director nominees</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.045in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No effect</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.045in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.045in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No effect</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditor Ratification Proposal</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Affirmative vote of the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders.</font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FOR, AGAINST, or ABSTAIN</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Against</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Not applicable </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reverse Stock Split Proposal</font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Affirmative vote of the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders.</font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FOR, AGAINST, or ABSTAIN</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Against</font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Not applicable </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjournment Proposal</font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Affirmative vote of the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders.</font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FOR, AGAINST, or ABSTAIN</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Against</font></p></td>
     <td style="padding-top:0.028in;vertical-align:middle;padding-bottom:0.028in;"><p style="font-size:2pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x200b;</font></p></td>
     <td style="padding-top:0.028in;vertical-align:top;padding-bottom:0.028in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Not applicable </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:5.48%;box-sizing:content-box;"></td>
     <td style="width:94.52%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;NYSE has advised us that this proposal should be considered a &#x201c;routine&#x201d; matter under NYSE rules. Although our shares are not listed with the NYSE, the NYSE regulates broker-dealers and their discretion to vote on stockholder proposals. Accordingly, if you hold your shares in street name and do not provide voting instructions to your broker that holds your shares, we believe your broker should have discretionary authority under NYSE rules to vote your shares on this proposal absent additional instructions from you. Given such discretionary authority, we do not anticipate broker non-votes for this proposal.</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What is the quorum requirement?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares of stock entitled to vote are present at the Annual Meeting virtually or represented by proxy. On the Record Date, there were 42,231,285 shares outstanding and entitled to vote. Thus, the holders of 21,115,643 shares must be present virtually or represented by proxy at the Annual Meeting to have a quorum.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote online at the Annual Meeting. Abstentions, withhold</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">votes and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the chairman of the Annual Meeting or the holders of a majority of shares present at the Annual Meeting or represented by proxy may adjourn the meeting to another date.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">How can I find out the results of the voting at the Annual Meeting?</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the Annual Meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="p1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proposal 1 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Election of Directors</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board is divided into three classes. Each class consists, as nearly as possible, of one-third of the total number of directors, and each class has a three-year term. Vacancies on the Board may be filled by persons elected by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#x2019;s successor is duly elected and qualified.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board presently has eight members. There are three directors in the class whose term of office expires in 2025: Percival Barretto-Ko, Bali Muralidhar, M.D, Ph.D. and Daniel Spiegelman. Each is currently a director of the Company. If elected at the Annual Meeting, each of Mr. Barretto-Ko, Dr. Muralidhar and Mr. Spiegelman would serve until the Company&#x2019;s 2028 annual meeting of stockholders and until the director&#x2019;s successor has been duly elected and qualified, or, if sooner, until the director&#x2019;s death, resignation or removal.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Muralidhar and Mr. Spiegelman were each previously elected by stockholders at the Company&#x2019;s 2022 annual meeting of stockholders. Mr. Barretto-Ko was recommended as a director by the Nominating and Corporate Governance Committee (&#x201c;Nominating Committee&#x201d;).</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is the Company&#x2019;s policy to invite directors and nominees for director to attend the Annual Meeting, including virtually if applicable. All of the directors attended the 2024 Annual Meeting of Stockholders.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors are elected at the Annual Meeting by a plurality of the votes of the holders of shares present virtually or represented by proxy and entitled to vote on the election of directors. Accordingly, the three nominees receiving the highest number of affirmative votes will be elected. Each person nominated for election has agreed to serve if elected. The Company&#x2019;s management has no reason to believe that any nominee will be unable to serve.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Nominating Committee seeks to assemble a board that, as a whole, is diverse and possesses the appropriate balance of professional and industry knowledge, financial expertise and high-level management experience necessary to oversee and direct the Company&#x2019;s business. To that end, the Nominating Committee has identified and evaluated nominees in the broader context of the Board&#x2019;s overall composition, with the goal of recruiting members who complement and strengthen the skills of other members and who also exhibit integrity, collegiality, sound business judgment and other qualities that the Nominating Committee views as critical to effective functioning of the Board. The brief biographies below include information, as of the date of this Proxy Statement, regarding the specific and particular experience, qualifications, attributes or skills of each director or nominee that led the Nominating Committee to believe that that nominee should serve or continue to serve on the Board. However, each of the members of the Nominating Committee may have a variety of reasons why he or she believes a particular person would be an appropriate nominee for the Board, and these views may differ from the views of other members. The following is a brief biography as of the Record Date of each nominee and each director whose term will continue after the Annual Meeting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominees for Election for a Three-year Term Expiring at the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s 2028 Annual Meeting of Stockholders</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Percival Barretto-Ko</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 52, has served as a member of the Board since May 2023. Most recently, Mr. Barretto-Ko served as President and Chief Executive Officer at Plexium, Inc., a pharmaceutical company (&#x201c;Plexium&#x201d;). Prior to joining Plexium, Mr. Barretto-Ko served in numerous roles, including Chief Business Officer and President U.S., at Astellas Pharma Inc., a pharmaceutical company, from 2005 to 2021. Prior to joining Astellas, Mr. Barretto-Ko served in increasingly senior roles at Roche UK and US, a pharmaceutical company, from 2001 to 2005. Mr. Barretto-Ko has served on the board of directors for Alessa Therapeutics, Inc., a private pharmaceutical company, since January 2022. Mr. Barretto-Ko earned a B.S. in Biological Sciences with Honors from Cornell University and an M.B.A. from Yale University. In addition, Mr. Barretto-Ko served as a Sloan Fellow for Innovation and Global Leadership at the MIT Sloan School of Management, where he was awarded an M.Sc. in Management.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board and Nominating Committee believes that Mr. Barretto-Ko&#x2019;s business and managerial experience as well as his extensive experience in the pharmaceutical industry qualifies him to serve on the Board.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bali Muralidhar, M.D, Ph.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 45, has served as a member of the Board since February 2020. Dr. Muralidhar has served as a managing partner at Abingworth LLP (&#x201c;Abingworth&#x201d;), a leading transatlantic life sciences investment firm, since December 2020, and as a partner from March 2019 to December 2020. Dr. Muralidhar has over 15 years of professional experience in healthcare across a range of functions including venture investing, research and development, clinical practice and teaching. Prior to joining Abingworth, Dr. Muralidhar was a senior partner at MVM Partners LLP (&#x201c;MVM&#x201d;), a healthcare investment company, from November 2012 to March 2019. Prior to MVM, he was a member of the leveraged buyout team at Bain Capital LP, a private investment company, focusing on healthcare from April 2011 to November 2012. Dr. Muralidhar represents Abingworth on the boards of several private life sciences and biopharmaceutical companies, including Anjarium Biosciences AG, since August 2021, Ascend Gene and Cell Therapies Limited, since February 2023, Wugen Inc., since July 2021, Cytospire Therapeutics Limited, since May 2023, Advancell Pty Ltd since February 2025, Launch Therapeutics since April 2022 and Pathlys Pharma, Inc., since January 2023. He has served on the boards of NuCana PLC, a life sciences company, since October 2020. He was an executive officer on the joint steering committee of CymaBay Therapeutics, Inc., a biotechnology company until March 2024. Dr. Muralidhar previously served on the board of directors of Wilson Therapeutics, a public biopharmaceutical company, from March 2014 to April 2018, Exicure, Inc., a public biotechnology company, from August 2019 to December 2022, Reneo Pharmaceuticals, Inc., a public biopharmaceutical company, from April 2021 until October 2024 and Valneva SE, a public biotechnology company headquartered in France, from May 2017 to December 2019. Dr. Muralidhar earned a degree in clinical medicine from the University of Oxford and has a Ph.D. in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board and Nominating Committee believes that Dr. Muralidhar&#x2019;s investment experience in the healthcare industry qualifies him to serve on the Board.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Daniel Spiegelman</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 66, has served as a member of the Board since September 2020. Mr. Spiegelman currently provides consulting services to various life sciences companies and has served as a Venture Partner at Samsara BioCapital since 2023. From May 2012 to January 2020, Mr. Spiegelman was the Executive Vice President and Chief Financial Officer of BioMarin Pharmaceutical Inc. (&#x201c;BioMarin&#x201d;), a biotechnology company. Prior to BioMarin, Mr. Spiegelman served as a consultant to provide strategic financial management support a portfolio of public and private life science companies. From January 1998 to May 2009, Mr. Spiegelman was the Chief Financial Officer of CV Therapeutics, Inc., a biopharmaceutical company. From July 1991 to January 1998, Mr. Spiegelman served in various roles at Genentech, Inc., (now a member of the Roche Group) most recently as Treasurer. Mr. Spiegelman has served as a director of Maze Therapeutics, Inc., a public biologics drug developer, since October 2020, of vTv Therapeutics, Inc., a public biopharmaceutical company, since June 2024 and of Kyverna Therapeutics, Inc., a public pharmaceutical company, since April 2021. Mr. Spiegelman served as a director of Myriad Genetics, Inc. a public molecular diagnostic company, from May 2020 to June 2024 and as a director of Opthea Limited, a public biologics drug developer, from October 2020 to April 2024. Mr. Spiegelman has served as director and chair of Tizona Therapeutics, Inc., a private biopharmaceutical company, since May 2019 and as director of BlueJay Therapeutics, Inc., a private biopharmaceutical company, since October 2024. Mr. Spiegelman received a B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board and Nominating Committee believes that Mr. Spiegelman&#x2019;s substantial experience as an executive officer in the pharmaceutical and biotechnology industries, including his financial expertise, qualifies him to serve on the Board.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board Recommends<br>a Vote in Favor of Each Named Nominee.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors Continuing in Office Until the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s 2026 Annual Meeting of Stockholders</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">MPH</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 55, has served as our Chief Executive Officer and a member of the Board since January 2022. Dr. Szwarcberg previously served as Group Vice President, Head of Product and Portfolio Development for BioMarin from February 2020 to January 2022. Prior to joining BioMarin, Dr. Szwarcberg served as Senior Vice President, Program and Portfolio Management for Ultragenyx Pharmaceutical Inc., a biotechnology company, from October 2017 to February 2020. From October 2016 to October 2017, Dr. Szwarcberg served as Vice President of Clinical Development and Business Development for Horizon Pharma plc (&#x201c;Horizon&#x201d;), a public biopharmaceutical company. Dr. Szwarcberg received an M.D. from the University of Buenos Aires and an MPH from the Harvard T.H. Chan School of Public Health.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board and Nominating Committee believes that Dr. Szwarcberg&#x2019;s extensive experience in the biotechnology and pharmaceutical industries qualify him to serve on the Board.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Michael Grey</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 72, has served as Executive Chairman of the Board since April 2017 and served as our Interim Chief Executive Officer from November 2021 to January 2022. In addition, Mr. Grey has served as Chairman of Mirum Pharmaceuticals, Inc., a public biopharmaceutical company, since January 2020, and has been a director of Mirum since May 2018. Mr. Grey previously served as Executive Chairman of Mirum from March 2019 to December 2019 and Chief Executive Officer of Mirum from May 2018 to March 2019. Mr. Grey served as Executive Chairman of Reneo Pharmaceuticals, Inc. from December 2017 to October 2024 (merged with OnKure, Inc., a biopharmaceutical company, in 2024) and has served as a director for OnKure since October 2024. Mr. Grey has served as Executive Chairman of Plexium since September 2020. He has served as Chairman of Sorriso Pharmaceuticals, Inc., a private pharmaceutical company since May 2021 and as Executive Chair of Theolytics Ltd., a private biotechnology company, since November 2023. Mr. Grey previously served as a director of BioMarin from December 2005 to May 2021 and as director of Mirati Therapeutics, Inc., a biopharmaceutical company, from November 2014 to June 2021. He has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010, as a director of Curzion Pharmaceuticals, Inc., a private biopharmaceutical company, which was acquired in April 2020 by Horizon, from January 2019 to April 2020, and as a director at Horizon from September 2011 to October 2023. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion, from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001), and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc., and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey received a B.S. in chemistry from the University of Nottingham in the United Kingdom.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board and Nominating Committee believes that Mr. Grey&#x2019;s extensive experience managing and leading both early stage and established companies within the pharmaceutical and biotechnology industries qualify him to serve on the Board.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Camilla V. Simpson, M.Sc.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 53, has served as a member of the Board since October 2017. Since April 2021, Ms. Simpson has served as Chief Executive Officer of Zehna Therapeutics, Inc., a private biotechnology company and spin-out from the Cleveland Clinic. Since April 2019, Ms. Simpson has been the Managing Member and President of Rare Strategic, LLC where she provides strategic advice and consulting services to biotechnology companies. Ms. Simpson joined the board of directors of Dyve Biosciences, Inc., a private biopharmaceutical company, in December 2020 and the board of directors of GRI Bio, Inc., a public biopharmaceutical company, in April 2023. From April 2017 to April 2019, Ms. Simpson was SVP, Head of Product Portfolio Development at BioMarin, where she was responsible for corporate and R&amp;D governance, program leadership, project management, competitive intelligence, portfolio strategy, and business analytics. From October 2014 to April 2017, Ms. Simpson was Group Vice President Global Regulatory Affairs at BioMarin, and from March 2014 to October 2014, Ms. Simpson was Vice President Regulatory Affairs EU at BioMarin. She also spent 12 years at Shire, where after multiple roles of increasing responsibility, she held the position of Vice President Regulatory Affairs Early Development and Business</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development. Ms. Simpson holds a B.Sc. from University College Galway, Ireland, a B.Sc. Hons. from Kingston University, United Kingdom, and an M.Sc. with distinction from the University of London, United Kingdom.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board and Nominating Committee believes that Ms. Simpson&#x2019;s significant experience as a senior executive in the pharmaceutical and biotechnology industries, including her experience in a wide range of drug development, organizational strategy and global regulatory affairs matters, qualifies her to serve on the Board.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors Continuing in Office Until the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x2019;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s 2027 Annual Meeting of Stockholders</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tiba Aynechi, Ph.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 49, has served as a member of the Board since May 2016. Since December 2021, Dr. Aynechi has been a General Partner at Norwest Venture Partners (&#x201c;Norwest&#x201d;), a private investment company. Prior to Norwest, Dr. Aynechi was a senior partner at Novo Ventures (US) Inc. (&#x201c;Novo Ventures&#x201d;), which provides certain consultancy services to Novo Holdings A/S (&#x201c;Novo&#x201d;), a Danish limited liability company that manages investments and financial assets. Prior to joining Novo Ventures in March 2010, Dr. Aynechi was employed from June 2006 to March 2010 by Burrill &amp; Company, a financial firm specializing in biotechnology and life sciences investment, in various positions, including from January 2009 to March 2010 as a director in merchant banking where she was responsible for regional and cross-border mergers and acquisitions, licensing, and financing transactions. Dr. Aynechi served as a director of Nkarta, Inc., a public biopharmaceutical company, from October 2015 to August 2022, as a director of Aristea Therapeutics, Inc., a private biopharmaceutical company, from August 2018 to December 2021, MDLIVE, a private telehealth company, from July 2018 to May 2021, Arcellex, Inc, a then-private biotechnology company, from July 2015 to November 2021, and as a director of Mirum from November 2018 to August 2021. She currently serves as a member of the board of directors of several private biotechnology and medical device companies, including Avalyn Pharma Inc. (&#x201c;Avalyn&#x201d;), since April 2017, Engrail Therapeutics, Inc., since May 2024, Nuvig Therapeutics, Inc., since December 2024, Rezo Therapeutics, Inc., since July 2022 and Ray Therapeutics, Inc., since May 2023. She has served on the board of directors of MBX Biosciences, Inc, a biopharmaceutical company, since December 2022. Dr. Aynechi received her Ph.D. in biophysics from the University of California, San Francisco, where her research involved developing computational methods for drug discovery. She received her B.S. in physics from the University of California, Irvine.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board and Nominating Committee believes that Dr. Aynechi&#x2019;s extensive experience in the biotechnology and pharmaceutical industries, including her expertise in handling a wide range of financing transactions, qualifies her to serve on the Board.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Kirk Ways, M.D., Ph.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 73, has served on the Board since June 2021 and as interim Chief Medical officer since December 2024. Dr. Ways has served as interim Chief Medical Officer of MBX from November 2023 to July 2024. From October 2018 to January 2021, Dr. Ways served as Chief Medical Officer of Nuvelution Pharma, Inc. (&#x201c;Nuvelution&#x201d;), a biopharmaceutical company. Prior to joining Nuvelution, Dr. Ways served as Development Head of Cardiovascular and Metabolism at Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;), a biopharmaceutical company. Prior to joining Janssen, Dr. Ways served in leadership capacities at several life sciences companies, including BioStratum Incorporated as Vice President and Chief Development Officer, Aventis, Inc. as Senior Global Medical Leader and Project Team Leader and Lilly Research Laboratories as a Research Fellow with responsibilities for the preclinical and clinical development for agents treating the chronic complications of diabetes. Prior to joining the pharmaceutical industry, Dr. Ways served as Director of the Diabetes Center, Vice Chairman for the Department of Internal Medicine, Endocrinology Section Head and Professor of Medicine at East Carolina School of Medicine. Dr. Ways has authored more than one hundred publications in the fields of diabetes and cancer. Dr. Ways earned his M.D. with honors and a Ph.D. in Pharmacology from the University of North Carolina and graduated with a B.A. magna cum laude from Bridgewater College.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board and Nominating Committee believes that Dr. Ways&#x2019; significant experience in leadership roles with pharmaceutical and biotechnology companies qualifies him to serve on the Board.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="p1_info"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</font></h1><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="p1_indep"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Independence of the Board of Directors</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required under the Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;) listing rules, a majority of the members of a listed company&#x2019;s board of directors must qualify as &#x201c;independent,&#x201d; as affirmatively determined by the board of directors. The Board consults with the Company&#x2019;s counsel to ensure that the Board&#x2019;s determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#x201c;independent,&#x201d; including those set forth in the Nasdaq listing rules, as in effect from time to time.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and the Company, its senior management and its independent auditors, the Board has affirmatively determined that all of the directors who served on our board in 2024, except for Dr. Szwarcberg, Dr. Ways and Mr. Grey, are independent directors within the meaning of the applicable Nasdaq listing rules. Prior to his service as Interim Chief Medical Officer, Dr. Ways was determined to be independent during his time on the Board. In making this determination, the Board found that none of these directors or nominees for director had a material or other disqualifying relationship with the Company.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="p1_structure"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Leadership Structure</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board is currently chaired by Mr. Grey, who has authority, among other things, to call and preside over Board meetings, to set meeting agendas and to determine materials to be distributed to the Board. Accordingly, the Chair of the Board has substantial ability to shape the work of the Board. The Company believes that separation of the positions of Chair of the Board and Chief Executive Officer reinforces the independence of the Board in its oversight of the business and affairs of the Company. In addition, the Company believes that having an independent Chair of the Board creates an environment that is more conducive to the Board&#x2019;s objective evaluation and oversight of management&#x2019;s performance, increasing management accountability, and improving the ability of the Board to monitor whether management&#x2019;s actions are in the best interests of the Company and its stockholders, including with respect to evaluating whether steps management is taking to manage risks are appropriate for the Company. Mr. Grey&#x2019;s responsibility is to ensure that our Board functions properly and to work with our Chief Executive Officer to set the Board&#x2019;s agenda. We expect him to facilitate communications among our directors and between the Board and senior management. While Mr. Grey provides independent leadership, he also works closely with our Chief Executive Officer to ensure that our directors receive the information that they need to perform their responsibilities, including discussing and providing critical review of the matters that come before the Board and assessing management&#x2019;s performance. As a result, we believe that such separation can enhance the effectiveness of our Board as a whole. That said, the Company does not believe there should be a fixed rule regarding the positions of Chief Executive Officer and Chair of the Board being held by different individuals, or whether the Chair of the Board should be elected from among the non-employee directors. The needs of the Company and the individuals available to assume these roles may require different outcomes at different times, and the Board believes that retaining flexibility in these decisions is in the best interests of the Company.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Company has a separate Chair for each committee of the Board. The Chair of each committee reports periodically to the Board on the activities of their committee in fulfilling their responsibilities as detailed in their respective charters.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="p1_role"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Role of the Board in Risk Oversight</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the Board&#x2019;s key functions is informed oversight of the Company&#x2019;s risk management process. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight. In particular, the Board is responsible for monitoring and assessing strategic risk exposure, such as cybersecurity-related risks, including a determination of the nature and level of risk appropriate for the Company. The Audit Committee has the responsibility to consider and discuss our major risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken, and to provide oversight assistance in connection with our strategic, financial, operational, information security and data privacy (including cybersecurity), regulatory,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and other risks related to the Company&#x2019;s business, including compliance programs as established by management and the Board. The Company&#x2019;s assessment and management of material risks from cybersecurity threats are integrated into the Company&#x2019;s overall risk management processes. For example, cybersecurity risk is addressed as a component of the Company&#x2019;s enterprise risk management program, which is evaluated periodically by the Company&#x2019;s Chief Compliance Officer, which together with the Audit Committee, evaluates material risks from cybersecurity threats against the Company&#x2019;s overall business objectives and reports to the Board. The Nominating Committee monitors the effectiveness of our corporate governance guidelines. The Compensation Committee of the Board (the &#x201c;Compensation Committee&#x201d;) assesses and monitors whether any of our compensation policies and practices has the potential to encourage excessive risk-taking. Typically, the entire Board meets with the personnel in charge of the Company&#x2019;s risk management efforts at least annually, and the applicable Board committees meet at least annually with the personnel responsible for risk management efforts in the committees&#x2019; respective areas of oversight. Both the Board as a whole and the various standing committees receive periodic reports from the head of risk management, as well as incidental reports as matters may arise. It is the responsibility of the committee Chairs to report findings regarding material risk exposures to the Board as quickly as possible.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Role of the Board in Strategy Oversight</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board is deeply engaged and involved in overseeing our long-range strategy. Our Board&#x2019;s oversight of risk is another integral component of the Board&#x2019;s oversight and engagement on strategic matters. Strategy-related matters are regularly discussed at board meetings and, when relevant, at Committee meetings. We also dedicate at least one board meeting every year to an even more intensive review and discussion of our strategic plan. Matters of strategy also inform committee-level discussions of many issues, including enterprise risk. Engagement of the Board on these issues and other matters of strategic importance continues in between meetings, including through updates to the Board on significant items and discussions between the CEO and our Chair of the Board on a periodic basis. Each director is expected to and does bring to bear their own talents, insights, and experiences to these strategy discussions.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="p1_mtg"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Meetings of the Board of Directors</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board met eleven times during the last fiscal year. All directors, except Dr. Muralidhar, attended at least 75% of the aggregate number of meetings of the Board and of the committees on which they served, held during the portion of the last fiscal year for which they were directors or committee members, respectively.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, the Company&#x2019;s non-employee directors met four times in regularly scheduled executive sessions at which only non-employee directors were present.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Composition</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our directors collectively have an appropriate balance of knowledge, experience, attributes, skills and expertise to ensure that the Board appropriately fulfills its oversight responsibilities and acts in the best interests of our stockholders. Although specific qualifications for membership on the Board may vary from time to time, desired qualities include (A) the highest personal integrity and ethics, (B) relevant expertise upon which to be able to offer advice and guidance to management, (C) demonstrated excellence in his or her field, (D) sound business judgment, (E) sufficient time to devote to the affairs of the Company, and (F) commitment to rigorously represent the long-term interests of our stockholders.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table depicts the key skills and experience that we consider important in light of our current business structure and that our directors bring to our company.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:15.797%;box-sizing:content-box;"></td>
     <td style="width:10.618%;box-sizing:content-box;"></td>
     <td style="width:11.578%;box-sizing:content-box;"></td>
     <td style="width:8.398%;box-sizing:content-box;"></td>
     <td style="width:11.578%;box-sizing:content-box;"></td>
     <td style="width:9.458%;box-sizing:content-box;"></td>
     <td style="width:11.738%;box-sizing:content-box;"></td>
     <td style="width:12.557%;box-sizing:content-box;"></td>
     <td style="width:8.278%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
     <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">T. Aynechi</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">P. Barretto-Ko</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">M. Grey</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">B. Muralidhar</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">C. Simpson</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">D. Spiegelman</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">J. Szwarcberg</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">K. Ways</font></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial and Accounting</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:9.35pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Senior Leadership</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Healthcare</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
    </tr>
    <tr style="height:9.35pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Research and Development</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Commercial</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:9.35pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Governance</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Global Business</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
    </tr>
    <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Public Policy and Regulatory</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x25cf;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-4.467%;padding-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	Financial and Accounting: knowledge of the financial markets, corporate finance, accounting regulations, and accounting and financial reporting processes;</font></p><p style="margin-left:3.333%;text-indent:-4.467%;padding-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2..	Senior Leadership Experience: serving in a senior leadership role at another organization and experience with human capital management;</font></p><p style="margin-left:3.333%;text-indent:-4.467%;padding-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3..	Healthcare: experience in or with the biotechnology, life sciences and/or pharmaceutical industries, including experience in the clinical development of pharmaceutical products;</font></p><p style="margin-left:3.333%;text-indent:-4.467%;padding-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	Research and Development: experience in the research and development of therapeutic investigational products, including those within endocrine and/or rare diseases;</font></p><p style="margin-left:3.333%;text-indent:-4.467%;padding-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	Commercialization: experience executing corporate commercial and/or marketing strategies and initiatives;</font></p><p style="margin-left:3.333%;text-indent:-4.467%;padding-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.	Governance: experience serving on the board of directors of other public companies, and knowledge regarding public company governance and compensation, policies and practices</font></p><p style="margin-left:3.333%;text-indent:-4.467%;padding-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.	Global Business: experience outside of the United States, including knowledge of and experience with research and development and commercial operations; and</font></p><p style="margin-left:3.333%;text-indent:-4.467%;padding-left:4.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.	Public Policy and Regulatory: experience with government, public policy or regulatory affairs.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="p1_comminfo"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information Regarding Committees of the Board of Directors</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board has three committees: the Audit Committee, Compensation Committee and Nominating Committee. The following table provides membership and meeting information for 2024 for each of the Board committees:</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:34.88%;box-sizing:content-box;"></td>
     <td style="width:20.96%;box-sizing:content-box;"></td>
     <td style="width:22.26%;box-sizing:content-box;"></td>
     <td style="width:21.9%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:0.5pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Audit</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Compensation</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Grey</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tiba Aynechi, Ph.D.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">*</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Percival Barretto-Ko</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bali Muralidhar, M.D., Ph.D.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Niall O&#x2019;Donnell, Ph.D. </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Camilla V. Simpson, M.Sc. </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X*</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Daniel Spiegelman</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">*</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kirk Ways, M.D., Ph.D. </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">*</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total meetings in 2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:66.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Committee Chairperson</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	Dr. O&#x2019;Donnell served on our Board and was a member of the Audit Committee until his resignation on May 22, 2024.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	Ms. Simpson became a member of the Audit Committee effective May 22, 2024 and became Chairperson of the Nominating Committee on March 26, 2025</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) 	Dr. Ways was the Chairperson of the Nominating Committee until March 26, 2025. Ms. Simpson was appointed Chairperson as of such date.</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding &#x201c;independence&#x201d; and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below is a description of each committee of the Board.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="p1_ac"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee was established by the Board in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), to oversee the Company&#x2019;s corporate accounting and financial reporting processes and audits of its financial statements. The primary purpose of the Audit Committee is to discharge the responsibilities of the Board with respect to our corporate accounting and financial reporting processes, systems of internal control and financial-statement audits, and to oversee our independent registered accounting firm.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific responsibilities of the Audit Committee include:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overseeing our corporate accounting and financial reporting processes;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing the selection, engagement, qualifications, independence, and performance of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing related person transactions;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting to the Board with respect to material issues that arise regarding the quality or integrity of our financial statements, our compliance with applicable legal or regulatory requirements and other matters; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approving, or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting firm.</font></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee is composed of three directors: Mr. Spiegelman, Mr. Barretto-Ko, and Ms. Simpson. Ms. Simpson succeeded Dr. O&#x2019;Donnell, who served on the Audit Committee until his resignation from the Board on May 22, 2024. The Audit Committee met five times during the fiscal year. The Board has adopted a written Audit Committee charter that is available to stockholders on the Company&#x2019;s website at www.sprucebio.com. The information on our website is not incorporated by reference into this Proxy Statement or our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the &#x201c;Annual Report&#x201d;).</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board reviews the Nasdaq listing rules definition of independence for Audit Committee members on an annual basis and has determined that all members of the Audit Committee are independent (as independence is currently defined in Rule 5605(c)(2)(A)(i) and (ii) of the Nasdaq listing rules).</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board has also determined that Mr. Spiegelman qualifies as an &#x201c;audit committee financial expert,&#x201d; as defined in applicable SEC rules. In making this determination, the Board made a qualitative assessment of Mr. Spiegelman&#x2019;s level of knowledge and experience based on a number of factors, including his formal education and experience as a chief financial officer.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of the Audit Committee of the Board*</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2024 with management of the Company. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (&#x201c;PCAOB&#x201d;) and the SEC. The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants&#x2019; communications with the Audit Committee concerning independence, and has discussed with the independent registered public accounting firm the accounting firm&#x2019;s independence. Based on the foregoing, the Audit Committee has recommended to the Board that the audited financial statements be included in the Annual Report.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Daniel Spiegelman<br>Percival Barretto-Ko<br>Camilla V. Simpson, M.Sc.</font></p><p style="text-indent:-5.263%;padding-left:5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">*</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The material in this report is not &#x201c;soliciting material,&#x201d; is not deemed &#x201c;filed&#x201d; with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="p1_cc"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee is composed of three directors: Dr. Aynechi, Dr. Muralidhar, and Ms. Simpson. All members of the Compensation Committee are independent (as independence is currently defined in Rule 5605(d)(2) of the Nasdaq listing rules). The Compensation Committee met two times during the fiscal year. The Board has adopted a written Compensation Committee charter that is available to stockholders on the Company&#x2019;s website at www.sprucebio.com. The information on our website is not incorporated by reference into this Proxy Statement or our Annual Report.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary purpose of the Compensation Committee is to discharge the responsibilities of the Board in overseeing our compensation policies, plans, and programs and to review and determine the compensation to be paid to our executive officers, directors, and other senior management, as appropriate.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific responsibilities of the Compensation Committee include:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and approving the compensation of our Chief Executive Officer, other executive officers and senior management;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and approving the compensation paid to our directors;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and approving the compensation arrangements with our executive officers and other senior management;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">administering our equity incentive plans and other benefit programs;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing, adopting, amending, and terminating the terms of any employment agreements, stock option plans, stock appreciation rights plans, severance arrangements, pension and profit sharing plans, incentive plans, stock bonus plans, stock purchase plans, bonus plans, deferred compensation plans, </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">change-of-control protections, and any other compensatory arrangements for our executive officers and other senior management;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing, evaluating and recommending to the Board succession plans for our executive officers; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and establishing general policies relating to compensation and benefits of our employees, including our overall compensation philosophy.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation Committee Processes and Procedures</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Typically, the Compensation Committee meets quarterly or as needed. The Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. Our Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under the charter, the Compensation Committee has the authority to obtain, at the expense of the Company, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising the Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation. In addition, under the charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the compensation committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq that bear upon the adviser&#x2019;s independence; however, there is no requirement that any adviser be independent.`</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In fiscal year 2023, after taking into consideration the six factors prescribed by the SEC and Nasdaq described above, the Compensation Committee engaged Aon Consulting, Inc. (&#x201c;Aon&#x201d;) as compensation consultant. As part of its engagement, Aon was requested by the Compensation Committee to develop a comparative group of companies and to perform analyses of competitive performance and compensation levels for that group for purposes of developing recommendations on the amount and form of executive and director compensation that were presented to the Compensation Committee for its consideration. The Compensation Committee did not engage Aon for any consulting services in 2024. In addition, management of the Company engaged affiliates of Aon for other services in 2024 that were not related to Aon&#x2019;s Compensation Committee consulting services. Specifically, we engaged an affiliate of Aon for insurance brokerage services, for which we paid $150,000 in 2024. Although the Compensation Committee was aware of the nature of these additional services, the committee did not review and approve such services, insurance premiums or policies, as those were reviewed and approved by management in the ordinary course of business.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aon maintains certain policies and practices to protect the independence of the executive compensation consultants engaged by the Compensation Committee. In particular, Aon provides a report to the Compensation Committee on the financial relationship between Aon and the Company, and provides written assurances that, within Aon, the compensation of the affiliate consultants who perform executive compensation services for the Compensation Committee is determined separately from Aon&#x2019;s other lines of business and from the other services it provides to the Company. These safeguards were designed to help ensure that the Compensation Committee&#x2019;s compensation consultants continued to fulfill their role in providing independent, objective advice.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under its charter, the Compensation Committee may form, and delegate authority to, subcommittees as appropriate. The Board previously formed an Equity Award Committee (the &#x201c;Equity Award Committee&#x201d;), currently composed solely of our Chief Executive Officer, to which it delegated authority to grant, without any further action required by the Board or the Compensation Committee, stock options and restricted stock units to employees who are not executives of the Company, in each case pursuant to the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;). The purpose of this delegation of authority is to enhance the flexibility of equity award administration within the Company and to</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilitate the timely grant of equity awards to non-executive employees, particularly new employees, within specified limits approved by the Board. During fiscal 2024, the Equity Award Committee exercised its authority to grant an aggregate of 300,000 restricted stock units with both performance-based and time-based vesting conditions to non-executive employees.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Typically, the Compensation Committee makes most of the significant adjustments to annual compensation, determines bonus and equity awards and establishes new performance objectives at one or more meetings held during the first quarter of the year. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of the Company&#x2019;s compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee&#x2019;s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year. For executives other than our Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee by our Chief Executive Officer.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the case of our Chief Executive Officer, the evaluation of his performance is conducted by the Compensation Committee, which determines any adjustments to his compensation as well as awards to be granted. For all executives and directors as part of its deliberations, the Compensation Committee may review and consider, as appropriate, materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels and recommendations of the Compensation Committee&#x2019;s compensation consultant, including analyses of executive and director compensation paid at other companies identified by the consultant.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="p1_nom"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Nominating Committee is responsible for identifying, reviewing and evaluating candidates to serve as directors of the Company, reviewing and evaluating incumbent directors, recommending to the Board for selecting candidates for election to the Board, making recommendations to the Board regarding the membership of the committees of the Board, assessing the performance of the Board, and developing and making recommendations regarding corporate governance matters.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific responsibilities of the Nominating Committee include:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders, to serve on the Board;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">considering and making recommendations to the Board regarding the composition and chairmanship of the committees of the Board;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">instituting plans or programs for the continuing education of the Board and orientation of new directors;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing and making recommendations to the Board regarding corporate governance guidelines and matters; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overseeing periodic evaluations of the Board&#x2019;s performance, including committees of the Board and management.</font></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Nominating Committee is currently composed of two directors: Ms. Simpson and Mr. Spiegelman. Dr. Ways also served on the Nominating Committee until March 26, 2025. All members of the Nominating Committee are independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing rules). The Nominating Committee met three times during 2024. The Board has adopted a written Nominating Committee charter that is</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available to stockholders on the Company&#x2019;s website at www.sprucebio.com. The information on our website is not incorporated by reference into this Proxy Statement or our Annual Report.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Nominating Committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements, being over 21 years of age and having the highest personal integrity and ethics. The Nominating Committee also intends to consider such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of the Company&#x2019;s stockholders. However, the Nominating Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the Nominating Committee typically considers diversity (including gender, racial and ethnic diversity), age, skills and such other factors as it deems appropriate, given the current needs of the Board, to maintain a balance of knowledge, experience and capability.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Nominating Committee appreciates the value of thoughtful Board refreshment, and seeks to identify and consider qualities, skills and other director attributes that would enhance the composition of the Board. In the case of incumbent directors whose terms of office are set to expire, the Nominating Committee reviews these directors&#x2019; overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors&#x2019; independence. The Nominating Committee also takes into account the results of the Board&#x2019;s self-evaluation, which was conducted in 2024 on an individual basis. In the case of new director candidates, the Nominating Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing rules, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating Committee then uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Nominating Committee meets to discuss and consider the candidates&#x2019; qualifications and then selects a nominee for recommendation to the Board by majority vote.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Nominating Committee will consider director candidates recommended by stockholders. The Nominating Committee does not intend to alter the manner in which it evaluates candidates, including the minimum criteria set forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Nominating Committee to become nominees for election to the Board may do so by delivering a written recommendation to the Nominating Committee no later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#x2019;s annual meeting at 611 Gateway Boulevard, Suite 740, South San Francisco, California 94080, Attention: Corporate Secretary. Submissions must include the full name of the proposed nominee, a description of the proposed nominee&#x2019;s business experience for at least the previous five years, complete biographical information, a description of the proposed nominee&#x2019;s qualifications as a director and a representation that the nominating stockholder is a beneficial or record holder of the Company&#x2019;s stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Environmental, Social and Governance Matters</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are committed to developing and commercializing novel therapies for rare disorders with significant unmet medical need. We believe that our success depends on our ability to attract, develop and retain key personnel. We strive toward having a diverse team of employees and are committed to equality, inclusion and workplace diversity. For example, we provide various training and development programs that are intended to build and strengthen our employees&#x2019; leadership and professional skills, and have multiple employee community groups to foster dialogue and other actions related to diversity and inclusion.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="p1_stock"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholder Communications With the Board</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board has adopted a formal process by which stockholders may communicate with the Board or any of its directors. Stockholders who wish to communicate with the Board may do so by sending written communications addressed to 611 Gateway Boulevard, Suite 740, South San Francisco, California 94080, Attention: Corporate Secretary. Such written communications must set forth the name and address of the stockholder on whose behalf the communication is sent and the number of shares of our capital stock that are owned beneficially by such stockholder as of the date of the communication. All communications will be compiled by our Corporate Secretary and submitted to the Board or the individual directors on a periodic basis.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These communications will be reviewed by our Corporate Secretary, who will determine whether the communication should be presented to the Board. The purpose of this screening is to allow the Board to avoid having to consider irrelevant or inappropriate communications (such as advertisements, solicitations and hostile communications). The screening procedures have been approved by a majority of the independent directors.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;" id="p1_code"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code of Conduct</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a Code of Conduct that applies to all our employees, officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The full text of our Code of Conduct is posted on our website at www.sprucebio.com. The information on our website is not incorporated by reference into this Proxy Statement or our Annual Report. If we ever were to waive or amend any provision of the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or any person performing similar functions, we intend to satisfy our disclosure obligations, if any, with respect to any such waiver or amendment by posting such information on our website set forth above rather than by filing a Current Report on Form 8-K.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted an insider trading policy governing the purchase, sale, and/or other dispositions of the Company&#x2019;s securities by directors, officers, employees and consultants that is designed to promote compliance with insider trading laws, rules and regulations, as well as procedures designed to further the foregoing purposes. A copy of our insider trading policy is filed as an exhibit to our Annual Report on Form 10-K for our fiscal year ended December 31, 2024. In addition, it is the Company&#x2019;s intent to comply with applicable laws and regulations relating to insider trading.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibition on Speculative Trading</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of our insider trading policy, none of our employees, directors or consultants may engage in short sales, transactions in put options, call options or other derivative securities on an exchange or in any other organized market, or in any other inherently speculative transactions with respect to our capital stock. Further, none of our employees, directors or consultants may engage in hedging or monetization transactions at any time, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds with respect to our capital stock. In addition, none of our employees, directors or consultants may hold any of our securities in a margin account or otherwise pledge any of our securities, including as collateral for a loan, at any time.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The disclosure under the caption &#x201c;Prohibition on Speculative Trading&#x201d; is not to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clawback Policy</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, if we are required to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws as a result of misconduct, the Chief Executive Officer and Chief Financial Officer may be legally required to reimburse our Company for any bonus or other incentive-based or equity-based compensation they receive in accordance with the provisions of section 304 of the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sarbanes-Oxley Act of 2002, as amended. As required by SEC rules, we have also implemented an incentive recoupment policy that is compliant with the Dodd-Frank Wall Street Reform and Consumer Protection Act.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="p2"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proposal 2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Ratification of Selection of Independent Registered Public Accounting Firm</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee has selected BDO USA, P.C. as the Company&#x2019;s independent registered public accounting firm for the fiscal year ending December 31, 2025 and has further directed that the Board submit the selection of its independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. BDO USA, P.C. has audited the Company&#x2019;s financial statements since 2020. Representatives of BDO USA, P.C. are expected to be virtually present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the Company&#x2019;s amended and restated bylaws nor other governing documents or law require stockholder ratification of the selection of BDO USA, P.C. as the Company&#x2019;s independent registered public accounting firm. However, the Audit Committee is submitting the selection of BDO USA, P.C. to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of different independent auditors at any time during the year if they determine that such a change would be in the best interests of the Company and its stockholders.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The affirmative vote of the holders of a majority of the shares present virtually or represented by proxy and entitled to vote on the matter at the Annual Meeting will be required to ratify the selection of BDO USA, P.C..</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table represents aggregate fees charged by BDO USA, P.C. for the fiscal years ended December 31, 2024 and 2023.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:68.36%;box-sizing:content-box;"></td>
     <td style="width:15.74%;box-sizing:content-box;"></td>
     <td style="width:15.9%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:7.9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</font></p></td>
    </tr>
    <tr style="height:7.9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</font></p></td>
    </tr>
    <tr style="height:10.1pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit fees</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	473</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	577</font></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit-related Fees</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	&#x2014;</font></p></td>
    </tr>
    <tr style="height:10.1pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax fees</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	72</font></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Other Fees</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	&#x2014;</font></p></td>
    </tr>
    <tr style="height:10.1pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fees</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:2.25pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	473</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;border-bottom:2.25pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$	649</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audit Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Consists of fees billed for professional services for audit and quarterly review of our financial statements and review of our registration statements on Form S-8 and Form S-3, our definitive proxy statement and related services that are normally provided in connection with statutory and regulatory filings or engagements.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Consists of fees billed for tax advisory services.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Audit Fees and Tax Fees described above were pre-approved by the Audit Committee.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Approval Policies and Procedures</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to its pre-approval policy, the Audit Committee must review and approve, in advance, the scope and plans for the audits and the audit fees and approve in advance (or, where permitted under the rules and regulations of the SEC, subsequently) all non-audit services to be performed by the independent registered public accounting firm that are not otherwise prohibited by law and any associated fees. The Audit Committee may delegate to one or more members of the Audit Committee the authority to pre-approve audit and permissible non-audit services, as long as this pre-approval is presented to the full committee at scheduled meetings.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board Recommends<br>a Vote in Favor of Proposal 2</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="p3"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proposal 3 </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Reverse Stock Split</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board has approved and declared advisable an amendment to our Amended and Restated Certificate of Incorporation to combine the outstanding shares of our Common Stock into a lesser number of outstanding shares, a so-called &#x201c;reverse stock split.&#x201d; If approved by the stockholders as proposed, the Board would have the sole discretion to effect the Reverse Stock Split at any time after approval of such amendment and to fix the specific ratio for the Reverse Stock Split, provided that the ratio would be not less than one-for-five and not more than one-for-thirty, inclusive. The Board would also have the discretion to abandon the Reverse Stock Split prior to its effectiveness.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that enabling the Board to fix the specific ratio of the Reverse Stock Split within the stated range will provide our Board with the flexibility to react to then-current conditions and to implement the Reverse Stock Split in a manner designed to maximize the anticipated benefits for our stockholders. In fixing the ratio, the Board may consider, among other things, factors such as: the historical trading price and trading volume of our common stock; the number of shares of our common stock outstanding; the then-prevailing trading price and trading volume of our common stock; the anticipated impact of the Reverse Stock Split on the trading market for our common stock; potential financing opportunities; and prevailing general market and economic conditions.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Reverse Stock Split, if approved by our stockholders, would become effective upon the filing of a Certificate of Amendment setting forth the Reverse Stock Split (the &#x201c;Certificate of Amendment&#x201d;) with the Secretary of State of the State of Delaware, or at the later time set forth in the Certificate of Amendment. The exact timing of the amendment will be determined by the Board based on its evaluation as to when such action will be the most advantageous to our Company and our stockholders. In addition, the Board reserves the right, notwithstanding stockholder approval and without further action by the stockholders, to abandon the Reverse Stock Split if, at any time prior to the effectiveness of the filing of the amendment with the Secretary of State of the State of Delaware, the Board, in its sole discretion, determines that it is no longer in our best interest and the best interests of our stockholders to proceed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The proposed form of amendment to our Certificate of Incorporation to effect the Reverse Stock Split is attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to this proxy statement. However, the text of the proposed amendments is subject to revision to include such changes as may be required by the Secretary of State of the State of Delaware and as our Board deems necessary or advisable to effect the proposed amendment of our Certificate of Incorporation. Any amendment to our Certificate of Incorporation to effect the reverse stock split will include the reverse stock split ratio fixed by the Board, within the range approved by our stockholders.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reasons for the Reverse Stock Split</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary objective in effectuating the Reverse Stock Split would be to attempt to raise the per-share trading price of our common stock to meet Nasdaq&#x2019;s minimum listing requirements, which include, among other things, that our common stock have a per share bid price that is greater than or equal to $1.00 per share. On the Record Date, the closing bid price for our common stock on Nasdaq was $0.2951 per share. The Board also believes that a higher stock price may increase trading volume in our common stock and facilitate future financings by the Company.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nasdaq Listing Requirements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#x2019;s common stock is currently listed on the Nasdaq Capital Market under the symbol SPRB. As previously disclosed, on April 26, 2024, the Company received a deficiency letter (the &#x201c;Nasdaq Letter&#x201d;) from The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) notifying the Company that, for the last 30 consecutive business days, the closing bid price of the Company&#x2019;s common stock had not been maintained at the minimum required closing bid price of at least $1.00 per share, as required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#x201c;Bid Price Rule&#x201d;). In accordance with Nasdaq Listing Rule 5810(c)(3), the Company had 180 calendar days, or until October 23, 2024, to regain compliance with the Bid Price Rule. Subsequently, the Company received written notice from Nasdaq indicating that although the Company was not in compliance with the Bid Price</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule, Nasdaq determined that the Company was eligible for an additional 180 calendar day compliance period, or until April 21, 2025. Nasdaq&#x2019;s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market with the exception of the Bid Price Rule, and the Company provided written notice of its confirmation to cure the deficiency during the additional compliance period, by effecting a reverse stock split, if necessary.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to approve the Reverse Stock Split may have serious, adverse effects on the Company and its stockholders. Our common stock could be delisted from Nasdaq because shares of our common stock may continue to trade below the requisite $1.00 per share price needed to comply with the listing requirements of Nasdaq and maintain our listing. Our shares may then be quoted on the OTC Bulletin Board or other small trading markets, which are generally considered to have less trading volume and be less efficient markets. Any such alternative would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of or obtain accurate quotations as to the market value of our common stock. Many investors likely would not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange, or other reasons. Any such alternative would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of or obtain accurate quotations as to the market value of our common stock. Moreover, if our common stock is delisted, it may come within the definition of &#x201c;penny stock&#x201d; under the Exchange Act, which imposes additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors. These requirements may reduce trading activity in the secondary market for our common stock and may impact the ability or willingness of broker-dealers to sell our securities which could limit the ability of stockholders to sell their securities in the public market and limit our ability to attract and retain qualified employees or raise additional capital in the future.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On the Record Date, our common stock closed at $0.2951 per share on Nasdaq. The Reverse Stock Split, if effected, should have the immediate effect of increasing the price of our common stock as reported on Nasdaq, therefore reducing the risk that our common stock could be delisted from Nasdaq. However, we cannot assure you that the price of our common stock will not decline after the Reverse Stock Split. Under new Nasdaq Rule 5810(c)(3)(A)(iv), if the price of our common stock fails to satisfy the $1.00 minimum bid price requirement for a 30 consecutive trading day period within one year after effectiveness of the Reverse Stock Split or if the Company has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, then the Company shall not be eligible for any compliance period specified in Rule 5810(c)(3)(A) and the Listing Qualifications Department will issue a Staff Delisting Determination under Rule 5810 with respect to that security, then the common stock would be subject to delisting by Nasdaq without any opportunity for a cure period.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board strongly believes that the Reverse Stock Split is necessary to maintain our listing on Nasdaq. Accordingly, the Board recommended that our stockholders approve the Reverse Stock Split Proposal to effect the Reverse Stock Split and directed that this proposal be submitted to our stockholders for approval at the Special Meeting, including for the reasons discussed below.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Appeal to a Broader Range of Investors to Generate Greater Investor Interest in the Company</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An increase in our stock price may make our common stock more attractive to investors. Brokerage firms may be reluctant to recommend lower-priced securities to their clients. Many institutional investors have policies prohibiting them from holding lower-priced stocks in their portfolios, which reduces the number of potential purchasers of our common stock. Investment funds may also be reluctant to invest in lower-priced stocks. Investors may also be dissuaded from purchasing lower-priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide coverage of lower-priced stocks. Giving the Board the ability to effect the Reverse Stock Split, and thereby increase the price of our common stock, would give the Board the ability to address these issues if it is deemed necessary.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improve the Perception of Our common stock as an Investment Security</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		The Board believes that effecting the Reverse Stock Split is one potential means of increasing the share price of our common stock to improve the perception of our common stock as a viable investment security.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lower-priced stocks have a perception in the investment community as being risky and speculative, which may negatively impact not only the price of our common stock, but also our market liquidity.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Increase the Number of Shares of Common Stock Available for Issuance</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board believes that the effective increase our available for issuance shares of common stock that would result from a Reverse Stock Split is necessary in order to provide us with the flexibility to issue additional shares in the future on a timely basis in connection with potential financings, strategic relationships, business combinations and strategic transactions, among other purposes, without the potential delay and expense associated with convening a special meeting of the stockholders. We have funded our operations to date primarily from the issuance and sale of our securities, and we currently have a limited number of authorized and unreserved shares that are available for future issuance.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, the report of our independent registered public accounting firm that accompanies our audited consolidated financial statements for the year ended December 31, 2024 contained an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. As discussed in our Annual Report, based on our current operating plan, the Company&#x2019;s cash and cash equivalents of $38.8 million as of December 31, 2024 will be insufficient to fund its planned operations and debt obligations for at least 12 months following the filing date of the Annual Report. The Company&#x2019;s ability to continue as a going concern will require the Company to raise additional capital to fund the Company's operations and there can be no assurance that additional financing will be available to the Company or that such financing, if available, will be available on terms acceptable to the Company. Accordingly, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. Our estimate as to how long we expect our existing cash and cash equivalents to be available to fund our operations is based on assumptions that may prove inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. If we are unable to raise sufficient additional capital in the very near term, our current cash, cash equivalents and restricted cash would be insufficient to sustain our operations and, among other things, stockholder value would be harmed. Accordingly, if our stockholders do not approve this proposal, we will be limited in our ability to raise additional capital, which would materially and adversely affect our financial condition and our ability to continue as a going concern may be materially and adversely affected. Even if this proposal is approved by our stockholders, there is no assurance that we will be successful in raising additional financing. Based on our current business plans, we will continue to require additional capital in the very near term to fund our operating expenses and capital expenditure requirements, or we may need to further curtail or cease operations.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success also depends in part on our continued ability to attract, retain and motivate highly qualified directors, management and key personnel. If the Reverse Stock Split Proposal is not approved by our stockholders, the lack of available authorized shares of common stock to provide future equity incentive opportunities could adversely impact our ability to achieve these goals. In short, if our stockholders do not approve this proposal, we may not be able to access the capital markets, complete corporate collaborations or partnerships, attract, retain and motivate directors and employees, and pursue other business opportunities integral to our growth and success. The effective increase in the number of available shares of common stock upon approval and implementation of a Reverse Stock Split will not, by itself, have an immediate dilutive effect on our current stockholders. However, if this proposal is approved, unless otherwise required by applicable law or stock exchange rules, the Board will be able to issue additional shares of common stock from time to time in its discretion without further action or authorization by the stockholders. The newly available authorized shares of common stock would be issuable for any proper corporate purpose, including capital raising transactions of equity or convertible debt securities, the establishment of collaborations or other strategic agreements, stock splits, stock dividends, issuance under current or future equity incentive plans, future acquisitions, investment opportunities, or for other corporate purposes. The future issuance of additional shares of common stock or securities convertible into our common stock may occur at times or under circumstances that could result in a dilutive effect on the earnings per share, book value per share, voting power and percentage interest of the present holders of our common stock, some of whom have preemptive rights to subscribe for additional shares that we may issue.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than future issuances under our 2020 Equity Incentive Plan, 2016 Equity Incentive Plan, outstanding warrants, possible issuances of equity, convertible debt, or other securities, and the possible issuance of securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercisable for our common stock to banks or other financial institutions, the Board currently has no specific plans, arrangements or understandings to issue the additional authorized shares of common stock that will effectively result from approval and implementation of a Reverse Stock Split. As of the date of this proxy statement, we have a sufficient number of authorized shares of common stock under our Amended and Restated Certificate of Incorporation, as amended, as presently in effect to issue shares of common stock upon the exercise of all outstanding equity-linked obligations as they come due.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Reverse Stock Split alone would have no effect on our authorized capital stock, and the total number of authorized shares would remain the same as before the reverse stock split. This would have the effect of increasing the number of shares of common stock available for issuance. As of the Record Date, the number of authorized shares of our common stock was 200,000,000 shares, which will not be affected by the Reverse Stock Split.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Criteria to be Used for Determining Whether to Implement Reverse Stock Split</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In determining whether to implement the Reverse Stock Split and selecting the exchange ratio, the Board will consider various factors such as:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the total number of shares of common stock outstanding;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Nasdaq Capital Market requirements for the continued listing of our common stock;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the historical trading price and trading volume of our common stock;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the then prevailing trading price and trading volume for our common stock;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the anticipated impact of the Reverse Stock Split on the trading price of and market for our common stock;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential financing opportunities; </font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prevailing general market and economic conditions; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and when our Board desires to have the additional authorized but unissued shares of common stock that will effectively result from the implementation of a Reverse Stock Split when available to provide the flexibility to use our common stock for business and/or financial purposes.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board will have sole discretion as to any implementation of, and the exact timing and actual ratio of, the Reverse Stock Split within the range of ratios specified in this proposal. The Board may also determine that the Reverse Stock Split is no longer in the best interests of our Company and our stockholders and decide to abandon the Reverse Stock Split at any time before, during or after the Special Meeting and prior to its effectiveness, without further action by the stockholders.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Associated with the Reverse Stock Split</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are risks associated with the Reverse Stock Split, including that the Reverse Stock Split may not result in a lasting increase in the per share price of our common stock.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company cannot predict whether, or for how long, the Reverse Stock Split will increase the market price for our common stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market price per share will achieve the $1.00 minimum bid price requirement for a sufficient period for our common stock to be approved for continued listing by Nasdaq;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we would otherwise meet the listing requirements that would allow continued listing of our common stock on Nasdaq;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market price per share of our common stock after the Reverse Stock Split will rise in proportion to the reduction in the number of shares of our common stock outstanding before the effective time of the Reverse Stock Split (the &#x201c;Effective Time&#x201d;);</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Reverse Stock Split will result in a per share price that will attract brokers and investors who do not trade in lower-priced stocks;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Reverse Stock Split will result in a per share price that will increase the ability of the Company to attract and retain employees; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Reverse Stock Split would promote greater liquidity for our stockholders with respect to their shares.</font></div></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Reverse Stock Split would reduce the number of outstanding shares of our common stock without reducing the number of shares of available but unissued common stock, increasing the number of authorized but unissued shares of common stock. Therefore, the number of shares of our common stock that are authorized and unissued will increase relative to the number of issued and outstanding shares of our common stock following the Reverse Stock Split. The effective increase in the authorized number of shares of our common stock as a result of a Reverse Stock Split could, under certain circumstances, have anti-takeover implications. The additional shares of common stock that would become available for issuance if this proposal is approved and a Reverse Stock Split is implemented could be used by us to oppose a hostile takeover attempt or to delay or prevent changes in control or our management. For example, without further stockholder approval, the Board could adopt a &#x201c;poison pill&#x201d; which would, under certain circumstances related to an acquisition of our securities that is not approved by the Board, give certain holders the right to acquire additional shares of our common stock at a low price. The Board also could strategically sell shares of common stock in a private transaction to purchasers who would oppose a takeover or favor the current Board. Although this proposal has been prompted by business and financial considerations and not by the threat of any hostile takeover attempt (nor is the Board currently aware of any such attempts directed at us), stockholders should be aware that approval of this proposal could facilitate future efforts by us to deter or prevent changes in control, including transactions in which the stockholders might otherwise receive a premium for their shares over then current market prices.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Board may authorize the issuance of the remaining authorized and unissued shares without further stockholder action for a variety of purposes, except as such stockholder approval may be required in particular cases by our Certificate of Incorporation, applicable law, or the rules of any stock exchange on which our securities may then be listed. The issuance of additional shares would be dilutive to our existing stockholders and may cause a decline in the trading price of our common stock.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock will also be based on the performance of the Company and other factors, some of which are unrelated to the number of shares outstanding. If the Reverse Stock Split is effected and the market price of our common stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of the Company may be greater than would occur in the absence of the Reverse Stock Split.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principal Effects of a Reverse Stock Split</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below illustrates certain, but not all, possible reverse stock split ratios, together with the implied number of issued and outstanding shares of the common stock resulting from implementation of the Reverse Stock Split based on 42,231,285 shares of the common stock outstanding as of the Record Date.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:16.667%;box-sizing:content-box;"></td>
     <td style="width:16.667%;box-sizing:content-box;"></td>
     <td style="width:16.667%;box-sizing:content-box;"></td>
     <td style="width:16.667%;box-sizing:content-box;"></td>
     <td style="width:16.667%;box-sizing:content-box;"></td>
     <td style="width:16.667%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.017in;vertical-align:middle;padding-bottom:0in;padding-right:0.017in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">After Reverse Stock Split if 5:1 Ratio is Selected</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:5pt;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">After Reverse Stock Split if 10:1 Ratio is Selected</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:5pt;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">After Reverse Stock Split if 20:1 Ratio is Selected</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:5pt;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">After Reverse Stock Split if</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.1pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">30:1 Ratio is Selected</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:5pt;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares of common stock issued and outstanding</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,231,285</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,446,257</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,223,128</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,111,564</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,407,709</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock issuable upon exercise of stock options</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,284,576</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">656,915</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328,457</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,228</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109,485</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock issuable upon exercise of warrants</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,794,341</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,958,868</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,479,434</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739,717</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">493,144</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock issuable upon vesting of restricted stock units</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,279,435</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">455,887</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,943</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,971</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,981</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock reserved under the 2020 Plan for future grants</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,312,253</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">862,450</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">431,225</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">215,612</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,741</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock reserved under the 2020 ESPP</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,349,079</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269,815</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134,907</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,453</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,969</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorized but unissued and reserved</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,749,031</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,349,806</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,174,903</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,587,451</font></p></td>
     <td style="padding-top:0.021in;padding-left:0.017in;vertical-align:bottom;padding-bottom:0.021in;padding-right:0.017in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,391,634</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(1)</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Excludes the effect of fractional share treatment.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exploring various sources of financing, including through potential future sales of common stock or other securities. There can be no assurance, however, even if the Reverse Stock Split is approved and implemented, that any financing transaction would be undertaken or completed. If we are unable to successfully raise sufficient additional capital, through future sales of common stock or other securities or through strategic and collaborative arrangements, we will not have sufficient cash to fund our planned business operations and or may not be able to continue as a going concern.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the Record Date, we had 42,231,285 shares of common stock issued and outstanding, 3,284,576 shares of common stock reserved for issuance upon the exercise of outstanding options, 2,279,435 shares reserved for issuance upon vesting of restricted stock units, 14,794,341 shares of common stock reserved for issuance upon the exercise of outstanding warrants,  no shares of common stock reserved for future issuance under the Company&#x2019;s 2016 Equity Incentive Plan, 4,312,253 shares of common stock reserved for future issuance under the Company&#x2019;s 2020 Equity Incentive Plan and 1,349,079 shares of common stock reserved for future issuance under the Company&#x2019;s 2020 Employee Stock Purchase Plan. As of the Record Date, we have no shares of preferred stock outstanding, which would not change with the effectiveness of the Reverse Stock Split.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Procedure for Implementing the Reverse Stock Split</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Beneficial Holders of Common Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the implementation of the Reverse Stock Split, we intend to treat shares of our common stock held by stockholders through a bank, broker or other nominee in the same manner as registered stockholders whose shares are registered in their own names. Banks, brokers or other nominees will be instructed to effect the Reverse Stock Split for their beneficial holders holding our common stock in street name. However, these banks, brokers or other nominees may have different procedures than registered stockholders for processing the Reverse Stock Split. Stockholders who hold shares of our common stock with a bank, broker or other nominee and who have any questions in this regard are encouraged to contact their banks, brokers or other nominees.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Registered &#x201c;Book-Entry&#x201d; Holders of Common Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our registered holders of common stock may hold some or all of their shares of our common stock electronically in book-entry form with the transfer agent. These stockholders do not have stock certificates evidencing their ownership of the common stock. They are, however, provided with statements reflecting the number of shares registered in their accounts. Stockholders who hold shares of our common stock electronically in book-entry form with the transfer agent will not need to take action to receive evidence of their shares of post-Reverse Stock Split common stock.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Holders of Certificated Shares of Common Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders holding shares of our common stock in certificated form will be sent a transmittal letter by the transfer agent after the effective time of the Reverse Stock Split. The letter of transmittal will contain instructions on how a stockholder should surrender his, her or its certificate(s) representing shares of our common stock (the &#x201c;Old Certificates&#x201d;) to the transfer agent. Unless a stockholder specifically requests a new paper certificate or holds restricted shares, upon the stockholder&#x2019;s surrender of all of the stockholder&#x2019;s Old Certificates to the transfer agent, together with a properly completed and executed letter of transmittal, the transfer agent will register the appropriate number of shares of post-Reverse Stock Split common stock electronically in book-entry form and provide the stockholder with a statement reflecting the number of shares registered in the stockholder&#x2019;s account. No stockholder will be required to pay a transfer or other fee to exchange his, her or its Old Certificates. Until surrendered, we will deem outstanding Old Certificates held by stockholders to be cancelled and only to represent the number of shares of post-Reverse Stock Split common stock to which these stockholders are entitled. Any Old Certificates submitted for exchange, whether because of a sale, transfer or other disposition of stock, will automatically be exchanged for the appropriate number of shares of post-Reverse Stock Split common stock. If an Old Certificate has a restrictive legend on its reverse side, a new certificate will be issued with the same restrictive legend on its reverse side.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATE(S) AND SHOULD NOT SUBMIT ANY STOCK CERTIFICATE(S) UNTIL REQUESTED TO DO SO.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fractional Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No fractional shares of common stock will be issued as a result of any Reverse Stock Split. Instead, in lieu of any fractional shares to which a stockholder of record would otherwise be entitled as a result of a Reverse Stock Split, we will pay cash (without interest) equal to such fraction multiplied by the average of the closing sales prices of the common stock on The Nasdaq Capital Market during regular trading hours for the five consecutive trading days immediately preceding the Effective Date (with such average closing sales prices being adjusted to give effect to a Reverse Stock Split) (&#x201c;Fractional Share Payment&#x201d;). After such Reverse Stock Split, a stockholder otherwise entitled to a fractional interest will not have any voting, dividend or other rights with respect to such fractional interest except to receive payment as described above.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where we are domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective time may be required to be paid to the designated agent for each such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds may have to seek to obtain them directly from the state to which they were paid.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effect of the Reverse Stock Split on Outstanding Stock Options, Warrants, and Employee Plans</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based upon the reverse stock split ratio, proportionate adjustments are generally required to be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding options, warrants entitling the holders to purchase shares of common stock. This would result in approximately the same aggregate price being required to be paid under such options, warrants or convertible preferred stock upon exercise, and approximately the same value of shares of common stock being delivered upon such exercise immediately following the Reverse Stock Split as was the case immediately preceding the Reverse Stock Split. The number of shares reserved for issuance pursuant to these securities will be reduced proportionately based upon the reverse stock split ratio.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential Effects of the Reverse Stock Split</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our stockholders approve the Reverse Stock Split and the Board effects it, the number of shares of common stock authorized and issued and outstanding will be reduced due to the Reverse Stock Split, depending upon the ratio determined by the Board. The Reverse Stock Split will affect all holders of our common stock uniformly and will not affect any stockholder&#x2019;s percentage ownership interest in the Company, except that as described above in &#x201c;-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Fractional Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; record holders of common stock otherwise entitled to a fractional share as a result of the Reverse Stock Split because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will automatically be entitled to receive the Fractional Share Payment automatically and without any action by the holder. In addition, the Reverse Stock Split will not affect any stockholder&#x2019;s proportionate voting power (subject to the treatment of fractional shares).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Reverse Stock Split will not change the terms of the common stock. After the Reverse Stock Split, the shares of common stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to the common stock now authorized. The common stock will remain fully paid and non-assessable. The Reverse Stock Split may result in some stockholders owning &#x201c;odd-lots&#x201d; of less than 100 shares of our common stock. Brokerage commissions and other costs of transactions in odd-lots are generally higher than the costs of transactions in &#x201c;round-lots&#x201d; of even multiples of 100 shares.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the Effective Time, we will continue to be subject to the periodic reporting and other requirements of the Exchange Act. Subject to our compliance with applicable continued listing requirements, our common stock will continue to be listed on the Nasdaq Capital Market and traded under the symbol &#x201c;SPRB,&#x201d; although the exchange will add the letter &#x201c;D&#x201d; to the end of the trading symbol for a period of 20 trading days after the Effective Time to indicate that a Reverse Stock Split has occurred. If a Reverse Stock Split is effected, then after the Effective Time, our common stock will have a new Committee on Uniform Securities Identification Procedures (&#x201c;CUSIP&#x201d;) number, which is a number used to identify our equity securities, and stock certificates for our common stock with the older CUSIP number will need to be exchanged for stock certificates with the new CUSIP number by following the procedures described above under &#x201c;-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Procedure for Implementing the Reverse Stock Split</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; The Reverse Stock Split is not intended as, and will not have the effect of, a &#x201c;going private transaction&#x201d; as described by Rule 13e-3 under the Exchange Act.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Matters</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The proposed amendment to our Certificate of Incorporation will not affect the par value of our common stock. As a result, at the effective time of the Reverse Stock Split, the stated capital on our balance sheet attributable to the common stock will be reduced in the same proportion as the reverse stock split ratio, and the additional paid-in capital account will be credited with the amount by which the stated capital is reduced. The per share net income or loss and net book value of the common stock will be reclassified for prior periods to conform to the post-Reverse Stock Split presentation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain U.S. Federal Income Tax Consequences of the Reverse Stock Split</font></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of certain material U.S. federal income tax consequences of the Reverse Stock Split that generally are expected to be applicable to U.S. Holders (as defined below) of our common stock who hold their common shares, both before and after the Reverse Stock Split, as capital assets within the meaning of Section 1221 of Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;) (generally property held for investment). This summary is based on provisions of the Code, applicable Treasury Regulations promulgated thereunder, judicial authority and current administrative rulings and practices as in effect on the date of this proxy statement. Changes to these laws could alter the tax consequences described below, possibly with retroactive effect, which may result in the U.S. federal income tax consequences of the Reverse Stock Split differing substantially from the consequences summarized below. We have not sought and will not seek an opinion of counsel or a ruling from the Internal Revenue Service regarding the U.S. federal income tax consequences of the Reverse Stock Split and there can be no assurance that the Internal Revenue Service or the courts will accept the positions expressed below.</font></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This discussion is for general information only and does not purport to consider all aspects of U.S. federal income taxation that might be relevant to a U.S. Holder. This discussion does not address the tax consequences which</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may apply to stockholders subject to special rules, such as financial institutions, insurance companies, tax-exempt organizations, dealers in securities, real estate investment trusts, regulated investment companies, stockholders who hold their pre-Reverse Stock Split shares through individual retirement or other tax-deferred accounts, stockholders who are not U.S. Holders (as defined below), stockholders who have a functional currency other than the U.S. dollar, partnerships, S corporations or other entities or arrangements classified as partnerships or disregarded entities for U.S. federal income tax purposes (or persons holding our common stock through such entities), stockholders who hold the pre-Reverse Stock Split shares as part of a straddle, hedge, conversion transaction or other integrated or risk reduction transaction, stockholders who hold the pre-Reverse Stock Split shares as qualified small business stock within the meaning of Section 1202 of the Code or Section 1244 stock for purposes of Section 1244 of the Code, stockholders who acquired their common stock in a transaction subject to the gain rollover provisions of Section 1045 of the Code, or stockholders who acquired their pre-Reverse Stock Split shares pursuant to the exercise of employee stock options or otherwise as compensation.</font></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, this summary does not address: (a) the tax consequences of transactions effectuated before, after or at the same time as the Reverse Stock Split, whether or not they are in connection with the Reverse Stock Split; (b) any U.S. federal non-income tax consequences of the Reverse Stock Split, including estate, gift or other tax consequences; (c) any state, local or non-U.S. tax consequences of the Reverse Stock Split; (d) the application of the alternative minimum tax, the Medicare contribution tax on net investment income, or the special tax accounting rules under Section 451(b) of the Code, or (e) tax consequences to holders of options, warrants or similar rights to acquire our common stock. Stockholders are urged to consult their own tax advisors to determine the particular consequences to them.</font></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this discussion, a &#x201c;U.S. Holder&#x201d; means a beneficial owner of shares of our common stock that is any of the following:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an individual who is a citizen or resident of the United States or someone treated as a U.S. citizen or resident for U.S. federal income tax purposes;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a trust if (i) a U.S. court can exercise primary supervision over the trust&#x2019;s administration and one or more &#x201c;United States persons&#x201d; (within the meaning of Section 7701(a)(30) of the Code) are authorized or have the authority to control all substantial decisions of the trust or (ii) it has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes.</font></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax Consequences of the Reverse Stock Split</font></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Reverse Stock Split should constitute a &#x201c;recapitalization&#x201d; for U.S. federal income tax purposes. In general, the U.S. federal income tax consequences of a Reverse Stock Split will vary depending upon whether a U.S. Holder receives cash for fractional shares or solely a reduced number of shares of common stock in exchange for its pre-Reverse Stock Split shares of common stock. A U.S. Holder that receives solely a reduced number of shares of common stock generally will not recognize gain or loss in the Reverse Stock Split. A U.S. Holder&#x2019;s aggregate tax basis in the reduced number of shares of common stock should equal the U.S. Holder&#x2019;s aggregate tax basis in its pre-Reverse Stock Split shares of common stock and such U.S. Holder&#x2019;s holding period in the reduced number of shares will include the holding period in its pre-Reverse Stock Split shares of common stock exchanged. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of common stock surrendered to the shares of common stock received in a recapitalization pursuant to the Reverse Stock Split. U.S. Holders should consult their tax advisors as to application of the foregoing rules where shares of common stock were acquired at different times or at different prices.</font></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No gain or loss will be recognized by the Company as a result of the proposed Reverse Stock Split.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash in Lieu of Fractional Shares</font></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A U.S. Holder that receives cash in lieu of a fractional share as a result of the Reverse Stock Split will be treated as having received the fractional shares pursuant to the Reverse Stock Split and then as having exchanged the fractional shares for cash in a redemption by the Company and generally should recognize gain or loss equal to the difference, if any, between the amount of cash received in lieu of fractional shares and the stockholder&#x2019;s adjusted basis allocable to the fractional share interests. Such gain or loss will be a long-term capital gain or loss if the pre-Reverse Stock Split shares were held for more than one year. Long-term capital gains of individuals are generally subject to tax at reduced rates. There are limitations on the deductibility of capital losses under the Code. A U.S. Holder&#x2019;s aggregate tax basis in the reduced number of shares of common stock should equal the U.S. Holder&#x2019;s aggregate tax basis in its pre-Reverse Stock Split shares of common stock decreased by the basis allocated to the fractional share for which such U.S. Holder is entitled to receive cash, and the holding period of the reduced number of shares of common stock received should include the holding period of the pre-Reverse Stock Split shares of common stock exchanged.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Information Reporting and Backup Withholding</font></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A holder of shares of common stock may be subject to information reporting and backup withholding on cash paid in lieu of fractional shares in connection with the Reverse Stock Split. To avoid backup withholding, each holder of shares of common stock that does not otherwise establish an exemption should provide its taxpayer identification number and comply with the applicable certification procedures. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or credit against a U.S. Holder&#x2019;s U.S. federal income tax liability, provided the required information is timely and properly furnished to the Internal Revenue Service. Holders of shares of common stock should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption, as well as the procedures for obtaining a credit or refund if backup withholding is imposed.</font></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preceding discussion is intended only as a summary of certain material U.S. federal income tax consequences of the Reverse Stock Split. It is not a complete analysis or discussion of all potential tax effects that may be important to a particular holder. All holders of our common stock should consult their own tax advisors as to the specific tax consequences of the Reverse Stock Split them, including record retention and tax-reporting requirements, and the applicability and effect of any U.S. federal, state, local and non-U.S. tax laws.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE FOREGOING IS A SUMMARY OF CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT, AND DOES NOT CONSTITUTE A TAX OPINION. EACH HOLDER OF OUR COMMON SHARES SHOULD CONSULT ITS TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment Effective Date</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the proposed amendment to the Certificate of Incorporation as described in this Proposal No. 3 is approved by the stockholders, upon the Board&#x2019;s determination, if any, to effectuate the Reverse Stock Split and of the ratio (within the range approved pursuant to this Proposal No. 3) of such Reverse Stock Split, the Company will file the Certificate of Amendment reflecting the adopted amendment with the Secretary of State of the State of Delaware. The Certificate of Amendment will be effective upon its filing or at such later time as specified in the Certificate of Amendment. If the stockholders do not approve this Proposal No. 3, the Certificate of Amendment will not be filed with the Secretary of State of the State of Delaware.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dissenters&#x2019; Rights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No dissenters&#x2019; rights are available under the General Corporation Law of the State of Delaware or under the Certificate of Incorporation or the Bylaws to any stockholder who dissents from this Proposal No. 3.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Appraisal Rights</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stockholders are not entitled to appraisal rights with respect to the Reverse Split, and we will not independently provide stockholders with any such right.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interests of Directors and Executive Officers</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our directors and executive officers do not have substantial interest, directly or indirectly, in the matters set forth in this proposal except to the extent of their ownership of shares of common stock or any other of our securities.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board Recommends<br>a Vote in Favor of Proposal 3.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h2><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="p4"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proposal 4</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Approval of an Adjournment to the Annual Meeting, if Necessary,</font></h2><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to Solicit Additional Proxies</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Annual Meeting is convened and a quorum is present but there are not sufficient votes to approve Proposal 3, our proxy holders may move to adjourn the Annual Meeting at that time in order to enable the Board to solicit additional proxies.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this proposal, we are asking our stockholders to authorize the holder of any proxy solicited by the Board to vote in favor of adjourning the Annual Meeting to another time and place, if necessary or appropriate (as determined in good faith by the Board), to solicit additional proxies in the event there are not sufficient votes to approve Proposal 3. If our stockholders approve this proposal, we could adjourn the Annual Meeting and any adjourned or postponed session of the Annual Meeting and use the additional time to solicit additional proxies, including the solicitation of proxies from our stockholders that have previously voted. Among other things, approval of this proposal could mean that, even if we had received proxies representing a sufficient number of votes to defeat Proposal 3, we could adjourn the Annual Meeting without a vote on such proposal and seek to convince our stockholders to change their votes in favor of such proposal.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If it is necessary or appropriate (as determined in good faith by the Board) to adjourn the Annual Meeting, no notice of the adjourned meeting is required to be given to our stockholders, other than an announcement at the Annual Meeting of the time and place to which the Annual Meeting is adjourned, so long as the meeting is adjourned for 30 days or less and no new record date is fixed for the adjourned meeting. At the adjourned meeting, we may transact any business which might have been transacted at the original meeting.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board Recommends<br>a Vote in Favor of Proposal 4.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="execo"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTIVE OFFICERS</font></h1><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our executive officers serves at the discretion of the Board. The determination as to which of our employees qualify as executive officers was made by the Board in accordance with the rules of the SEC. Biographical information for our executive officers as of the Record Date is set forth below. The following table identifies our current executive officers, their age, and their respective offices and positions. Biographies of Dr. Szwarcberg and Mr. Grey are described under the section titled &#x201c;Proposal 1 Election of Directors &#x2013; Directors Continuing in Office until the Company&#x2019;s 2026 Annual Meeting of Stockholders&#x201d;.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:43.28%;box-sizing:content-box;"></td>
     <td style="width:9.12%;box-sizing:content-box;"></td>
     <td style="width:47.6%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:0.25pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:0.25pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Samir Gharib</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Financial Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, biographical information regarding Dr. Szwarcberg is set forth under &#x201c;Proposal 1: Election of Directors.&#x201d;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Samir Gharib</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our President since January 2022 and as our Chief Financial Officer since May 2020. From September 2019 to May 2020, Mr. Gharib provided consulting services to various companies with Benchmark Financial Partners (&#x201c;Benchmark&#x201d;), a strategic financial advisory firm. From October 2018 to September 2019, Mr. Gharib was the Chief Financial Officer of Stemedica Cell Technologies, Inc., a global pharmaceutical company focused on the development and commercialization of cell therapeutics for underserved medical conditions. From September 2017 to October 2018, Mr. Gharib served as Managing Director of Benchmark. From October 2013 to September 2017, Mr. Gharib held positions of increasing responsibility at Revance Therapeutics, Inc., a commercial-stage biotechnology company, including Vice President of Finance and Administration. From January 2011 to September 2013, Mr. Gharib was the Corporate Controller, Director of Finance for Talon Therapeutics, Inc. Mr. Gharib has been an advisor to Berkeley SkyDeck since January 2020. Mr. Gharib received a Bachelor of Science and M.B.A. from the Haas School of Business at the University of California at Berkeley, and is an active Certified Public Accountant licensed in the State of California.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="security"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information regarding beneficial ownership of our common stock as of April 1, 2025 (the &#x201c;Ownership Measurement Date&#x201d;) by:</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each of our directors, including the nominees named herein;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each of our named executive officers; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all of our current executive officers and directors as a group.</font></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. In computing the number of shares beneficially owned by a stockholder and the percentage ownership of such stockholder, we deemed to be outstanding all shares subject to options held by the stockholder that are currently exercisable or exercisable as of May 31, 2025, which is 60 days after the Ownership Measurement Date. These shares are deemed to be outstanding and beneficially owned by the stockholder holding such options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other stockholder. Except as indicated by the footnotes below and subject to community property laws where applicable, we believe, based on information furnished to us, that the stockholders named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to applicable community property laws. This table is based upon information supplied by officers and directors and Schedules 13D and 13G filed with the SEC.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable percentage ownership is based on 42,231,285 shares of our common stock outstanding as of the Ownership Measurement Date.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise indicated, the address for each stockholder listed in the table below is c/o Spruce Biosciences, Inc., 611 Gateway Boulevard, Suite 740, South San Francisco, California 94080.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:63.48%;box-sizing:content-box;"></td>
     <td style="width:18.7%;box-sizing:content-box;"></td>
     <td style="width:17.82%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:0.25pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Beneficial Owner</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:0.25pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares Beneficially Owned</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:0.25pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage of Shares Beneficially Owned</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Greater than 5% Holders:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bradley L. Radoff</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,975,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4%</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities affiliated with Rock Springs Management LP</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,437,125</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Abingworth Bioventures VII LP</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,989,018</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">HealthCap VIII, L.P.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,977,621</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1%</font></p></td>
    </tr>
    <tr style="height:2.15pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Armistice Capital Master Fund Ltd.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,169,245</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1%</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="text-indent:7.006%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Named Executive Officers and Directors:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="text-indent:7.006%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,217,191</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8%</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Samir Gharib</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">777,768</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ralph William Charlton III, M.D., M.A.S.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(8)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333,214</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Grey</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(9)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">439,745</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Camilla V. Simpson, M.Sc.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(10)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,617</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Daniel Spiegelman</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(11)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,565</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bali Muralidhar, M.D., Ph.D.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(12)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,500</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Percival Barretto-Ko</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(13)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:63.48%;box-sizing:content-box;"></td>
     <td style="width:18.7%;box-sizing:content-box;"></td>
     <td style="width:17.82%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kirk Ways, M.D., Ph.D.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(14)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,625</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tiba Aynechi, Ph.D.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(15)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,500</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All current executive officers and directors as a group (9 persons)</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(16)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,061,511</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;margin-right:4.843%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9%</font></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:66.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Represents beneficial ownership of less than 1%.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	Consists of (i) 3,800,000 shares of common stock held by Bradley Radoff and (ii) 175,000 shares of common stock owned by The Radoff Family Foundation (&#x201c;Radoff Foundation&#x201d;). Mr. Radoff, as a director of Radoff Foundation, may also be deemed the beneficial owner of the 175,000 shares owned by the Radoff Foundation. Mr. Radoff has sole voting and dispositive power over all of the shares owned by himself and the Radoff Foundation. The address of the principal office of Mr. Radoff and Radoff Foundation is 2727 Kirby Drive, Unit 29L, Houston, Texas 77098.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	Consists of (i) 2,328,500 shares of common stock held by Rock Springs Capital Master Fund LP (&#x201c;Master Fund&#x201d;), (ii) 280,625 shares of common stock held by Four Pines Master Fund LP (&#x201c;Four Pines&#x201d;), (iii) 690,907 shares of common stock subject to warrants exercisable within 60 days of the Ownership Measurement Date held by Master Fund and (iv) 137,093 shares of common stock subject to warrants exercisable within 60 days of the Ownership Measurement Date held by Four Pines. Rock Springs Capital Management, LP (&#x201c;RSCM&#x201d;) serves as the investment manager to each of the Master Fund and Four Pines. Rock Springs Capital LLC (&#x201c;RSC&#x201d;) is the general partner of RSCM. Each of RSCM and RSC may be deemed to be the indirect beneficial owners of 2,726,689 shares of common stock, and may be deemed to have shared voting and dispositive power with respect to such shares. The address of RSCM and RSC is 650 South Exeter St., Suite 1070, Baltimore, MD 21202. The address of Master Fund is c/o Walkers Corporate Limited. Cayman Corporate Centre. 27 Hospital Road, George Town, Grand Cayman, KY1-9008, Cayman Islands.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)	Consists of (i) 2,896,518 shares of common stock held by Abingworth Bioventures VII LP (&#x201c;Abingworth VII&#x201d;) and (ii) 92,500 shares of common stock issuable upon the exercise of vested stock options held by Bali Muralidhar, a managing partner of Abingworth. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth VII. The shares subject to the options held by Dr. Muralidhar are deemed to be beneficially owned by Abingworth LLP. The number of shares beneficially owned by Abingworth LLP is limited by beneficial ownership limitations applicable to the exercise of warrants purchased in the Private Placement by Abingworth VII, which limit the number of shares such entity can beneficially own after the exercise of warrants to a maximum of 4.99% of our outstanding common stock, unless the holder changes such limitations upon written notice to us. As a result of such limitations, the number of shares beneficially owned does not include up to an aggregate of 828,000 shares of common stock issuable upon exercise of certain warrants purchased in the Private Placement by Abingworth VII. The address of Abingworth VII is c/o Abingworth LLP, 38 Jermyn Street, London SW1Y 6DN, U.K.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	Consists of 2,977,621 shares of common stock held by HealthCap VIII, L.P. HealthCap VIII GP SA, a Swiss registered L.C.C. (&#x201c;HCSA&#x201d;), is the sole general partner of the fund HealthCap VIII, L.P. (&#x201c;HCLP&#x201d;). HCSA has voting and dispositive power over the shares held by HCLP. HCSA disclaims beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Fabrice Bernhard serves as General Manager of HCSA and each of Dag Richter and Daniel Schafer serves as Director of HCSA. Each of Messrs. Bernhard, Richter and Schafer may be deemed to share voting and investment power with respect to the shares held by HCLP except to the extent of their pecuniary interest therein. The number of shares beneficially owned by such entities is limited by beneficial ownership limitations applicable to the exercise of warrants purchased in the Private Placement by HCLP, which limit the number of shares HCLP can beneficially own after the exercise of warrants to a maximum of 4.99% of our outstanding common stock, unless the holder changes such limitations upon written notice to us. As a result of such limitations, the number of shares beneficially owned does not include up to an aggregate of 708,000 shares of common stock issuable upon exercise of certain warrants purchased in the Private Placement by HCLP. The address of HealthCap VIII, L.P. is c/o HealthCap VIII GP SA Avenue Villamont 23 &#x2013; CH 1005, Lausanne, Switzerland.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5)	Consists of 2,169,245 shares of common stock held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the &#x201c;Master Fund&#x201d;), and may be deemed to be indirectly beneficially owned by (i) Armistice Capital, LLC (&#x201c;Armistice&#x201d;), as the investment manager of the Master Fund, and (ii) Steven Boyd, as the Managing Member of Armistice. Armistice and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein. The number of shares beneficially owned by Armistice and Mr. Boyd is limited by beneficial ownership limitations applicable to the exercise of the warrants purchased in the Private Placement by the Master Fund, which limit the number of shares such entity can beneficially own after the exercise of warrants, to a maximum of 4.99% of our outstanding common stock, unless the holder changes such limitations upon written notice to us. As a result of such limitations, the number of shares beneficially owned does not include up to an aggregate of 3,546,000 shares of common stock issuable upon exercise of warrants purchased in the Private Placement by the Master Fund. The address of the Master Fund is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6)	Consists of 467,191 shares of our common stock held by Dr. Szwarcberg and 750,000 shares of our common stock subject to options exercisable within 60 days of the Ownership Measurement Date held by Dr. Szwarcberg.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7)	Consists of 350,550 shares of our common stock held by Mr. Gharib and 427,218 shares of our common stock subject to options exercisable within 60 days of the Ownership Measurement Date held by Mr. Gharib.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(8)	Consists of 161,339 shares of our common stock held by Dr. Charlton and 171,875 shares of our common stock subject to options exercisable within 60 days of the Ownership Measurement Date held by Dr. Charlton.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(9)	Consists of 439,745 shares of our common stock subject to options exercisable within 60 days of the Ownership Measurement Date held by Mr. Grey.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(10)	Consists of 157,617 shares of our common stock subject to options exercisable within 60 days of the Ownership Measurement Date held by Ms. Simpson.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(11)	Consists of 123,565 shares of our common stock subject to options exercisable within 60 days of the Ownership Measurement Date held by Mr. Spiegelman.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(12)	Consists of 92,500 shares of our common stock subject to options exercisable within 60 days of the Ownership Measurement Date held by Dr. Muralidhar.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(13)	Consists of 70,000 shares of our common stock subject to options exercisable within 60 days of the Ownership Measurement Date held by Mr. Barretto-Ko.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(14)	Consists of 100,625 shares of our common stock subject to options exercisable within 60 days of the Ownership Measurement Date held by Dr. Ways.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(15)	Consists of 82,500 shares of our common stock subject to options exercisable within 60 days of the Ownership Measurement Date held by Dr. Aynechi.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(16)	Consists of (i) 817,741 shares of common stock held by our current directors and executive officers as a group and (ii) 2,243,770 shares of common stock issuable upon the exercise of stock options held by our current directors and executive officers that are exercisable within 60 days of the Ownership Measurement Date.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delinquent Section 16(a) Reports</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(a) of the Exchange Act requires the Company&#x2019;s directors and executive officers, and persons who own more than ten percent of a registered class of the Company&#x2019;s equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officers, directors and greater than 10% stockholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to administrative delays, each of Dr. Szwarcberg, Dr. Charlton and Mr. Gharib failed to timely file three Form 4 reports reflecting the vesting and net settlement of certain RSUs.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="execcomp"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTIVE COMPENSATION</font></h1><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our named executive officers for the year ended December 31, 2024, consisting of our principal executive officer and the next two most highly compensated executive officers, were:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH, our Chief Executive Officer;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Samir Gharib, our President and Chief Financial Officer; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ralph William Charlton III, M.D., M.A.S., our former Chief Medical Officer</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.(1)</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Dr. Charlton ceased employment with us as of December 31, 2024.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; as that term is used in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and have elected to comply with the reduced compensation disclosure requirements available to emerging growth companies under the JOBS Act.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary Compensation Table</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents all of the compensation awarded to or earned by or paid to our named executive officers during the fiscal years indicated below.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10.02%;box-sizing:content-box;"></td>
     <td style="width:8.5%;box-sizing:content-box;"></td>
     <td style="width:12.38%;box-sizing:content-box;"></td>
     <td style="width:8.12%;box-sizing:content-box;"></td>
     <td style="width:13.54%;box-sizing:content-box;"></td>
     <td style="width:8.5%;box-sizing:content-box;"></td>
     <td style="width:13.94%;box-sizing:content-box;"></td>
     <td style="width:10.3%;box-sizing:content-box;"></td>
     <td style="width:14.7%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Principal Position</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal Year</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Salary ($)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Bonus<br>($)</font><font style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock Awards ($)</font><font style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards ($)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Equity Incentive Plan Compensation ($)</font><font style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Other Compensation ($)</font><font style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total ($)</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">610,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">335,500</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">581,687</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,532,187</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">580,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,850</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,205,568</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,157,418</font></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Samir Gharib</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">465,100</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">209,925</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,665</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">929,690</font></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President and Chief Financial Officer</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">447,200</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,186</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517,440</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201,240</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,201,066</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ralph William Charlton III, M.D., M.A.S.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">457,600</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183,040</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172,496</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">348,200</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,161,336</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Former Chief Medical Officer</font><font style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;font-style:italic;position:relative;font-kerning:none;min-width:fit-content;">(5)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">440,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,400</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">357,504</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,004,904</font></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:66.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	Amounts disclosed for fiscal year 2024 reflect retention bonuses earned and paid in 2024. Amounts disclosed for fiscal year 2023 reflect discretionary upward adjustments to target short-term incentive compensation earned in 2023 and paid in early 2024.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	The dollar amounts in this column reflect the aggregate grant date fair value of restricted stock unit (&#x201c;RSU&#x201d;) and performance stock unit (&#x201c;PSU&#x201d;) awards granted during the indicated fiscal year computed in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Committee (&#x201c;ASC&#x201d;) Topic 718, excluding the effect of estimated forfeitures. The grant date fair value of each RSU is measured based on the closing price of our common stock on the date of grant. For accounting purposes, the grant date fair value of PSUs was calculated based on the probable outcome of achieving the performance metric as of the grant date. The 2024 PSUs were granted on March 14, 2024, at a fair value of $0.8106 per share. Assuming the performance conditions will be achieved, the grant date fair value of the 2024 PSUs for each of our NEOs is as follows: Dr. Szwarcberg, $581,687; Mr. Gharib, $249,665; and Dr. Charlton, $172,496. These amounts do not necessarily correspond to the actual value recognized or that may be recognized by the named executive officers.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)	Amounts disclosed for fiscal year 2023 reflect short-term incentive compensation earned in 2023 and paid in early 2024.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	Amounts shown in this column represent $5,000 paid to each officer in matching payments under our 401(k) Plan, a qualified deferred compensation plan under Section 401(k) of the Internal Revenue Code of 1986, as amended. For Dr. Charlton, this amount also includes $343,200 in severance payments, paid in 2025 in connection with the termination of his employment on December 31, 2024.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5)	Dr. Charlton departed as Chief Medical Officer in December 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Base Salary</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2024 annual base salaries for our named executive officers are set forth in the table below.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:74.68%;box-sizing:content-box;"></td>
     <td style="width:25.32%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024 Base Salary</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$610,000</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Samir Gharib</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$465,100</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ralph William Charlton III, M.D., M.A.S.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$457,600</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation for our NEOs is reviewed and approved annually by the Board. The Board considers executive and company performance, compensation benchmarks of peer companies, and other discretionary factors in its overall assessment of and changes to compensation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Incentive Plan Compensation</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to motivate, reward and retain our executives for achievements relative to our corporate goals and expectations for each fiscal year. Each of our named executive officers is eligible to receive an annual performance bonus based on the achievement of performance goals as determined by the Board or an authorized committee thereof. Each named executive officer is assigned a target bonus expressed as a percentage of his base salary. The target bonus amounts for Dr. Szwarcberg, Mr. Gharib and Dr. Charlton for 2024 were set at 55%, 45%, and 40%, respectively. Annual performance bonuses for Dr. Szwarcberg, Mr. Gharib and Dr. Charlton for 2024 were approved in the amounts of $335,500, $209,295 and $183,040, respectively. These amounts were guaranteed as retention payments by the Compensation Committee in March 2024 and as such are reflected in the &#x201c;Bonus&#x201d; column of the Summary Compensation Table above.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity-Based Incentive Awards</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, we granted RSU and PSU awards to each of our named executive officers pursuant to the 2020 Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 14, 2024, we granted Dr. Szwarcberg 358,800 RSUs. The RSUs vest over a four-year period, with one quarter of the RSUs vesting on December 10, 2025 and one quarter of the total number of shares initially underlying the RSU will vest in annual installments on each anniversary of the thereafter, subject to Dr. Szwarcberg&#x2019;s continued service to us. On March 14, 2024, we also granted Dr. Szwarcberg 358,800 PSUs. The PSUs vest upon the achievement of specified financing and strategic objectives, subject to Dr. Szwarcberg&#x2019;s continued service to us.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Samir Gharib</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 14, 2024, we granted Mr. Gharib 154,000 RSUs. The RSUs vest over a four-year period, with one quarter of the RSUs vesting on December 10, 2025 and one quarter of the total number of shares initially underlying the RSU will vest in annual installments on each anniversary of the thereafter, subject to Mr. Gharib&#x2019;s continued service to us. On March 14, 2024, we also granted Mr. Gharib 154,000 PSUs. The PSUs vest upon the achievement of specified financing and strategic objectives, subject to Mr. Gharib&#x2019;s continued service to us.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ralph William Charlton III, M.D., M.A.S.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 14, 2024, we granted Dr. Charlton 106,400 RSUs. The RSUs would have vested over a four-year period, with one quarter of the RSUs vesting on December 10, 2025 and one quarter of the total number of shares initially underlying the RSU will vest in annual installments on each anniversary of the thereafter, subject to Dr.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Charlton&#x2019;s continued service to us. On March 14, 2024, we also granted Dr. Charlton 106,400 PSUs. The PSUs would have vested upon the achievement of specified financing and strategic objectives. These RSU and PSU awards will not vest since Dr. Charlton&#x2019;s service to the company terminated in December 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">401(k) Plan</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a 401(k) plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to defer eligible compensation up to certain Code limits, which are updated annually. We have the ability to make matching and discretionary contributions to the 401(k) plan. Currently, we make matching contributions, but no discretionary contributions, to the 401(k) plan. The 401(k) plan is intended to be qualified under Section 401(a) of the Code, with the related trust intended to be tax exempt under Section 501(a) of the Code. As a tax-qualified retirement plan, contributions to the 401(k) plan are deductible by us when made, and contributions and earnings on those amounts are not generally taxable to the employees until withdrawn or distributed from the 401(k) plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Compensation and Benefits</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our current named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, disability, and life insurance plans, in each case on the same basis as all of our other employees. We pay the premiums for the life, disability, accidental death, and dismemberment insurance for all of our employees, including our named executive officers. We generally do not provide perquisites or personal benefits to our named executive officers.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding Equity Awards as of December 31, 2024</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of December 31, 2024.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:9.562%;box-sizing:content-box;"></td>
     <td style="width:10.642%;box-sizing:content-box;"></td>
     <td style="width:9.762%;box-sizing:content-box;"></td>
     <td style="width:10.642%;box-sizing:content-box;"></td>
     <td style="width:10.782%;box-sizing:content-box;"></td>
     <td style="width:7.622%;box-sizing:content-box;"></td>
     <td style="width:9.522%;box-sizing:content-box;"></td>
     <td style="width:7.261%;box-sizing:content-box;"></td>
     <td style="width:8.322%;box-sizing:content-box;"></td>
     <td style="width:7.802%;box-sizing:content-box;"></td>
     <td style="width:8.082%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;"><p style="text-indent:6.667%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;"><p style="text-indent:6.667%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="5" style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-weight:bold;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td colspan="4" style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock Awards</font></p></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Securities Underlying Unexercised Options (#) Exercisable</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Securities Underlying Unexercised Options (#) Unexercisable</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Exercise Price Per Share ($)</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-weight:bold;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Expiration Date</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares or Units of Stock That Have Not Vested (#)</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-weight:bold;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Market Value of Shares or Units of Stock That Have Not Vested ($)</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-weight:bold;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-weight:bold;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="padding-bottom:1pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-weight:bold;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</font></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Javier</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/03/2022</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">546,875</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203,125</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.59</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2032</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Szwarcberg</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/03/2022</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(8)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.59</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/2/2032</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/05/2022</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(9)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,240</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/14/2023</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(10)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269,100</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,022</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/14/2024</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(11)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">358,800</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,696</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/14/2024</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(12)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">358,800</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,696</font></p></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Samir Gharib</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/08/2020</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(13)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,483</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.64</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/07/2030</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/07/2020</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(14)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,548</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.07</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/06/2030</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/28/2021</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(15)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,854</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,146</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.08</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/27/2031</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/16/2021</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(16)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,750</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,250</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.48</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/15/2031</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/03/2022</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(17)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,041</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,959</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.59</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/3/2032</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/05/2022</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(9)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,500</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,290</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/14/2023</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(10)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,500</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,510</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/14/2024</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(11)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,680</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
    <tr style="height:6pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">03/14/2024</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(12)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,680</font></p></td>
    </tr>
    <tr style="height:6pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ralph William Charlton III</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/01/2022</font><font style="color:#000000;top:-2.814pt;white-space:pre-wrap;font-size:4.0200000000000005pt;position:relative;font-kerning:none;min-width:fit-content;">(18)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,875</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.13</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">04/01/2032</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;padding-right:0.08in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:66.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	All of the option awards granted prior to our initial public offering in October 2020 were granted under our 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;). All of the option awards granted since our initial public offering in October 2020 were granted under the 2020 Plan, other than Dr. Szwarcberg&#x2019;s January 2022 option awards granted as inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4) outside the 2020 Plan but pursuant to the terms of the 2020 Plan as if such awards were made under the 2020 Plan.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	All of the option awards granted prior to our initial public offering in October 2020 were granted with a per share exercise price equal to the fair market value of one share of our common stock on the date of grant, as determined in good faith by the Board or compensation committee. All of the option awards granted since our initial public offering in October 2020 were granted with a per share exercise price equal to the closing sales price on the Nasdaq Global Select Market on the date of grant.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)	Awards in this column consist of RSU awards that were unvested as of December 31, 2024.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	Amounts in this column represent the market value for RSU awards that were unvested as of December 31, 2024. The market value of the RSU award is calculated by multiplying the number of shares underlying the RSU award shown in the table by $0.42, the closing price of our common stock on December 31, 2024.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5)	Awards in this column consist of PSU awards that were unearned and unvested as of December 31, 2024.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6)	Amounts in this column represent the market value for PSU awards that were unearned and unvested as of December 31, 2024. The market value of the PSU award is calculated by multiplying the number of shares underlying the PSU award shown in the table by $0.42, the closing price of our common stock on December 31, 2024.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7)	One-fourth of the shares subject to the option award vested on January 3, 2023, and the balance vests in equal monthly installments over the three years thereafter.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(8)	125,000 shares subject to the option award vested upon the achievement of a specified clinical development milestone.</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(9)	One-fourth of the shares vested on December 15, 2023, and one-third of the remaining shares vest on each anniversary thereafter, subject to continued service to us as of each such date.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(10)	One-fourth of the shares vested on December 15, 2024, and one-third of the remaining shares vest on each anniversary thereafter, subject to continued service to us as of each such date.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(11)	One-fourth of the shares will vest on December 10, 2025, and one-third of the remaining shares vest on each anniversary thereafter, subject to continued service to us as of each such date.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(12)	The shares will vest in a single installment upon either the achievement of certain financing metrics/consummation of a Change of Control (as defined in the 2020 Plan) or the completion of an equity financing of the Company resulting in at least $50 million of gross proceeds (prior to commissions and offering expenses).</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(13)	One-fourth of the shares subject to the option award vested on May 1, 2021, and the balance vests in equal monthly installments over the three years thereafter. The option includes an early exercise feature.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(14)	One-forty-eighth of the shares subject to the option award vested on each monthly anniversary of August 7, 2020, subject to continued service to us. The option includes an early exercise feature.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(15)	One-forty-eighth of the shares subject to the option award shall vest on each monthly anniversary of January 28, 2021, subject to continued service to us.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(16)	One-forty-eighth of the shares subject to the option award shall vest on each monthly anniversary of December 16, 2021, subject to continued service to us.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(17)	One-forty-eighth of the shares subject to the option award shall vest on each monthly anniversary of January 3, 2022, subject to continued service to us.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(18)	One-fourth of the shares subject to the option award vested on March 28, 2023, and the balance vested in equal monthly installments until Dr. Charlton&#x2019;s termination on December 31, 2024.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options held by our named executive officers are eligible for accelerated vesting under specified circumstances as further described under the section titled &#x201c;Executive Compensation&#x2014;Potential Payments Upon Termination or Change of Control&#x201d;.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment and Letter Agreements</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below are descriptions of our employment and letter agreements with our named executive officers. For a discussion of the severance pay and other benefits to be provided in connection with a termination of employment and/or a change in control under the arrangements with our named executive officers, see the section titled &#x201c;Executive Compensation&#x2014;Potential Payments Upon Termination or Change of Control&#x201d; below.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dr. Szwarcberg</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We entered into an offer letter agreement with Dr. Szwarcberg in December 2021, which governs the current terms of Dr. Szwarcberg&#x2019;s employment with us. Pursuant to the agreement, Dr. Szwarcberg is entitled to an initial annual base salary of $540,000, is eligible to receive an annual performance bonus with a target achievement of 50% of his base salary, as determined by the Board, and was granted options to purchase an aggregate of 1,000,000 shares of our common stock. In April 2022, we entered into an amendment to Dr. Szwarcberg&#x2019;s offer letter, pursuant to which we amended Dr. Szwarcberg&#x2019;s entitlement to certain severance benefits, the terms of which are described below under &#x201c;&#x2014;Potential Payments Upon Termination or Change of Control.&#x201d; In December 2023, the Board confirmed Dr. Szwarcberg&#x2019;s target bonus for 2024 performance was to be 55% of his annual base salary and approved an increase in his base salary to $610,000 for 2024. Dr. Szwarcberg is also eligible for standard benefits such as vacation and paid time off and to participate in employee benefit plans and programs, in each case, as generally available to our regular full-time employees. Dr. Szwarcberg&#x2019;s employment is at will.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mr. Gharib</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We entered into an offer letter agreement with Mr. Gharib in April 2020, which governs the current terms of Mr. Gharib&#x2019;s employment with us. Pursuant to the agreement, Mr. Gharib was entitled to an initial annual base salary of $330,000 (which was subsequently increased by the Board to $380,000, effective immediately prior to our initial public offering), was eligible to receive an annual performance bonus with a target achievement of 30% of his base salary (which was subsequently increased by the Board to 40%, effective immediately prior to our initial public offering), as determined by the Board. In December 2021, the Board increased Mr. Gharib&#x2019;s annual base salary for 2022 to $414,300. In January 2022, in connection with his appointment as President, the Board further increased Mr. Gharib&#x2019;s annual base salary for 2022 to $430,000 and increased his target bonus for 2022 performance to 45% of his annual base salary. In December 2023, the Board further increased Mr. Gharib&#x2019;s annual base salary for 2024 to $465,100 and confirmed that his target bonus for 2024 performance was to remain at 45% of his annual base salary. Mr. Gharib is also eligible for standard benefits such as vacation and paid time off and to participate in employee benefit plans and programs, in each case, as generally available to our regular full-time employees. Mr. Gharib&#x2019;s employment is at will. Mr. Gharib is also entitled to certain severance benefits, the terms of which are described below under &#x201c;&#x2014;Potential Payments Upon Termination or Change of Control.&#x201d;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dr. Charlton</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We entered into an offer letter agreement with Dr. Charlton in March 2022, which governed the current terms of Dr. Charlton&#x2019;s employment with us. Pursuant to the agreement, Dr. Charlton was entitled to an initial annual base salary of $400,000, was eligible to receive an annual performance bonus with a target achievement of 40% of his base salary, as determined by the Board, and was granted an option to purchase an aggregate of 250,000 shares of our common stock. Dr. Charlton was also entitled to certain severance benefits, the terms of which are described below under &#x201c;&#x2014;Potential Payments Upon Termination or Change of Control.&#x201d; Dr. Charlton  also eligible for standard benefits such as vacation and paid time off and to participate in employee benefit plans and programs, in each case, as generally available to our regular full-time employees. Dr. Charlton&#x2019;s employment was at will.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential Payments Upon Termination or Change of Control</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Severance Plan</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our current named executive officers, except Dr. Charlton whose employment ceased as of December 31, 2024,  is eligible for our severance and change in control plan (the &#x201c;Severance Plan&#x201d;), which was adopted by the Board in September 2020 and became effective in connection with our initial public offering. The Severance Plan provides for severance benefits upon (i) a &#x201c;change in control termination&#x201d; or (ii) a &#x201c;regular termination&#x201d; (each as described below). Upon a change in control termination, participants will be entitled to continued payment of base salary (for 18 months for Dr. Szwarcberg and for 12 months for Mr. Gharib), a lump sum payment equal to the participant&#x2019;s target cash bonus, payment of continued group health benefits (for up to 18 months for Dr. Szwarcberg and for up to 12 months for Mr. Gharib), and full accelerated vesting of all outstanding equity awards granted following effectiveness of the Severance Plan (including performance-based awards, which shall vest at 100% of target). Pursuant to the terms of his amended offer letter agreement with us, with respect to his option award for 250,000 shares of common stock granted January 3, 2022 only, the vesting acceleration benefits under the Severance Plan applicable to a change of control termination for Dr. Szwarcberg will only apply for a Change in Control (as defined in the Severance Plan) with an effective date on or after January 3, 2023. Upon a regular termination, participants will be entitled to continued payment of base salary (for 12 months for Dr. Szwarcberg and for nine months for Mr. Gharib) and payment of continued group health benefits (for up to 12 months for Dr. Szwarcberg and for up to nine months for Mr. Gharib).</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All severance benefits under the Severance Plan are subject to the participant&#x2019;s execution of an effective release of claims against the company and compliance with the terms of the company&#x2019;s standard confidentiality agreement. For purposes of the Severance Plan, a &#x201c;regular termination&#x201d; is an involuntary termination (i.e., a termination other than for &#x201c;cause,&#x201d; as defined in the 2020 Plan (and not as a result of death or disability), or a resignation for &#x201c;good reason,&#x201d; as defined in the Severance Plan) that does not occur during the period of time beginning three months prior to, and ending 12 months following, a &#x201c;change in control&#x201d; (as defined in the 2020 Plan), or the &#x201c;change in control period.&#x201d; A &#x201c;change in control termination&#x201d; is an involuntary termination that occurs during the change in control period (the period commencing 3 months prior to the effective date of the change in control and ending 12 months following the effective date of the change in control).</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with Dr. Charlton&#x2019;s departure in December 2024, Dr. Charlton is entitled to receive benefits pursuant to the Company&#x2019;s Severance and Change in Control Plan, including an amount equal to nine months of salary continuation at his base salary rate, or $343,200, and continued coverage under COBRA equal to nine months, in exchange for granting and not revoking a customary release of claims.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Benefit Plans</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders. In addition, we believe that our ability to grant options and other equity-based awards helps us to attract, retain and motivate employees, consultants, and directors, and encourages them to devote their best efforts to our business and financial success. The principal features of our equity incentive plans and our 401(k) plan are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which, other than the 401(k) plan, are filed as exhibits to the Annual Report.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2020 Equity Incentive Plan</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board adopted our 2020 Plan in September 2020 and our stockholders approved our 2020 Plan in October 2020. Our 2020 Plan provides for the grant of incentive stock options (&#x201c;ISOs&#x201d;) to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options (&#x201c;NSOs&#x201d;) stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors, and consultants, including employees and consultants of our affiliates. Our 2020 Plan is a successor to and continuation of our 2016 Plan, which is described below. The 2020 Plan became effective immediately prior to and contingent upon the execution of the underwriting agreement related to our initial public offering.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initially, the maximum number of shares of our common stock that may be issued under our 2020 Plan was 2,647,684 shares. In addition, the number of shares of our common stock reserved for issuance under our 2020 Plan is subject to an automatic increase on January 1 of each calendar year through January 1, 2030, in an amount equal to 5% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Board. Pursuant to the automatic increase provision of the 2020 Plan, the number of shares of our common stock reserved for issuance under our 2020 Plan was increased by 2,051,491 shares on January 1, 2024 and 2,111,564 shares on January 1, 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated 2016 Equity Incentive Plan</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our 2016 Plan was originally adopted by the Board and approved by our stockholders in April 2016. It was subsequently amended in October 2019 and amended and restated in February 2020. Our 2016 Plan allows for the grant of ISOs to employees, including employees of any parent or subsidiary, and for the grant of NSOs, restricted stock awards, restricted stock units and other stock-based awards to employees, directors, and consultants, including employees and consultants of our affiliates.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No further grants can be made under our 2016 Plan following the effectiveness of our 2020 Plan. Any outstanding awards granted under our 2016 Plan will remain subject to the terms of our 2016 Plan and applicable award agreements.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum number of shares of our common stock that may be issued under our 2016 Plan is 2,697,738 shares.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2020 Employee Stock Purchase Plan</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board adopted our 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), in September 2020 and our stockholders approved our ESPP in October 2020. The ESPP became effective immediately prior to the execution of the underwriting agreement related to our initial public offering. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our affiliates. The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase our common stock in a manner that may qualify for favorable tax treatment under Section 423 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;). In addition, purchase rights may be granted under a component that does not qualify for such favorable tax treatment because of deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ESPP initially authorized the issuance of 220,640 shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance is subject to an automatic increase on January 1 of each calendar year through January 1, 2030, by the lesser of (i) 1% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of the automatic increase, and (ii) 441,280 shares; provided, that before the date of any such increase, the Board may determine that such increase will be less than the amount set forth in clauses (i) and (ii). Pursuant to the automatic increase provision of the ESPP, the number of shares of our common stock reserved for issuance under our ESPP was increased by 410,298 shares on January 1, 2024 and 422,312, shares on January 1, 2025.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Compensation Plan Information</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides certain information as of December 31, 2024, with respect to all of our equity compensation plans in effect on that date.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:33.739%;box-sizing:content-box;"></td>
     <td style="width:23.141%;box-sizing:content-box;"></td>
     <td style="width:21.122%;box-sizing:content-box;"></td>
     <td style="width:21.998%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Category</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-average Exercise Price of Outstanding Options, Warrants and Rights</font><font style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans (Excluding Securities Reflected<br>in Column (a))</font></p></td>
    </tr>
    <tr style="height:7.9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="text-indent:6.667%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(a)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(b)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(c)</font></p></td>
    </tr>
    <tr style="height:10.1pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans approved by security holders</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,825,865 </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$2.81</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,990,602 </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</font></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans not approved by security holders</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">875,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$4.59</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</font></p></td>
    </tr>
    <tr style="height:10.1pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,700,865 </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$3.26</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,990,602 </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</font></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:66.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	Consists of the 2016 Plan, the 2020 Plan and the 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The number of shares of our common stock reserved for issuance under the 2020 Plan is subject to an automatic increase on January 1st of each year, for a period of ten years, commencing on January 1, 2021 and ending on (and including) January 1, 2030, in an amount equal to 5% of the total number of shares of our common stock outstanding on December 31 of the preceding year; provided, however, that the Board may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares of our common stock. The number of shares of our common stock reserved for issuance under the ESPP is subject to an automatic increase on January 1st of each year, for a period of ten years, commencing on January 1, 2021 and ending on (and including) January 1, 2030, in an amount equal to the lesser of (i) 1% of the total number of shares of our common stock outstanding on December 31st of the preceding calendar year, (ii) 441,280 shares of our common stock and (iii) a number of shares of our common stock designated by action of the Board prior to the applicable January 1st. On January 1, 2025, the numbers of shares of our common stock reserved for issuance under the 2020 Plan and the ESPP were increased by 2,111,564 shares and 422,312 shares, respectively, pursuant to the automatic increase provisions of such plans.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	Consists of shares of our common stock issuable upon exercise of 2,586,155 outstanding stock options and vesting of 2,239,710 outstanding RSUs and PSUs.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)	The weighted-average exercise price excludes RSUs and PSUs.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	Consists of shares available for future issuance under the 2020 Plan and the ESPP. As of December 31, 2024, 2,063,835 shares of our common stock were available for issuance under the 2020 Plan, and 926,767 shares of our common stock were available for issuance under the ESPP.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company grants stock options to its employees, including the named executive officers. The Company did not grant options to its executive officers in 2024. For more information on the Company&#x2019;s practices regarding grants for non-executive employees, please see the section &#x201c;&#x2014;Compensation Committee&#x2014;Compensation Committee Processes and Procedures&#x2014;&#x201d; above.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For executive officers, the Company has historically granted new-hire option awards on or soon after a new hire&#x2019;s employment start date. Also, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director&#x2019;s initial appointment or election to the board and at the time of each annual meeting of the Company&#x2019;s stockholders, respectively, pursuant to the Non-Employee Director Compensation Policy, as further described under the heading, &#x201c;Director Compensation&#x201d; below. The Company does not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. The Compensation Committee considers whether there is any material nonpublic information (&#x201c;MNPI&#x201d;) about the Company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to the Company&#x2019;s public disclosure of MNPI. The Company has not timed the release of MNPI for the purpose of affecting the value of executive compensation.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="dir"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Compensation</font></h2><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information for the fiscal year ended December 31, 2024 concerning the compensation paid to all of our non-employee directors. Dr. Szwarcberg, our Chief Executive Officer did not receive additional compensation in connection with his service as a director, and therefore is not included in the Director Compensation table below. See the section titled &#x201c;Executive Compensation&#x201d; for more information regarding the compensation earned by Dr. Szwarcberg.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Compensation for Fiscal 2024</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:42%;box-sizing:content-box;"></td>
     <td style="width:15.54%;box-sizing:content-box;"></td>
     <td style="width:15.66%;box-sizing:content-box;"></td>
     <td style="width:15.96%;box-sizing:content-box;"></td>
     <td style="width:10.84%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fees Earned or Paid in Cash ($)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards ($)</font><font style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Other Compensation ($)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;text-align:left;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total ($)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tiba Aynechi, Ph.D.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,224</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.083%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,224</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Percival Barretto-Ko</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,500</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,224</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="text-indent:7.098%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.083%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,724</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Grey</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,224</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.083%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,224</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bali Muralidhar, Ph.D.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,224</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.083%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,224</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Niall O&#x2019;Donnell, Ph.D.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(2)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,642</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.083%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,642</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Daniel Spiegelman</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,224</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.083%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,224</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Camilla Simpson, M.Sc.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,577</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,224</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.083%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,801</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kirk Ways, M.D., Ph.D.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(3)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.287%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,224</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.083%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,750</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,974</font></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:66.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	Amounts shown in this column do not reflect dollar amounts actually received by non-employee directors. Instead, these amounts reflect the aggregate grant date fair value of each stock option granted computed in accordance with the provisions of FASB ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note 10 to our consolidated financial statements included in our Annual Report. Our non-employee directors will only realize compensation to the extent the trading price of our common stock is greater than the exercise price of such stock options. As of December 31, 2024, Dr. Aynechi held options to purchase 82,500 shares of our common stock; Mr. Barretto-Ko held options to purchase 90,000 shares of our common stock; Mr. Grey held options to purchase 447,037 shares of our common stock; Dr. Muralidhar held options to purchase 92,500 shares of our common stock; Mr. Spiegelman held options to purchase 123,565 shares of our common stock; Ms. Simpson held options to purchase 157,617 shares of our common stock; and Dr. Ways held options to purchase 100,625 shares of our common stock.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	Dr. O&#x2019;Donnell resigned from the Board in May 2024.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)	Dr. Ways received $3,750 in consulting fees from his services as interim Chief Medical Officer in December 2024.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have reimbursed and will continue to reimburse all of our non-employee directors for their reasonable out-of-pocket expenses incurred in attending board of directors and committee meetings.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board adopted a non-employee director compensation policy in September 2020 that became effective immediately prior to the execution and delivery of the underwriting agreement related to our initial public offering, which is applicable to all of our non-employee directors. The non-employee director compensation policy was further amended in March 2023. This compensation policy provides that each such non-employee director will receive the following compensation for service on the Board:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an annual cash retainer of $40,000;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an additional annual cash retainer of $30,000 to the executive chairman of the Board;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an additional annual cash retainer (not applicable to committee chairs) of $7,500, $5,000, and $4,000 for service as a member of the audit committee, compensation committee and the nominating and corporate governance committee, respectively;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an additional annual cash retainer of $15,000, $10,000, and $8,000 for service as chair of the audit committee, compensation committee and the nominating and corporate governance committee, respectively;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an initial option grant to purchase 60,000 shares of our common stock on the date of each such non-employee director&#x2019;s appointment to the Board, vesting monthly over three years; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an annual option grant to purchase 30,000 shares of our common stock on the date of each of our annual stockholder meetings, vesting on the earlier of (i) the first anniversary of the grant date and (ii) the date of the next annual meeting, provided that such grant is pro-rated based on the number of full months the director has served on the Board, if less than 12 months prior to the applicable annual stockholder meeting.</font></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the option grants described above will be granted under our 2020 Plan, the terms of which are described in more detail under the section titled &#x201c;Executive Compensation&#x2014;Employee Benefit Plans&#x2014;2020 Equity Incentive Plan.&#x201d; Each such option grant will vest and become exercisable subject to the director&#x2019;s continuous service to us, provided that each grant will vest in full upon a change in control of our company, as defined in the 2020 Plan. The term of each option will be ten years, subject to earlier termination as provided in the 2020 Plan.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="rp"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION</font></h1><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following includes a summary of transactions since January 1, 2023 to which we have been a party in which the amount involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years, and in which any of our directors, director nominees, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#x201c;Executive Compensation.&#x201d; We also describe below certain other transactions with our directors, executive officers and stockholders.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participation in 2023 Private Placement Offering</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2023, we entered into Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional investors, relating to a private placement of shares of our common stock, pre-funded warrants to purchase shares of our common stock and warrants to purchase shares of our common stock (the &#x201c;Private Placement&#x201d;). Pursuant to the Purchase Agreement, we issued and sold an aggregate of 16,116,000 shares of our common stock to the purchasers, along with 800,000 shares of common stock subject to a pre-funded warrant and 12,687,000 shares of common stock subject to warrants (collectively, the &#x201c;Warrants&#x201d;). Our Private Placement closed on February 16, 2023. Certain holders of more than 5% of our capital stock (including shares of common stock acquired in the Private Placement), including those holders affiliated with members of our Board, purchased shares of our common stock in the Private Placement at the offering price offered to other investors.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the number of shares of our common stock purchased and the aggregate cash purchase price paid by each of these stockholders.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:41.34%;box-sizing:content-box;"></td>
     <td style="width:14.44%;box-sizing:content-box;"></td>
     <td style="width:11.58%;box-sizing:content-box;"></td>
     <td style="width:17.28%;box-sizing:content-box;"></td>
     <td style="width:15.36%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares of Common Stock Purchased</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Pre-funded Warrants Purchased</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrants Purchased</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.075in;"><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.25pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Cash Purchase Price $</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Novo Holdings A/S</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,208,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,656,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.5%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,999,360</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities affiliated with RiverVest Venture Fund III, L.P.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">788,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.5%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,497,960</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Abingworth Bioventures VII LP </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,104,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">828,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.5%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,499,680</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">HealthCap VIII, L.P.</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">944,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">708,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.5%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,992,480</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities affiliated with Rock Springs Management LP </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,104,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">828,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.5%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,499,680</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Armistice Capital Master Fund Ltd. </font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,928,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">800,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,546,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.5%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,979,760</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5AM Opportunities II, L.P. </font><font style="color:#000000;top:1pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,364,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.685%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,773,000</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0.01in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.5%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,493,880</font></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:66.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	Novo Holdings A/S is the beneficial owner of more than 5% of our outstanding capital stock. Tiba Aynechi, Ph.D. is a member of our board of directors and was previously employed as a Senior Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo Holdings A/S.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	Entities affiliated with RiverVest Venture Fund III, L.P. are the beneficial owners of more than 5% of our outstanding capital stock. At the time of the financing, Niall O&#x2019;Donnell, Ph.D. was a member of our board of directors and serves as Managing Director at RiverVest Venture Partners.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)	Abingworth Bioventures VII LP is the beneficial owner of more than 5% of our outstanding capital stock. Bali Muralidhar, M.D., Ph.D. is a member of our board of directors and serves as Managing Partner of Abingworth LLP, an affiliate of Abingworth Bioventures VII LP.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	HealthCap VIII, L.P. is the beneficial owner of more than 5% of our outstanding capital stock. Jonas Hansson, a former member of our board of directors, was formerly employed as a partner at HealthCap Advisor AB, an entity affiliated with HealthCap VIII, L.P.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5)	Entities affiliated with Rock Springs Management LP collectively beneficially own more than 5% of our outstanding capital stock.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6)	Armistice Capital Master Fund Ltd. is the beneficial owner of more than 5% of our outstanding capital stock.</font></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7)	5AM Opportunities II, L.P. was the beneficial owner of more than 5% of our outstanding capital stock at the time of the financing.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policies and Procedures for Transactions with Related Persons</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a written policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of the Board or our Audit Committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, in which the amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets in a fiscal year) and such person would have a direct or indirect interest, must be presented to the Board or our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, the Board or our Audit Committee is to consider the material facts of the transaction, including whether the transaction is on terms comparable to the terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#x2019;s interest in the transaction.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="house"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HOUSEHOLDING OF PROXY MATERIALS</font></h1><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as &#x201c;householding,&#x201d; potentially means extra convenience for stockholders and cost savings for companies.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This year, a number of brokers with account holders who are Company stockholders will be &#x201c;householding&#x201d; the Company&#x2019;s proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be &#x201c;householding&#x201d; communications to your address, &#x201c;householding&#x201d; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#x201c;householding&#x201d; and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify your broker or the Company by telephone at (415) 655-4168 or by written request to 611 Gateway Boulevard, Suite 740, South San Francisco, California 94080, Attention: Corporate Secretary, and we will promptly deliver the requested documents or notice. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like to request &#x201c;householding&#x201d; of their communications should contact their brokers.</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="other"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OTHER MATTERS</font></h1><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATE OF AMENDMENT<br>TO AMENDED AND RESTATED<br>CERTIFICATE OF INCORPORATION<br>OF<br>SPRUCE BIOSCIENCES, INC.</font></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[_________], 2025</font></p><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Spruce Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), DOES HEREBY CERTIFY AS FOLLOWS:</font></p><p style="margin-left:4.44%;text-indent:-4.646%;padding-left:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.      The name of the corporation is &#x201c;Spruce Biosciences, Inc.&#x201d; The original certificate of incorporation was filed with the Secretary of State of the State of Delaware on April 7, 2016 (as amended on October 14, 2020, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certificate of Incorporation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p><p style="margin-left:4.44%;text-indent:-4.646%;padding-left:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.      Article IV, Part A of the Certificate of Incorporation of the Corporation is amended and restated in its entirety to read as follows:</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorized Capital Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The total number of shares of all classes of capital stock which the Corporation is authorized to issue is 210,000,000 shares, consisting of (a) 200,000,000 shares of common stock, par value $0.0001 per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and (b) 10,000,000 shares of preferred stock, par value $0.0001 per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective as of 5:00 pm Eastern time, on the date this Certificate of Amendment to this Second Amended and Restated Certificate of Incorporation is filed with the Secretary of State of the State of Delaware (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Time</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), each [_____]</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.695pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#x2019;s Common Stock, par value $0.0001 per share, issued and outstanding shall automatically and without any action on the part of the respective holders thereof, be combined and converted into one share of Common Stock without increasing or decreasing the par value of each share of Common Stock. No fractional shares shall be issued and, in lieu thereof, any holder of less than one share of Common Stock shall, upon surrender after the Effective Time of a certificate, which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, be entitled to receive cash for such holder&#x2019;s fractional share based upon the closing sales price of the Corporation&#x2019;s Common Stock as reported on the Nasdaq Capital Market on the date this Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Corporation is filed with the Secretary of State of the State of Delaware.&#x201d;</font></p><p style="margin-left:4.44%;text-indent:-4.646%;padding-left:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.      The foregoing amendment to the Certificate of Incorporation was duly approved by the Board.</font></p><p style="margin-left:4.44%;text-indent:-4.646%;padding-left:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.      Thereafter, pursuant to a resolution of the Board, this Certificate of Amendment was submitted to the stockholders of the Corporation for their approval, and was duly adopted and approved in accordance with the provisions of Section 242 of the Delaware General Corporation Law.</font></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Signature Page Follows</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p><p style="text-indent:-4.646%;padding-left:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">____________</font></p><p style="text-indent:-4.646%;padding-left:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4       The stockholders are requested to adopt an amendment approving the combination of any whole number of shares of the Corporation&#x2019;s Common Stock at any ratio between 5:1 and 30:1. By approving Proposal No. 3, stockholders are approving each whole number between 5 and 30 proposed by the Corporation&#x2019;s Board of Directors for the ratio. If the reverse stock split proposal is approved by stockholders, the Certificate of Amendment filed with the Secretary of State of the State of Delaware will include only that reverse stock split ratio determined by the Corporation&#x2019;s Board of Directors to be in the best interests of the Corporation and its stockholders. The other amendments will be abandoned pursuant to Section 242(c) of the General Corporation Law of the State of Delaware. The Corporation&#x2019;s Board of Directors may also elect not to effect any reverse stock split, in which case all proposed alternate amendments will be abandoned.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF,</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Spruce Biosciences, Inc. has caused this Certificate of Amendment to be duly executed and acknowledged in its name and on behalf by an authorized officer of the date first set forth above.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:1.54%;box-sizing:content-box;"></td>
     <td style="width:1.56%;box-sizing:content-box;"></td>
     <td style="width:16.623%;box-sizing:content-box;"></td>
     <td style="width:1.56%;box-sizing:content-box;"></td>
     <td style="width:78.716%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SPRUCE BIOSCIENCES, INC.</font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;text-align:right;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH</font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0.031in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
   </table><p style="text-indent:-4.646%;padding-left:4.44%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the Annual Report is available without charge upon written request to 611 Gateway Boulevard, Suite 740 South San Francisco, California 94080 Attention: Corporate Secretary.</font></p><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By Order of the Board of Directors</font></p><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img191538130_2.jpg" alt="img191538130_2.jpg" style="width:220px;height:114px;"></p><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Javier Szwarcberg, M.D., MPH</font></p><p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 18, 2025</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img191538130_3.jpg" alt="img191538130_3.jpg" style="width:624px;height:780px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ffffff;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">spruceBIO SPRUCE BIOSCIENCES, INC. 611 GATEWAY BOULEVARD, SUITE 740 SOUTH SAN FRANCISCO, CA 94080 SCAN TO VIEW MATERIALS &amp; VOTE VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 p.m. Eastern Time on June 8, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting - Go to www.virtualshareholdermeeting.com/SPRB2025 You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 p.m. Eastern Time on June 8, 2025. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: V74237-P30195 KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY SPRUCE BIOSCIENCES, INC. For All Withhold All For All Except To withhold authority to vote for any individual nominee(s), mark &#34;For All Except&#34; and write the number(s) of the nominee(s) on the line below. The Board of Directors recommends you vote FOR ALL of the following nominees nominated by the Board of Directors: 1. To elect the three Class II directors named below to hold office until the Company's 2028 annual meeting of stockholders. Nominees: 01) Percival Barretto-Ko 02) Bali Muralidhar, M.D., Ph.D. 03) Daniel Spiegelman The Board of Directors recommends you vote FOR proposals 2, 3 and 4, proposed by the Board of Directors: For Against Abstain 2. To ratify the selection by the Audit Committee of the Board of Directors (the &#34;Board&#34;) of BDO USA, P.C. as the independent registered public accounting firm of the Company for the Company's fiscal year ending December 31, 2025. 3. To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of the Company's common stock by a ratio of between one-for-five and one-for-thirty, with the exact ratio to be determined by the Board in its sole discretion and with such Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion. 4. To approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournments or postponements thereof. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img191538130_4.jpg" alt="img191538130_4.jpg" style="width:624px;height:731px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ffffff;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to Be Held on June 9, 2025 at 10:00 AM (Pacific Time): The Proxy Statement and Annual Report to Stockholders are available at www.proxyvote.com. V74238-P30195 SPRUCE BIOSCIENCES, INC. Annual Meeting of Stockholders June 9, 2025 10:00 AM Pacific Time This proxy is solicited by the Board of Directors The stockholder(s) hereby appoint(s) Javier Szwarcberg, Chief Executive Officer and Samir Gharib, President and Chief Financial Officer, or either of them, as proxies, each with the power to appoint his substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of Common Stock of SPRUCE BIOSCIENCES, INC. that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders to be held at 10:00 AM, Pacific Time on June 9, 2025, at the Virtual Stockholder Meeting at www.virtualshareholdermeeting.com/SPRB2025 and any adjournment or postponement thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors' recommendations. Continued and to be signed on reverse side</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img191538130_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img191538130_0.jpg
M_]C_X  02D9)1@ ! 0        #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M *X# 2(  A$! Q$!_\0
M&P   @,! 0$               4"! <& 0/_Q  R$  " 00! @0% P0" P
M   ! @, ! 41$@8A$S%!410B87&!!S)2%2.AT7*10K'P_\0 %P$! 0$!
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MZ8O#+9S2WEPD0NI@%*PIQ2-?XCW^I/G63L/J*** **** **** **** ****
M**** H7^0M,38R7E[.D$$8VSM_\ =S23%==]/9F]^#M+M_'()57C*\@!LZ_
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MHZ@QV2Z9P/3V*E,O@JGBL%( ;CK7?UV30'?W&0Z1PMC!E+R;FUV@DB>8%Y9
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+7AJ)M]E4S/*1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img191538130_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img191538130_1.jpg
M_]C_X  02D9)1@ ! 0        #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MP  +" !R -P! 1$ _\0 &P !  (# 0$               4& @,$!P'_Q !
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M$1$1$7!'DJ,MV6E%<KR6HAN2!DK2]@^+=["[T1$1$14^Q_(_:KCY=Z;D,7+
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MF1OJ/CV(4;EL%RGD<,&,RD^+@QAD8^V^H9/$F:T[Z '=F@Z&^Y5W: UH:T
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EBA5<?,P5F,/Z!2B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img191538130_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img191538130_2.jpg
M_]C_X  02D9)1@ ! 0        #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MP  +" !R -P! 1$ _\0 &P !  (# 0$               4& @,$!P'_Q !
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M$1$1$7!'DJ,MV6E%<KR6HAN2!DK2]@^+=["[T1$1$14^Q_(_:KCY=Z;D,7+
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MF1OJ/CV(4;EL%RGD<,&,RD^+@QAD8^V^H9/$F:T[Z '=F@Z&^Y5W: UH:T
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EBA5<?,P5F,/Z!2B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img191538130_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img191538130_3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /M R,# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO):<H58C:F[EU];I  H  P!T%+0(**** "BBB@ HHHH **** "BBB@ HHHH
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M (?:BFM^-_ &E:9IVG7T\RI&USIEC'-(5:3@#SDD50_'W0<9)KZ$T/\ 8_\
MVB/VQOCAH/BS]HBUMO#?A;0RJ&Q1H0T\2/O:"&*)FQYC?>D<YP>,X44P./\
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M[(C\PSAB1BL;0_V;/'WQNM;"?X[>(1;>'K>.,0?#OPQ.T-E\@ 'VVX!WW#8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9@6(C!"%CEB!ZG&: T.NHK(\+^+M"\<:2FJ^'-:T[7]+=F1+W2[J.YA9E.&
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M;#8W]SI=PWENGEW-O*T4T>& SM=6&1P<9!(YH VJ*** "BBB@ HHHH ****
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M&N:B=9L]:M%UX010 6UW!<K9%K:!2(6\@IO99''F$GS,;3Z310!\P^)_@/\
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M\6*OQ2T/6K-M.LM1M;KP[J6E1VNG6GF::EP[+=1[;>><7$[VOVB[FB</@CY
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M1^*7@"W\2A[2:"ZOM0BMIK$DPS6\-[/##(I).=T<:-G."6)&!@5V]!(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!X%_PTUJ>H?$35/!>C>%M/U#5E
MU./3M,NIM7GM[*ZRFHO*9)39DHT8TN92L*SKO=5W@J^RAXQ_:LUOPS''-9?#
MZ77X[S4M3L=-M=,N;NYO;E-.FE@NV>&"RD$3F6-%B4L582$R20;2*X?QA\>/
M@:OB[7]#C\$^&KN)]7NY?%LEUI-C<-?16-O?S3W!BC=I#+'/;$ W**6$I:,,
M'#T_6?C=\(/''A7QGXCT/X+V?CR\TN :KX@*VFB3QV\L8G6W>YN/M#),VV.8
MJT!G95)SM+!2#/5- _:"UG4==T?3]3\)6VAI=:U<Z-?RW&HW!.G2JL+VT4@^
MQA3-.LVY1N$) 7;.[.JGB/%?C_QG\)?B/9^ O _AW29M!M;^RFAAO=:G^T:@
M+RWU:YN#<3RP3,K&:U>0N"[$H,D^:P2>S^)OPM\-S27]I\%;G39?#]SJ]^+F
MVT;2D>S6T>.'4[Z,K/G"L8D8IF67;\B2!#B3Q-^TA\/+/QM8ZQK/P]N8-0CD
MU2TM_$>I6-H\\EIIR7OVM[9HWEE*I)"Z>6XB)%SN4')! .H^&O[3?_"T/B!;
M:)IGA#5%T.:T@F.N&"Y:.&:6P@O521A;^0J^7<*@/G^87&/*"LKMB7W[84&G
M_$2X\'R^%95U"&__ +*,IO<I]KDU+[-;P\1$[GLPU^V =D8Q\Q(-=-K'B'P%
M\*M+T;Q[KWP\C\%ZA)'+I9NI-/L#>:;;06L\RI+-;R.JPF.UVHJ2,,R1+@9.
MWD]2_:"\*2:A8WUE\+-2NM7OM?MA#/=VNGPRS3K<KI4]VKF<MYENSK;$MM8B
M1 I,1+@ X%?VJM8^('BKPOK\OP^N+;PYH^DW7BM8=2GNK/?"?LL,=U;/)9I]
MIN$AO;E# A,#&52L[DH:]R_:(^-6J?!?0UOK/1K6ZM9-/U"<ZIJ$\J6]O<PP
M[[> K'$V]IFW !WA4["H?>R*?(O#_P 5O@S):Z3K=Q\$K73KB2XMI[*_MM%T
MR2.76;BSMKU+>VDWK+]H9)HL2O'&K,GWQM%=WX[^+'@76/!FB>-?%/P\%^EM
MJ&L:1);:Y96D]]IOV:VO6O%CPTL;;_L#QX60*X8$M@8(!C0_M6>)=,CT^"_\
M"MK>HW^L:S#'#X?-Y=NMA8WT=JTA2*T<^=F885]D1$>6EC9U2O1/BO\ '6+X
M7>,O"NBOI\&HQZQ<16\YCN)Q<VOG2B&&3RTMWC\LR':6EEBZ$)YC?+7E/C3X
MP_#.UTF_OM1^#&=?M)+[5CI^M6&DQR17MMI]O=B5Y//8&62"6#;Y1DEQ&^5
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MP@ H=TQC81_5^@>%]&\*VAM=$TBQT>V(13#I]LD"82-8T&U !\L:(@]%10.
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M@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ'JWBRWF;Q+]IU#_ (G+V=Y#8KILB;%N8]2NI9(FNQ&^#,&W.W[M(U4#F/\
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MN9]0M;J\ACEO+K[3,]JMU*+5I)2S%V-OY)+,2Q.=WS9KL:**!!1110 4444
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M@Z5:^7+I^H74-TL5]"\DR#!FMXE\Q1"K.L1E0"9 )&.X#B]<_:,\2^ _%WQ
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M6MW<W-K=7RW"8 \J22T"_(2=EQ+D= =W7OV<_%/BW1/'M]JG_",Z+KGB74-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1K@W>D:I:QWMG<&-X_-AD4,C[7 8 J0>0#S6I02%%%% !1110 4444 %%%%
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M%XDN(1;3:PEG&+R2(8Q&TP7>5^5?E)QP/2MJB@ HHHH **** "BBB@ HHHH
M*H76@Z9?:M8ZI<Z=:7&IV"R):7LL"M-;K( )!&Y&4#!5#8(SM&>E7Z* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **R/%E]K&F^'[RZT+3['5-4B4-%:ZC>O9P.,C=NE2&5EP
MNXC$9R0!QG(\;\"_M >-OB+I&ERZ)X T:;4[K0;'Q-/9R>)W2.&SO1(;2-9#
M99:X;R9]R%5C78O[T[N #WNBO.;+XT66J6OPSU6TLF/ASQQ#NM]0GF$;VLKV
MINK>-X\$'>B3*3N&UU1?F+C'%^&?VCO$7Q"TK4=6\'^ [?5=,TN/[1=M>:T;
M::6&13/;"V06[B262T:WG*2-$JFYC3>W+  ]ZHKYF\0?M<:]H]KK.K1>$O#4
MOAFSLM$U2#5KGQ7+;K+9ZK=O;V<T@-@5BVA#)+\S!%^Z9.:]Z\!^)F\8^$=-
MUEI=(F-Y&9/,T'4O[1LF&X@&*X\N/S!QUV#G([9H&;]%?-6N_ML:7HGPE\?^
M+SX<FEU3PKK]UH*:%]KVO?F&5U\^.0Q\(8HIY#\IV^1*N6*YKT6Y^.4%O\9I
M_ QTB0V4=FP&N>>!$VI+"+DZ?LVY\S[*RS[LXVG&/4 ]0HKY7\&_MTVWB'0?
M#NJ7GA6%XM:OK33X1X>UC^TP+BYL)KF*TW&&(?:Q)%'#)"<+&9T9I,9QZY\4
M/BSJ/PI^$\'BO5](TNWU-KJPM+BSN]9,%C:/<W,4!>6\,!VQQ^;N9_*Z*>.]
M 'IE%>&^"_VI;#Q%X5\5>(-3T5]+T[P[X:@\27,EM="Y6>)Y+]&$!*)O0BP+
MQR<>8LR':O>SJWQ\UWP1=1:?XR\&6^FZOJ5JD^BVFDZT+U;N1KRULQ!*[PPB
M%Q-?VH) D3:[L&.P@@'M-%>)>)OC]KOP]\2>%O#7BGP?9GQ)XHCU Z18^'=8
MDOEN);?[+LB+RVL&PO\ :)69F 6-("Q+;L+T.D?%;5;[XM-X(O-'TG2Y;>PB
MN[A[C6'%S<%H]SM8P&V N8$?$;2EXRISE!\NX$>F45\W>-/VQ$\&^.O'OAY_
M#^GWI\+VM_.L4&N?\3"?[-I::AYDEKY'[FW<.81-O?\ >+C9Z=G\.?CT?'&O
M>&=+:#PY>?VW9:G>K?>%_$/]K6D(M'LD\LR>1%EV-YR,#;Y8^]N^4&>O45X-
M)^TIK*^'K#Q)%X(BN/#OB""];PQ+%K&;K4)H;2XNH4GA\C; D\5K(4=))B-R
M;E!; IVO[86F:QX]\3>%=(\/SWMY9:%INLZ--)="--8-ZT*11@A&\I!)=6R-
M)\V-[G;A/F /H6BO"OC1^U)!\&?'MEX?NO#DVI6<ATZ2[U"&ZVFUM[D:D\TY
MCV'<L$>F/(WS#*N>FWYM#Q%^T5'HOP;U[QZFE6?EZ;XAET!8K_5!;6IV:O\
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M6I6DEXDN@W,NI::8U=5!2]\F-&W"1" 0K-\^T,$9@".GHHHH **** "BBB@
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MYV\1>*/$OBJ\%JMG87VIW,"3Z8BSPW"M T$,0\P36UM)YD@=RT"9) (/J]%
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MF$=S+'YT5[/^\N(9-GF1R-C=&Z8 &  #T&BBB@04444 %%%% !1110 4444
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M)+37](\0:+K>BV5C?#1+JVA-YJ*W95(DM$25A*XE;RF&X;7!&<#=0!TO]O\
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MK\(7?B2:]CL_^$@M(($5+:U^U22R%9VPAC! (R=P((7K0!Z!X-U#QC??;/\
MA+-"T/1=NS[-_8VM3:CYN=V_?YEI;[,87&-V<G.W SS/]O\ QA_Z$7P/_P"%
MI>?_ "IKG/#O[5VB>*]-O]:TWP;XTE\)VUE=7\7B:32TBL+N*"-Y&,1>42?,
M$(0NBACCD9K-T?\ ;:^'_B#PEX0\0V%MK-Q9^)8=5E@A6"'SK5M/MGN9XYU\
MWY7,:?*%+ [E.0#F@#O]+UOXJS:E:)J/@SP=:Z>TR+<SVOBZ[FECC+#>R1MI
MB!V R0I=02 -PZC<\9:AXQL?L?\ PB>A:'K6[?\ :?[9UJ;3O*QMV;/+M+C?
MG+9SMQ@8W9./*X_VO-'3X.ZK\2[_ ,"^--(\-6<.GW%M]ML[59M2CO)5CB:V
M"W)# &2,MO9,!QC)XKL/A;\>-$^*6M:SH*:5K?ACQ/HZ1S7FA>(K,6UTD4F=
MDJ[6='0D$;D8X[XR* &_V_\ &'_H1? __A:7G_RIKK]/O/$DGA-[B^TG2K;Q
M-Y,K+IUOJDLUD9 6\I3<FW5PK )N;R25R<*^!GBE_:,\)M\?F^$.+X>)Q8_;
M/M'E)]C+;!)]GW[]WG>41)MVXV<Y[5R'@[]MKX?^.?#ECJ^FVVLXNO%=KX/:
MSF@A6X@N[A]L4KJ)2/))!^<$GY6^4D$4 =K_ &_\8?\ H1? _P#X6EY_\J:T
M_#>K_$FZUJWBU_PGX5TS26W>?=:;XGN;R=/E)7;"^G1*V6V@YD7 )/.,'SOX
M??MF>$?'VJ>'[<^'O%7AVQ\0WDVGZ/K&M6$:6-]<QNZ-"DL4L@#EHI  X7.T
MXK>^*'[26E_##QY;^$6\)>*_%.K2:0VN.OARQBN1#:++Y3.P:9'.&(X56^\*
M .F\2:O\2;76KB+0/"?A74])7;Y%UJ7B>YLYW^4%MT*:=*JX;<!B1L@ \9P,
MS^W_ (P_]"+X'_\ "TO/_E37->,_VQ_AQX+\*_#_ ,1RWEYJ6D>-I_*TV:PA
M4F., &6>9792D<61YA ++_=ZTOQ _:FMOA[\1[/P5/\ #?QUJ^JZAYQTV;2[
M*T>"_6&-'F:$O=(Q""1<[E'/K0!ZGJ%YXDC\)I<6.DZ5<^)O)B9M.N-4EALA
M(2OFJ+D6[.54%]K>2"V!E4R<<A_;_P 8?^A%\#_^%I>?_*FN5M_VM]&NI/'D
MT7@CQD^B^"Y-5AU/7!:6OV(R:>CM,D;?:-Q9MF$RJY++G;SC4^%?[4'ASXI>
M(K+03H?B/PEK.H:<-6TZT\26*0?VA:84F6!XY)$< ,I*[@P!SCK0!V7A'5/'
MM[J4J>*?#7AS1]/$):.?2/$-QJ$K2;EPICDL8 %QN.[>2" -ISD9NJ:W\58=
M2NTT[P9X.NM/69UMI[KQ==PRR1ACL9XUTQPC$8)4.P!)&X]3Z#10(\T_M_XP
M_P#0B^!__"TO/_E377^+KSQ)9:;$_A;2=*UC4#,%D@U?5)=/B6/:V6$D=O.2
MV=HV[ ""3N&,'<HH \T_M_XP_P#0B^!__"TO/_E373>#=0\8WWVS_A+-"T/1
M=NS[-_8VM3:CYN=V_?YEI;[,87&-V<G.W STM% 'FG]O_&'_ *$7P/\ ^%I>
M?_*FK6EZW\59M2M$U'P9X.M=/:9%N9[7Q==S2QQEAO9(VTQ [ 9(4NH) &X=
M1Z#7SU\?/$'A_3_C+X.L/%_C34/"'AZ;PYK%Q']B\07&E>??)<:>L(40R)]H
ME"23[8B'W9;Y&H&=Q\7_  #=>++JUN+'P7X?\62R:?=:5<G7M=N=-$5M-)!(
M5C$5K.&+/;QMO.QD,2%3R<>9:E\"_$VKR:H]U\/-#;^U)+>XO$3XM^((TFG@
M$ AN"JV(7SE^RV_[X#S,Q@EB<YXSX':UJOQ"^)^KZ#\1M=EM?$LUGI@ETH>/
MM1TG4H96T.QGN%@TF I&5\YIV:565E8R#'R\XFD^(O'MQ\(_A?:^!?\ A,_%
M'B2UT&Q\<:_+#KAN9;BZ>-%M[2X:\N@PM;CRKPO%#D@QH5CRQ- SZ=^'?@G5
M/"^E:GJUQX=L+7Q@;)=.MU?Q9?ZNEU!$TLUND]Y<P"5?WUS."?+D*JPP6 5%
MR+RQ^)E_XCMM>G^'7@>35K:QN--BN/\ A.+\;;>=XGE3:-*VG<T$1R1D;.",
MG/'_  A^(GA+XA>-)M8\0>-[RU\57NIO-X?\/3^()]/AFTQT#V3P6*RI'=+)
M RRL[)(?,>1<_NP%Q?V<_&WQ!U[4_@?'XI:--.U#P%?7@N(=;N+V74Y5.EXG
MNXY((PDH$C8^>7_6R#<.K CN- ^$>HZAJ/@ZS\1?#CPIINA^&;2*QTZXTWQC
MJ%W<64,$EO/ B1/90B7$UE:$EY,XC/+996VU\":[\.=0OH_ ?A72M=MM3AC-
M_J7BOQKJ1OI'7>JQ;Y;:[<QJIRO[T %WP@Y+>87OQ2\5_P#"]9_%:6VO#X9R
M7DG@Q+I;B Z3Y@;RTNQ&)O.%P=1#6N_RMAC*G?G KPJS^+GC*W\._"W0?&WB
M[6K"W;PWI6JZCKPU:>Q6\TZ]UC0P)IKA)%9)8HY+ZW>0L&"J7+#S30,^G;_X
M<^--0\*>'?#I^&O@^TTWP[%'!I+Z?\1=5M+JR2.+R5$=S%IJS+^[^0_/\P)#
M9S6['\%[6#X>R)%X#T"+Q-):V=HVE1^([Q;(I:WTES;M]M%OYOF+)+)/YGD;
MVE8AF/WZXV3Q1J$'[./QXU#P_K^I:AH6F6FJ-X2U][^6XGDMUTJ*0R0W;DR3
M*EV;E4F+L3L&&(4$^,'QEJGAOXG:+X;\5^)?["MH;K4Y)M'UWXFZGI]O OV?
M13;LFI$>=>;]]U*D4BJH,TR<>4:!'T+J/@?QMJUOJT%Y\+? =S#JNK6^N7L<
MGCG4"L]Y (!#*1_9?11:P?(/E.SD'+9K^!_V>[=VU'3?%/@#1K#0;C1Y](B6
MU\<:IK)M[>78KVMO#<6\2VD+(N#Y#+CRXU"X *\7J^EWOA&3XP:IINO^*]OA
MWQ;H4*-=^)=1NXK32\:/=WQV2SLNW8]TS-C(C9TSL^6O._BYX^\4^,_'GBW4
MO!GB/5-8\*K!K=[IE]HGB6ZMK:*.VTW05:[MA;$I>?9YY;MA;$B.1S,I.[((
M,^FKWP=XE\+_ !$\7Z_X0^'_ (1N9/$BVJ:AJE_XKO+.XOA!$43S($L)DC*[
MY%!1R6&">>!S.H?#/QGJ'AOPYH?_  K;PE8V7ARV2STF73/B1J]E=6<*QK'Y
M:7,.G)-M*(@8%R&VJ6R0#7E_B[XG>,](\8>,+NSUW4=3\'ZUX^\.Z+I]Q:3.
M1IK8T>X.QE/RVUU#-=*_1=RH,$SM7K_Q&\-+<?M%>#F75_$=M;W>@ZOJ-Q9V
M?B*_M[22XM)=.6W8V\<RQ8 FERNW:^\[PU &YXH^"^E:3H]L/!W@G1;^]C;3
M(1;W^M7.EQ0PV$LL]JT<D,,S!XY9&. HWB1][$?*8-6M_B=KFJ:)J-]\._ \
M]YHMR]Y82?\ "<7R^3,\$D#-@:4 V8YI5PV1\V>H!'SE:_$KXG2>&_@O)K%X
M^FP7WA71K@76G:_<W4^I%]:\.Q/-=JT$025HIY5(#2Y$\REL$EO:_P!GGQ/#
M=3>/=&C\2?\ ":7^G".XF\4V/B&;4[.[\UKC8@C9VCLIT\L^9;PX4!HF'#!5
M .D\#_"8S>+[OQ+XI\'Z3HFHQW8U"TAT?Q3?ZE9-=.KK+<FTE@@@BFP?]:L;
M.QD<D@Y+<-IOP/\ $&EA%A^%?A"2*+R!;0W7Q*UB>*R2&YAN8XK9)-.9;>(3
M6\#>7$$0^2@*E5 KS#X8R>)M"\%_#/4_B=XWU+1/ASXKTNWO;N^_X2O4'D6\
M%C$\37.HR&.2T6Y+RN88Y!&LD$:*S^:P.3XV\;>+)KRUGT'Q%KU[X+TF'6KW
M3=<77KR)QI<%YI*'4F"$C4EM_.O JSL5FA0OO<D!@#Z0T_P3XNN;<Z+J7PY\
M'6OAV]UR/6[X6OC6_F=+@7:733QQG3D!83()?+#HC-G. S&I/'GP42'6M*U?
MP?X5M;O48;F^NI9YO&NJ:$8GNIHIY@HM8I1*DLL8=XW"H&4':Q=L>7WEC=>%
M_$'CJ\TCQ%XHE-C\0_"^D627?B?4;N!;*Y;1IIX@DL[H5=IYLMM)VR,@.P[:
MX3Q)\1=3M?@_]O\ #GCC7+[XA3^#]6NO'%A_;-Q*^C7::>S[_(+D:?+'>;(H
MTC6+<K/][8" #V_2_AGXST6_U*XL_AMX2BM]26X6ZTD_$C5VTN03DF;_ $ Z
M<;8%RS%B(P268]6.=KP?\#[?3_"^H3:IX.TZ/Q''-;3V%O)XPU+5HF-G(MQ9
M(;RYA66");@9\J.-D4#=M?<5K%^!OB[Q;?\ QI\;^%?%%S=W%_X8\/:39R-*
MS+:WLIN-0*WT:_=#3P?9C(5'RNK)SY=>(>)/B+J=K\'_ +?X<\<:Y??$*?P?
MJUUXXL/[9N)7T:[33V??Y!<C3Y8[S9%&D:Q;E9_O; 0 >LR? G79-6-^?A3X
M/#-D2VJ_$K6!9SJ;J:Z$<UL-.\F6,3W$SJCHRKO(    [GP/X,\667Q*;Q)K
M7A#1;26YCGAFU%/'FIZO):1R%79+:UN+-(HE>2*'<L;1C"*<'8%KP*Z^,GB/
MPC\?=$T3QYXJN-!T_P /76E:5K%]>7QLM.OU:S\0.EV266/]^JV+/V$T83DQ
M+7L?P*77=:\<^(8+WQ7<:[X:\&,NDZ-+'>22'4TN;>&]2ZNI-Q%PR6]Q;PHQ
M+9*RR'+2#: >]4444$A14=Q<16L$DTTBPPQJ7>21@JJH&223T %?)/CS_@J+
M\$_!6M3Z;:S:YXK,+^6]UH-E&]N2.NUY98]XS_$N0>Q(YH ^NJ*^(/\ A[M\
M'O\ H6_''_@!9_\ R71_P]V^#W_0M^./_ "S_P#DN@=F?;]%?$'_  ]V^#W_
M $+?CC_P L__ )+H_P"'NWP>_P"A;\<?^ %G_P#)= 69]OT5\0?\/=O@]_T+
M?CC_ , +/_Y+H_X>[?![_H6_''_@!9__ "70%F?;]%?$'_#W;X/?]"WXX_\
M "S_ /DNC_A[M\'O^A;\<?\ @!9__)= 69]OT5\0?\/=O@]_T+?CC_P L_\
MY+H_X>[?![_H6_''_@!9_P#R70%F?;]%?$'_  ]V^#W_ $+?CC_P L__ )+H
M_P"'NWP>_P"A;\<?^ %G_P#)= 69]OT5\0?\/=O@]_T+?CC_ , +/_Y+H_X>
M[?![_H6_''_@!9__ "70%F?;]%?$'_#W;X/?]"WXX_\  "S_ /DNC_A[M\'O
M^A;\<?\ @!9__)= 69]OT5\0?\/=O@]_T+?CC_P L_\ Y+H_X>[?![_H6_''
M_@!9_P#R70%F?;]%?$'_  ]V^#W_ $+?CC_P L__ )+H_P"'NWP>_P"A;\<?
M^ %G_P#)= 69]OT5\0?\/=O@]_T+?CC_ , +/_Y+H_X>[?![_H6_''_@!9__
M "70%F?;]%?$'_#W;X/?]"WXX_\  "S_ /DNC_A[M\'O^A;\<?\ @!9__)=
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M#W_0M^./_ "S_P#DNC_A[M\'O^A;\<?^ %G_ /)= 69]OT5\0?\ #W;X/?\
M0M^./_ "S_\ DNC_ (>[?![_ *%OQQ_X 6?_ ,ET!9GV_17Q!_P]V^#W_0M^
M./\ P L__DNC_A[M\'O^A;\<?^ %G_\ )= 69]OT5\0?\/=O@]_T+?CC_P
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MM8:>_P"XLM3FM7C\D0M$L#%;=79%W!P2Q?<BY8C(/?T""BBB@ HHHH ****
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M.%X8O*\[RHU3?LR=N=N<9.,]: .JHHHH$%%%% !1110 4444 %%%% !1110
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M!&) 0?WN[( L?4=%? <?Q&_:BT[P6-1=O$^HZL^C6\WV23PK "MS/IFJ2/\
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MTO4-2U/Q1<W%Z^L^'+-;.^M_M^GW$IL'"13RZM<Y4R:9>1MOO4D5YVC3ROD
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M?$%SI4\=MJ<.GW$EK--$94CE$;%&9 RE@"!QD9]16Y10(_/&V_:2^(?A_P"
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M)?\ E))\?/\ N/\ _IX@K]*J_-7]B7_E))\?/^X__P"GB"OTJH&PKX?\6?\
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MO[0'PFET.Y&G?"Z\DTN?2[>&WAM](TX)J45Q'I2?8XX_/&?W=]IJLL@6,J@
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M\,^>%_\ H*>./_"^UW_Y-H_X9\\+_P#04\<?^%]KO_R;0!Z717FG_#/GA?\
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MX;O\-6^K:M$_AK7-1TZ'3QK5G<:7'$SMIZZ98ZA--,LLD>PJE\/E4L3Y;=R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=W1O9+^>Z:U26^FNH'@EEDDBMT=?W3!1'$R1?NXR4+*#0&A>^)/[8G@3P/\
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M\896&.,D ZZBO.-1_:#\#6]YX-MM.U_3_$3^+-4?2M-?1]1M9D9XXV>5RQE
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MZ!FE1110(\W_ &EHGG_9R^*D42-)(_A3555%&2Q-G*  .YKS;XP7D#_\$_\
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M,FUY#M$01-H!]K2:_ID6N0Z*^HVB:Q- UU'I[3J+AX58*TBQYW% S*"P& 6
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M+N>YO_&+^'H-+M&MH9+6W.HM9QO*S73I(ZE=K%& ,C<*(QYE<CI?[>WA?0_
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MW*6K"8&UC)D?,<!C0AL$$<5ZC10!YY'^S]X C\/C0U\/J-+&[%O]JG_BT_\
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MQN^7C:1F1E8YKTJB@#S)OV;?AVK.UKH<VE2>8LL4FD:G=V+VK!KAO]':"5#
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M!\#?!-OK%[J::.YN[N]CU%_,OKAXXYTNOM8:*,R%(0UP/-=8PJN_+AC7>44
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MERR*)D42#<2&!YKKE&T >GKS2T4 %%%% !1110 4444 %%%% !1110 4444
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M!(/HM%% !7P_XL_Y2P>"_P#L4Y/_ $5=U]P5\/\ BS_E+!X+_P"Q3D_]%7=
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M6- +G>JK<6]QNC=5BPD0(:-5 R_$GPH^.^L^(_$-_P#:]7DE6_U6XT]1>1)
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M3I+$:04BL1;BY7%P=2"R&1H@K1DJTVPF&@#ZBL=2M-4BDELKJ&[CCED@=X)
MX61&*2(2#PRLK*1U!!!Y%+J&H6NDV-S>WMS#9V5M&TT]Q<.$CBC4$L[,>%4
M$DG@ 5\B77P6^*>@^'[^X\(_\)'IEUJ]UJ]S?:;=>(6G,<4FLVD\"QI]M15G
M>S%X"\4\3%I6W3JQ5UZ;P;\'_B%-\)/BM9^)M0US5_$6M:++I6C6^KZD1$(F
MTY$5?(%W<11R>>TBM*9'=MNXN=Q) /IM6610RD,K#(8'((IU?'Y\)?&?0/#.
MLQZ'H?C)X=0T[4--TS3;[Q5;W-YI<TEOIBQ7,T\EV<J)H=1=2CR.HE "H&VI
M'9?!7XF^)/B1X/?5$\6:?X6L]5U9=1U&;Q0T&I7%E+%;20[W@O9&1&GB*^7
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MBBB@ HHHH **** "BBB@ KX?\6?\I8/!?_8IR?\ HJ[K[@KX?\6?\I8/!?\
MV*<G_HJ[H&C[@HHHH$?(O_!4K_DT_4/^PM9?^AFOI7X9?\DW\)_]@FT_]$I7
MS5_P5*_Y-/U#_L+67_H9KZ5^&7_)-_"?_8)M/_1*4#Z'2T444""BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *^'_%G_ "E@\%_]BG)_Z*NZ^X*^'_%G_*6#P7_V*<G_ **NZ!H^X****!'R
M+_P5*_Y-/U#_ +"UE_Z&:^E?AE_R3?PG_P!@FT_]$I7S5_P5*_Y-/U#_ +"U
ME_Z&:^E?AE_R3?PG_P!@FT_]$I0/H=+1110(**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX?\6?\I8/!?\ V*<G
M_HJ[K[@KX?\ %G_*6#P7_P!BG)_Z*NZ!H^X****!'R+_ ,%2O^33]0_["UE_
MZ&:^E?AE_P DW\)_]@FT_P#1*5\U?\%2O^33]0_["UE_Z&:^E?AE_P DW\)_
M]@FT_P#1*4#Z'2T444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *^'_%G_*6#P7_V*<G_ **NZ^X*^'_%
MG_*6#P7_ -BG)_Z*NZ!H^X****!'R+_P5*_Y-/U#_L+67_H9KZ5^&7_)-_"?
M_8)M/_1*5\U?\%2O^33]0_["UE_Z&:^E?AE_R3?PG_V";3_T2E ^ATM%%% @
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OA_Q9_P I8/!?_8IR?^BKNON"OA_Q9_RE@\%_]BG)_P"BKN@:
M/N"BBB@1\B_\%2O^33]0_P"PM9?^AFOI7X9?\DW\)_\ 8)M/_1*5\U?\%2O^
M33]0_P"PM9?^AFOI7X9?\DW\)_\ 8)M/_1*4#Z'2T444""BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^'_
M !9_RE@\%_\ 8IR?^BKNON"OA_Q9_P I8/!?_8IR?^BKN@:/N"BBB@1\B_\
M!4K_ )-/U#_L+67_ *&:^E?AE_R3?PG_ -@FT_\ 1*5\U?\ !4K_ )-/U#_L
M+67_ *&:^E?AE_R3?PG_ -@FT_\ 1*4#Z'2T444""BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+/8774-'@.D&UNK)URR6ZB,QSVT!2WE)B7]XJQ!,J/5O"L'PO\->*--\6_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPMCQ1_T1CQQ_X&:%_P#+.C_A;'BC_HC'CC_P,T+_ .6= 'I=%>:?\+8\4?\
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M3U;2K2TOI+?67LW\V&Y>X2-T:UN)E^]:S ABI&!P<T =Q1110 4444 %%%%
M!1110 4444 %%%% !1110 5\/^+/^4L'@O\ [%.3_P!%7=?<%?#_ (L_Y2P>
M"_\ L4Y/_15W0-'W!1110(^1?^"I7_)I^H?]A:R_]#-?2OPR_P"2;^$_^P3:
M?^B4KYJ_X*E?\FGZA_V%K+_T,U]*_#+_ ))OX3_[!-I_Z)2@?0Z6O-/V@_\
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M:;?01W5K=0^ -.9)HG4,CJ=_(*D$'WH ^H:*^:O^%$_M$_\ 1T/_ )C[3O\
MXNN/UKP]\:?#VNW^F7_[5$L/V!; 7-T/AUISPQ2WMS]FM83MD+>8\F.-N%5E
M9BH8$@'V+17S!J/P:_:$TN!)IOVG[AT>:* "W^&UE.VZ1U1251B0H+ LY&U%
MRS$*"1'K'PD^/6@6T5QJ7[5L-E!+<0VD<DW@'35#332+%%&/WG+,[JH'<L*
M/J.BOCSQQX?^,GP[N+>VUG]JR[^U3PO<K;:=\+;>_F6%" \SQVXD:.)2R@R,
M @) SDUTVG_!GX_ZOI]M?6/[545Y9742SP7$'@'37CEC8!E=6$F""""".H-
M'T[17S5_PHG]HG_HZ'_S'VG?_%T?\*)_:)_Z.A_\Q]IW_P 70!]*T5\GVGPW
M^/EUXPU'PT?VGYH-3L[2"^Q+\/=,"3P2M(@>,B4YVM$RL" 5)7(PRD[?_"B?
MVB?^CH?_ #'VG?\ Q= 'TK17S5_PHG]HG_HZ'_S'VG?_ !='_"B?VB?^CH?_
M #'VG?\ Q= 'TK17S5_PHG]HG_HZ'_S'VG?_ !='_"B?VB?^CH?_ #'VG?\
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M>::!_P G)>.O^Q2\/?\ I9K5>:_\*)_:)_Z.A_\ ,?:=_P#%UUWP6^#OQ \
M^-M?\1>-OBA!\19]6TZUT\EO#<6F2P+;RSR1;6AE*%<W5QD&,L2R?, N" >S
MT444""BBB@ HHHH **** "BBB@ HHHH **** "OA_P 6?\I8/!?_ &*<G_HJ
M[K[@KX?\6?\ *6#P7_V*<G_HJ[H&C[@HHHH$?*'_  4[TN?4/V1]>FA4LMG?
MV5Q+@$X3S@F?S<5[M\#/$5CXM^#'@;5].G2XL[O1;1T>-L@'R5#*?=6!4CJ"
M"#TKI/%7A?2_&WAO4] UNSCU#2-2MWM;JUE^[)&X(8<<C@]1R#R.:^"M<_8F
M\7?!75;C2_AQ\=_%'A7PS=L;J+2EB=Q"22#EDG16/'W@BDX&<XH&?H565XJT
MW^V/"^KV']FV.L_:K.: Z;J4ACM;K<A7RIF"/B-L[6.QN"?E/2OS\_X47\:_
M^CF?%7_@-+_\E4?\*+^-?_1S/BK_ ,!I?_DJ@=CUWQA\!/&-CX<AU77+FTOM
M-TNWN(D\-QS:AK8-L^J:5=)IS2+:O<7$#I8W$;N86*)<!=CQH:P?A[^R7J'B
MOP)XIUFZ\,Z!X;UG4M*O(?"EI<6\B-X?NFU;5+NWEC#6Z/ BI=6A0^6DBA6!
MCC.5K@/^%%_&O_HYGQ5_X#2__)5'_"B_C7_T<SXJ_P# :7_Y*H&=YJ7[%WC?
M7/%=]K^JV/@/4&DN;>_?2_+A@M-0N8M4MKDR.(M-5X]]NMY"3*UTX^T,N]E=
MZZ?Q7^RGXQ\936NB:DOAN7PG9:AJ4XDDU">2:_M[WQ%9:I)%+!]F"Q[8;:6+
MB1PS,OW03CQS_A1?QK_Z.9\5?^ TO_R51_PHOXU_]',^*O\ P&E_^2J!'TI\
M#?V<-1^$WQ:\2^()6LSI5V+Z.Q:QG@BS!-=)-##+;I8QOB"-%BC9[J8(JE8T
MC5]B\]^SO\ UU;2/ GB7Q58WUN-+\':#HZZ->2WMB\6HZ=<74CM<6IV1S*LD
MD31-('&Y"Z8!5F\,_P"%%_&O_HYGQ5_X#2__ "51_P *+^-?_1S/BK_P&E_^
M2J /9]#^ /Q.L;'X3VU]I7AR=? FA3Z(#IGCG5-,>]WBRVS&2"Q5@!]D;,#%
MD;>,GY:ZC5OV=?%-WXLN?'?]OV^H>)9==EO&\.7IA&CSV#I]C^SO,+1K@$V0
M5BI+1>>"=ASOKYP_X47\:_\ HYGQ5_X#2_\ R51_PHOXU_\ 1S/BK_P&E_\
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MDEM;JQ,5C:64XMK5(FC<-'9JT9\V+RFDX#!!GYU_X47\:_\ HYGQ5_X#2_\
MR51_PHOXU_\ 1S/BK_P&E_\ DJ@#V3XH?!/Q?X?\*?%SQDD=GJNO^.?#VJ:?
MKFCZ3:RW#@_97ATM++RX?,E=<K'*7"A_-,A*")4KZLTZ-HM/M4<;76)00>Q
M%?G?_P *+^-?_1S/BK_P&E_^2J/^%%_&O_HYGQ5_X#2__)5 6/T8HK\Y_P#A
M1?QK_P"CF?%7_@-+_P#)5'_"B_C7_P!',^*O_ :7_P"2J L?HQ17YS_\*+^-
M?_1S/BK_ ,!I?_DJC_A1?QK_ .CF?%7_ (#2_P#R50%C]&*^>M+^"OCU+LVL
MTWARPT_2?$>O^)](O8[B>[ENKB^^WK!'<0&*-8HXUU!BX623>4 &T$U\V?\
M"B_C7_T<SXJ_\!I?_DJC_A1?QK_Z.9\5?^ TO_R50%CTO2OV,?%EOX;T^.1?
M"MGK-IXEN-3M)K;RE&E6\^D?8FEMFAT^",31W*Q72QK#&K-#&6DWCS*]=_99
M^!VJ_!+0M8MM6^RQW%\\!,6G7D$MJQCCVF58X;"S6-WS\Q(D9MJ;I#BOE?\
MX47\:_\ HYGQ5_X#2_\ R51_PHOXU_\ 1S/BK_P&E_\ DJ@#]&**_.?_ (47
M\:_^CF?%7_@-+_\ )5'_  HOXU_]',^*O_ :7_Y*H"Q^C%%?G/\ \*+^-?\
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M^-?_ $<SXJ_\!I?_ )*H"Q^C%%?G/_PHOXU_]',^*O\ P&E_^2J/^%%_&O\
MZ.9\5?\ @-+_ /)5 6/T8HK\Y_\ A1?QK_Z.9\5?^ TO_P E4?\ "B_C7_T<
MSXJ_\!I?_DJ@+'Z,45^<_P#PHOXU_P#1S/BK_P !I?\ Y*H_X47\:_\ HYGQ
M5_X#2_\ R50%CZ2UWX%^+M;\0>(GL4T;PQH-]JVG:E_9EKJUQ=17LUOJ]O>2
M7C1M;HMK,\4,@9(MZR22@N^5WGR+X3_L^7_C"WUK2IO">EZ;H\,/A*SO[R_T
MR[M$\2OI^HS7%]<W$%U9PR/--$5W[EE1C(J^<^'V\5_PHOXU_P#1S/BK_P !
MI?\ Y*H_X47\:_\ HYGQ5_X#2_\ R50,]'O/V,?&NI^(M&CNW\'-X?TO5?\
M1F2"$SIHQOY9#ISA[!I73[+*80JW,404^68V7+MM^%?V8_'OA?PKX;T*UL_"
M5K;C3O"UCJS6NJ7"+"^D:G+=RSPH+,"9KE9-S!S$5D9LM)]X^._\*+^-?_1S
M/BK_ ,!I?_DJC_A1?QK_ .CF?%7_ (#2_P#R50!ZKX+_ &)M2\$ZY\,KJU_L
MA+?0M/TM=4_L^XBM9%U"WG:6YNHG?3YI9/M&41PLMLSI$$=F0JL?IGCSX2>*
M=:\::];:7!8/X=\1:SH&OWFI7EXT<UI)87%NTL,<0C;S-\=G!M!9%!DE).0
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M(UPPC4$;O=:_.?\ X47\:_\ HYGQ5_X#2_\ R51_PHOXU_\ 1S/BK_P&E_\
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HJ7?BKQEK2C^T?$6H+B612V\HBY8HI;#-EF+$ DG   V/?Z***"3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img191538130_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img191538130_4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" .Q R8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "UZIX+^+_BSQ?X^L/ OA&RT'1K#0?#VEZGJEQJ<,\QE6XCRL%JBR+M"JO\
MK'9\' VGK6<?>MZ)_>F]?1(;=M>FOX.*_%R/HJBOE'X;_M<^+_B!XVTPVW@C
M4+GPEJ.MS:1_HOA_42]C$DDD8NY;XI]F==Z*&C !3<<L2I%9W[<>EVVM?%/X
M$6=WX1/CRWDU'4]_AX/$AO,6H.W,K*@QC=R1]WCG%3TB^C-.7WI0>Z3?W7_R
M_7:Q]?T5\)?"OXZ:M\)O@;X.M]"2;5[[QCXEU2+3[2:SOM5_X1ZWC+L;0P1
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M^\CJ2&'N#7S9K7B;XC3?M;>*/#9\1::?"%OX._M$:4;*;B)Y73(/G8\_<O\
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M+U9M/N[WRX$9,-YT2G:?F^9QQNQG.#23A+1;W7IH[_.WY^8]*B<6]E?[MO\
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M1\4?#?2_V@-8\$^*-=\3^"_#>EPVMAJ.N79U$PZTSE9S;RR9+1QAU++DJ&&
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MW2_".GRZ:GVWX;^'?A[PCKGB/6-*T[[/J?B*Y6[U2Y::25KB14"*?G8[0%&
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MM\[DIK6WE_DOSL=_X;\.MX=\/QZ8VK:EJSJ'W:AJ4PDN7+$DDL%"C&> %
M %>;V_[/:Z+_ &[K-CXIUS6O'%SI4^EZ9KWB2Z%PVF)(,@1+&D8 #;6)QO;8
M,M1XH^-^N>";'58-8\(VS>(;5;"6VL=.U<S6]W'=7:VORSO!&59';E3'C!7#
M<G;=\/>,/'5Y\8GT+5]+T:RTI-"@O9HK/5)+AHI7EE4LA:UC+\H%P2HP-W4[
M:BW._6Z_!W_"ZT]"]8KF[6?XJWYIZ^IM?\*R>^^#J>!-0\2:U)+)I2Z;<Z_!
M>$:A(VP*\PF<,=[')R<]:XGP%^R?H/@;P;=^#9?%7B?Q+X,N--DTL^']8FM/
MLJ1N02R^1;Q/OZ_,6/WB>O-:GCCXGZ[X)^*%PEW;V7_"%6'AJZUF[<73?:/W
M3Q[G6/R#E@"5">8 0Q)(( K<\._$+7)?$FEZ1XE\.6VAOJ]K+<V$EGJ1O,F/
M:6BF!AC\N3:X/REU^5QNX&Y_Q+S?VKW^3DO3H[$+W+17V=ONB_U5SB+G]C_P
MO>>$?$VBS^)?%DMWX@LK?3+K76U"/^T$L86S':QOY6Q8\$J<H2P8[B3S6SX-
M_9X/@GPA<^&[+XC^-I-/:WAMK,O<V<;Z<L; K]G\JU0#( 4APP(XQR:B^*22
M:3XT76/$\GB!O @LHHTN= U2ZM$TR<.YEFNDMY$=XF4Q?/\ .L8C8L$!+&"/
MXN^(M!\1?$%]7TZQN]&TR^L;'28K*^+32S7*0+!&08% $CS EBYV9P P&:+M
M_/\ 3]==/73<KEM9+I_P/PV7E:QUGPM^#.B_"J36KRSO-3UK7-;E2;5-;UJX
M$]Y>,B[(PS*JJ%5> J*H&>E<;J7[)'A/4=1OYUUKQ'9V=YX@A\3OIEO>Q_9A
M?I*LIDPT18ARH!5F( ^Z%/-;6H?&;4_#-Q=Z5XA\-06_B/;:'3[/3-2-S;WI
MN)O(0><\,10K)]_,9PI!&XY4<GXZ\?ZGX3^,'PYG\2:-:1:YJ&GZQ8:=I>C7
M[W:W4S/8LB^;)#"$.%<DLN %SDDXIQNY1DO1?+5)?-+3H[!:]X/U?W/5_*^O
M:YZ-X9^#^F>#_B-XC\7:5J6J6[^(2LNHZ094:REN J(+@*4WJ^U O#[>3\N>
M:E^(OPETCXFZIX/O]4N;Z";POJ\>M62V;HJR3(C*%DW(V4PYX7:>G->>ZQXE
M\4:#\;O$-[8>'+#4KF/P;I]S?0RZLT$4(2XOB4CD\AC(QYVY1 =IR5X%=,_Q
MBU37!=7'A+PU#K=A8:?;ZA>2WFI&SD_?1"98H4$,@>01$,=[1KET&[DE9NHI
M/^6WRLW;\M.F@2C[SA_,OONE?_TK7[RGXA_9>\'>)?&UWXANIM5C@O[ZVU34
M=#AN@NG7]Y;X\F>6/;N++M7A656VC<K8J[KW[/FB^*M%UW3=:UWQ'JJ:CK*:
M[:SW>H[Y='N4*F,61V_ND0KD(0PY;.0<5R>D?%)(/&VO:AH%BNLWGBF;2(M)
MM[BX-K&^^PDGW22!'**L4;L<(QR  .:Q]$^,%QX!\4?$!]<T[2M*UW5?%5O8
MQ6]_K2P6"E-)MI&D:[:+.S8AQ^ZW$LHVCDAJ+5XO2WYWBOPTUZ6MT'%\RY^Z
MOZK7_@^OS.S;]ECP>WA%]&:ZUAM1;61XB/B0W2_VG_:0QBZ\S9LW8&W;LV;>
M-N*ZWP#\)='^&WA"_P!!T6XOD.H3W%Y>:I/*LEY<74Q)DN'<KM,A//W=HP %
MP,5QFF_M :EXDO?#-AX?\,V.K7FJ'4/M,BZT!:6XLY(4D>*986\]7$P*$*N3
MM#!<L5ZKX2?$J[^)FFW=[<6&FZ8(2J&RM]3>YO+:0@EHKN%H(_(E4;<KE^2>
M< %BUXM=&OPT7W:):=EV0G=6;[_C=_C>_P![[L\];]A?X0-\,?\ A#3X8M?.
M\GR_^$H%K;?VWYF_?Y_VORL^9N[XQCC&.*Z#Q-^S!X6\82>+I-6U#6+N;Q1H
M-MH%](TT(81P%C'-'B+Y9MS;BQRN0,**O>)/C9'X7^)%AX9NAX?DBO+RWLDC
MAU\-JJ-,IV.UCY/$>[C/F9Q\V.,5SS?M(7MOI<>H:CH&CZ+;:AK-UHVDRZKX
MA%O',UM+<)--.Y@Q"FVWRH7S&8N%V@#<4_?BV]G_ ,-^3_JPK\LK=5_G?\X_
M@=#X)_9T\+_#_P 0>$=6TJ?45F\,^'V\.6<,LL9CDMV=':20! 3*60'<"!R?
MEI?&7P4'B+XKZ9XVL=3.G2G2+G0-8MO+W?;K*7YD"MGY)(Y/F#$,,,PQS72?
M#7X@0_$3PJ=6AB@B>*XFM95M;I;FW,D;%2T4P $D9X*M@<'D Y \W@_:<CCO
M+^WN++P_J!LD@N;B7PYXC748[>V:Z6WG>8^0FQXMX<I@@A6^8;:<KU)*+U;O
M_P"37O\ ?=W\F)/DBY+967W62^YI6\T=OX4^"OA[PG\&;?X8QO>W_AJ+39-*
M9KN8"XD@<,&W/&J8;#'E0*X[1_V1_"%C<6KZAJFO>(K>WT"X\,K9ZK=1-!]@
MF*9BVQQ)@J$ #*0<?>+'!&_K7QFDLK#7+VWM]!L['3M9_L>*^\1Z\--MKEEC
M4R,LGDR8*REH@N#DHQR,8KSSQK\5+3XD> [BZMK6:'[;H<%X6CU!IK92NI+"
MRJ@ 1_F4XF&"RXX -)OGES/7F_&\6_R;^]^@?PXI+3E_#WDOSM]R.KM_V7-'
M73/#>FWGBWQ7JVG^'-7L]7TFWO[NWD%JULKK%"&$ 9H\/SN)<[5^<8J[X@_9
MG\,>)-+^)UA<W^KQP_$*6*;5&AFB#0F.-(U\C,9VC"#.[?SFK&J?&R/1_BA8
M^$;H>'Y%OKS[#$MGKZRZG$QA:57FLO*&Q#L89$C$94XY.WD?@=\0-;T7X??#
M^QU;PY!::'JP;3;/4(M1,MQYH25T:6#R@J(XB?!61SRF5&3M4I-Q<M[_ (WM
M^+Y8^;T+MRM/^7\$K_@M3L;7]G_1]'\?R>+=#UW7O#]Y>?9SJEGI]S$+75#
MH2,SH\;$': I,90D=:V_C%\)](^-W@&^\(ZY<WMIIMY+#+)+I[HDP,4JRK@N
MC#&Y!GCIGIUKQ'X>?M!6?@'X5^#=&CCT::?3?"MCJ%XFJ:Y'I\TB.C;8[:-D
M;SI"(W."47)0;OF./??%'C)-%\#R>([9]-2'R8[A9-<U#^SK54;;\TLQ1_+
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MQ\JX]'HI>1=W:QY+J'P;TCP9X7UQ=!TC4M<;4M).E7FD17,"C4V8M_I,[2E
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M>+M?U^U:YL[J(WPLT>%K:=)T"F*W3(9HU#;]Q('!!YKO**MRDWS-Z_\ !O\
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ME=>URTT^^FL[F[TVWDMQ#/-:B(1.SF$RCB"+*JX0[?N_,V?3Z*KF;;DWJ_\
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M99#M>1@-W& J@1^#_@3IOA!M%A'B#7M6TS19))].TS49H&AMI75U,@*0K(Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:\8Z;!-,\D=E:VFBM% I8D1H9-/9RJ@X&]F; &23S57_ (5/XH_Z+/XX_P#
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M%<[S&07NKQ6D<J*54>6!;00IM!!/*ELL>2, ;E% 'FG_  J?Q1_T6?QQ_P"
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MUZWBM#>LR%=TA5X&@W/M(;$6T;SM"\8Y#_A4_BC_ *+/XX_\ ]"_^5E>ET4
M<AX1\$ZSX;U*6ZU'X@>(_%<#PF,66KV^FQQ(Q93Y@-M9PON !'+%<,>"<$9N
MJ?#/Q'?ZE=W4'Q:\8Z;!-,\D=E:VFBM% I8D1H9-/9RJ@X&]F; &23S7H-%
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MY_:?_0R>38?;_P#6;_N?9OL_W?W?^I^[S][YJZ6B@#S3_A4_BC_HL_CC_P
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M[_4KNZ@^+7C'38)IGDCLK6TT5HH%+$B-#)I[.54' WLS8 R2>:J_\*G\4?\
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MNK_HC'@?_P #(O\ Y9T?\+8_;J_Z(QX'_P# R+_Y9T!8^WZ*^(/^%L?MU?\
M1&/ _P#X&1?_ "SH_P"%L?MU?]$8\#_^!D7_ ,LZ L?;]%?$'_"V/VZO^B,>
M!_\ P,B_^6='_"V/VZO^B,>!_P#P,B_^6= 6/M^BOB#_ (6Q^W5_T1CP/_X&
M1?\ RSH_X6Q^W5_T1CP/_P"!D7_RSH"Q]OT5\0?\+8_;J_Z(QX'_ / R+_Y9
MT?\ "V/VZO\ HC'@?_P,B_\ EG0%C[?HKX@_X6Q^W5_T1CP/_P"!D7_RSH_X
M6Q^W5_T1CP/_ .!D7_RSH"Q]OT5\0?\ "V/VZO\ HC'@?_P,B_\ EG1_PMC]
MNK_HC'@?_P #(O\ Y9T!8^WZ*^(/^%L?MU?]$8\#_P#@9%_\LZ/^%L?MU?\
M1&/ _P#X&1?_ "SH"Q]OT5\0?\+8_;J_Z(QX'_\  R+_ .6='_"V/VZO^B,>
M!_\ P,B_^6= 6/M^BOB#_A;'[=7_ $1CP/\ ^!D7_P LZ/\ A;'[=7_1&/ _
M_@9%_P#+.@+'V_17Q!_PMC]NK_HC'@?_ ,#(O_EG1_PMC]NK_HC'@?\ \#(O
M_EG0%C[?HKX@_P"%L?MU?]$8\#_^!D7_ ,LZ/^%L?MU?]$8\#_\ @9%_\LZ
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MKX@_X6Q^W5_T1CP/_P"!D7_RSH_X6Q^W5_T1CP/_ .!D7_RSH"Q]OT5\0?\
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M\95OT8UF?L/Z/::)^RA\-(;.%88Y=*6Z<*/O22LTCL?<LQJ[^V5_R:O\4/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\8_M@?\
MGA?LM_\ 83O/_0K>OLZOC']L#_D\+]EO_L)WG_H5O0-'V=1110(\:_;*_P"3
M5_BA_P!@*X_]!H_8U_Y-7^%__8"M_P#T&C]LK_DU?XH?]@*X_P#0:/V-?^35
M_A?_ -@*W_\ 0:!]#V6BBB@04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7QC^V!_R>%^RW_P!A.\_]"MZ^
MSJ^,?VP/^3POV6_^PG>?^A6] T?9U%%% CQK]LK_ )-7^*'_ & KC_T&C]C7
M_DU?X7_]@*W_ /0:/VRO^35_BA_V KC_ -!H_8U_Y-7^%_\ V K?_P!!H'T/
M9:***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?&/[8'_)X7[+?_ &$[S_T*WK[.KXQ_; _Y/"_9;_["
M=Y_Z%;T#1]G4444"/&OVRO\ DU?XH?\ 8"N/_0:/V-?^35_A?_V K?\ ]!H_
M;*_Y-7^*'_8"N/\ T&C]C7_DU?X7_P#8"M__ $&@?0]EHHHH$%%%% !1110
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M7_)J_P 4/^P%<?\ H-'[&O\ R:O\+_\ L!6__H- ^A[+1110(**** "BBB@
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M7&%)1-X* ' -?<_C#X@>%_A[9P7?BKQ)I'AFTGD\J*?6+^*TCD?!.U6D8 G
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MO_Z#1^V5_P FK_%#_L!7'_H-'[&O_)J_PO\ ^P%;_P#H- ^A[+1110(****
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M^,WQ?T/P?\!?'GB+QC9:U8>-]4L=&U#0(](AA0)<*VRX$RC?YOR[F PF6P%
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M5U7Q0L;?QA^V1\(?#VNVL6H:!:^'=1U2"RNE#P27?RQ[F1AAF5#QZ;LU[/\
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M # XSVQ7+^+OV;M$\1>+[GQ1I7B/Q/X)UR^BB@U&Y\,:@ML-02,8C\Y'1U+
M<!U 8#C=7IFAZ3'H&BV&F13W-U%9P) L]Y,TTT@50 TDC<NQQDL>2>:PC90L
M]]/UO]^GZ)=:=W)/^NGY:EZBBBD,**** "BBB@ HHHH **** "BBB@ HHHH
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M./PGX:L-1LM3AG<.C/=21EX)!@*1(Z!=HVFOL3XI^'[S_AGKQ9H=FEUJU_\
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M^Y4M))=U_7Y_/7;8[JBBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KXQ_; _P"3POV6_P#L)WG_ *%;U]G5\8_M@?\
M)X7[+?\ V$[S_P!"MZ!H^SJ***!'C7[97_)J_P 4/^P%<?\ H-'[&O\ R:O\
M+_\ L!6__H-'[97_ ":O\4/^P%<?^@T?L:_\FK_"_P#[ 5O_ .@T#Z'LM%%%
M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY?U_P_\ P+FW-Y'N-C?VVJ6D5U9W$-W:RC='- X=''J&'!JQ7R;\.]4T+2?
M_P /-*U#Q5=:3X/2&]BUJ\7Q%<0&WU2,PB&TFN1,'MQM,S>5N0%E (YPV[9^
M*I)K7PS'XF\3ZAIWPXEO-52#Q!)J<MD]V(YHQIZRWBNKA&0S[7+CS?+C)9MW
MS'I_7_!?1=4-QM_7K_EKV9[YI?BJTU;Q%K>C0QS+=:3Y/GNZ@(WFH77:0<G
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M9-RJ3)B%>015;P)>:GX^7P)IE[X@UB+3?[:UR)O[-UVZ)N[> G[.C7?[N:9
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M%_P?P:7Z_=YZ$/W4WZ?BF_T_%=-3Z;JO?W]MI=C/>7MQ#9V=NC2S7%PX2.-
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M)M0FTZTN9H Z73QF0.Z^6SF./,3@-*$R0,?>7/65\R>"H[SPC\/?AI%H5YJ
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M3_KS+4'*<H]4[/[^7[OT/;O#_A&S\-ZIXBO[:2>2;7+Y=0N5F92J2""* !,
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M /)FOTZGLE9?AWPSIGA.QEL]*M1:6\MS/>2+O9R\TTC2RN2Q))9W8]>,X&
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M_58=$*0>1(^+]EC!$0DP&7(^?)+')(V@;2BXN2?V;_K^=F5&#E9=7;\7%?\
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MT5(M.:R2WGO%A:YLCMCZ>8%"W;\-LR&&2RM\-OM;>>MOT?RU8]/>OTW^Z_\
M7X7/I&JU]J5II<<<E[=0VD<DJ0(\\@0-([!40$GEF8@ =22 *XOX9S^+FM=;
MA\0QWRI%./[-N=:^Q?:WC,8+"86;&+Y7W8("DJ1D9&3YI#XX\6>'K.'2?$.L
MZB_C!=6T1;N"Z@L9+(V]Q?")Y+-HH5;RW_>*!-^]78IX/S,XKFFH=VOQ=OPZ
M_J*3Y8.?:_X'NVN^(M/\,VUO<:E<?9H;BZALHVV,^Z::18XU^4'&791D\#/)
M K2KYB\4ZQKGB;P_X:\0:CXND6.Y\?6MA_PCAM[86\:PZIY:1HPC\[S5$(=B
MTA!^?Y0,;>E\ ^-O'WB_Q%!JL<&JMI+:Y>6%Y9SC3%TZWMHI98@8RLGVOS@8
MT8[\@Y<; "I!%<T;^;7X1?\ [=Z"D^637E?\9?\ R/J>\5C:EXNTO2O$&FZ)
M<32G5-1622WMX+:68[$*AG<HI$: NHW.5&6 SFN$\2:MK>O?$+Q%HUMXKG\(
M66AZ3;:A&UM;VTAN6E:?=)*9XG_=)Y*KA-AR6RW3'+?#^^U;QK\5O WBF_U&
M]T^;4O _VV?24CA$"L\MON0;HO,"EFW??SD#G&05!<TDOZVDU_Z2.;Y8N7I^
M+BO_ &X]YN)TM8))I6VQQJ79L9P ,DUCKJND^+O!?]I17H_L+4]/\];PYB'V
M>2/=YGS@;?E.?F''<5YMJFE7G_"_/$5T=>U#[*/"<<@T[9;^009;A=N?*\S
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M_OXY%"+NRV%SROS#G.U1M5/>[RO\DW_7D84^7V7N]%%KYM+_ #^9[;7/77Q
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MV\67GCOX=Z=X@U!D>^U#X8:K/,\84*SF:SRP"DJ,GG@D<\'%.$55ER2V=_\
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MED5W,;E4VDQOA5.-O:> ;F?XE?"/4[#Q)>27#23:IHEU?1[8))8X;F>U\T[
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MMP?4ZC4-0\#1ZQ)X6OKGP\NJZI(+M]%N'@$]W)P1*83\SM^Z!W8)_=_[-/\
M%/A+P5)=CQ1XDT;06N=-02#6=4M8"]JJ'<&\YQE IR<Y&.M>0>(&B_X5O\3#
M(8O^$B'BP"+=_K/M7GV_V'WSL^S[?;I79?%2WDMYM$DOM6:_T>;Q5I[7%K<)
M$(K)-N(X\JH)!N!"_P"\+'+X!Q@!QU4&MWR_*_+^5_N72X/1S71<WSM?\[?\
M.=+K4GP_^(7A,:MJ[>&O$OABU9K@7UZ;>[LH2A(9][912N#DYXQ4&G>#_AMX
MZ\.Z2;#1/"OB'0=/1X---O:6US:VRY =(< J@RH!"X^Z,]*\N\5-$/B1K8!B
M_P"$=_X2S0QJ'_//[5Y!^]VSO^P=>^VO1/ ++_PM'XE?9-GV$7%CYGE]/M?V
M8>;G_:\O[/G\*(V:;_K:+O\ ^3?U?1-M-+R_5K]/Q.BU2Q\(W\-OX+U&WT6X
MBFMA+#X>NDA97@B9,,MNW5$;R^0N%.WIQ570=!\"V\>H>%M$T[P[$FGSQ7-[
MHMA! !;3,1+%))"@^1R55U9@"2H8=,U\V>*?'4#>)-4^+*6>L27&B^((8+26
M/1KQK=M#@#V]TWV@1&+83-=3YW8/EQYY%=(NK6'P[^-GC_XCSSQV^BG5;;2=
M9NL@(+9],M)+:9CW"3?*/07+&G'5<S=NOY6_-+U3[&G*[N*Z;??9_P">FZMW
M/;-8\,> ?&WBIX=4TGPWK_B32XHY'CO+:WN;RTC=BT;$,"\:ED)4\ E3CI1X
MZ\,^ 6">(_&6E>&R+!4C75M=MK?_ $9?,&Q1+*/D&\K@9'S$8YKRCX Z;<K\
M7O%.OZG T&L^)O#VFZS=QR##Q"2YO1#"WO'"L4?U0^M=Q^T<TZ?"]FM8XYKD
M:SHYBCFD,:,W]IVV S!6*@GJ0IQZ'I3Y7%QB]'=?)MV?]=024JCC>ZT^::3_
M %.ADL? ?QCTF&XDM_#OCC3+:9A%*R0:A#%*.&"GY@K#H<<UJ?\ "$^'?L,5
ME_8.F?8HK)M-CM_L<?EI:,%#6X7;@1$*N4^Z=HXXKRW6[76O"M[?:A>7M]9>
M*/%VH016VF^#5MII MO Y*B2^18B2BL7D94^5551D G%^'OQ%\4?$J/POHD_
MB&[\/2W$>L--JD$%F][=M97WV9(^4DMPQ3YY-BD$CY-HI)7T2_JS;_"_Y$7L
MN9_UKI_7S/3)-%^''@72=?C72?#ND6-K;1WFJVMK90KMA7<T;RQ(N2,H^W(.
M2IQR*V=-N/#GBG5K35(K>UGUNSMM\37=IY5_9PSYX*2*)85D\H\$+NV=\5XG
M\;KG5[_0_BEX??7KQ+73/#^E3I/'!;":5WDN5D,A\G!W^6A(  !'R[<D'9\8
M>//$/A3Q)XCTB#6,QPP^'[1-4O+:$M:F[NIX9KE]J*K-A5P"-@;'R@$@U9W\
M]$OGI^OD9\RU\M_Z_P"'/2=3\"^!]/UB7Q?J/A_P_;:K;?Z3)KUU90)/%M4C
MS#.R[EPI8;L\ FN9T+5O@K<:Y?ZOHUYX#DUB$3W=Y?6,MD;A!M+3RR2*=PX8
MEV)Z$YZUW?AO1KS0]/-O>Z]J'B*8N7%WJ4=ND@! ^7$$428&,_=SR>>F/(FU
MJ\\.?#?X\:MI\H@O[&_U2YMY&C5PDB6$+*2K J<$#@@@]Q4+=KHHM_C%6_'\
M#:*<I0BOM22_!O\ 3\3NW^#G@T>%-;T70]$T_P ,6FMV3V5S<^'K2"TE:)U*
MY5D3&0&."0<9KI_^$?TS^Q8='>PMYM+BB2%+26)7B")C8-I&.-HQ]!7A/CKQ
MCXVMXO'VJZ7XKDTZ+PW8Z?<6>GBPMI()I)8@T@G+(7*'C 1T(RWS= )/%_Q
M\6_#^3Q5H:ZS?>()X)-$6WU*:WLDN;<7UQ)!+M&V& [?*RGF<!G^8L!BJL[V
M\TOQLOS,5-22?S]+[_D>XW'AG1[O3=0TZ?2K&;3]1,AO;62V1HKDN,/YB$8?
M<.#N!SWJKKG@;PWXHTVUT[6?#^EZMI]J5:WM;ZRBFBA*C"E$92%P.F!Q7/\
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MKXQ_; _Y/"_9;_["=Y_Z%;TAH^SJ***!'C7[97_)J_Q0_P"P%<?^@T?L:_\
M)J_PO_[ 5O\ ^@T?ME?\FK_%#_L!7'_H-'[&O_)J_P +_P#L!6__ *#0/H>R
MT444",2X\$>'+S4KW49] TN?4+V-(;J[DLHVEGC4@HCN5RR@J" 3@$"IM4\)
MZ)K2WZZCHVGWZZA MK>"ZM4D%S"I8K')N!WH"[D*<@;F]37DGBCQ5=^"OB%\
M3M9L8X9;JVT?0MB7"DH=UQ=H<@$'HQ[UJ?$3XM:YX5U3QQ9Z;::?</HFCZ9?
MVBW(<>9-<W-Q$ZR%6^Z!"F,#()).>!0UI8$]WVM^B.ZA^'/A.WT.ZT6+PQHT
M6C70 N-.33XA;S8Z;XPNUOQ%7[[PSH^J:"VB7NDV-WHK1+"=.GMD>W,:XVIY
M9&W:,# Q@8%>2>(OC'XD^'R^+-/UU--UG5--ATJ6SN=+T^XBB8WUR]LBO ))
MI&V21ECL.65@ H(Y[#X6^,-=\2S:Q::U:NZV9A:#5%T2[TF*Z#AMR""Y+.&0
MKR0Q!#KT.13LW?\ K^MP^&W]>9U'_"(Z%]AO++^Q=/\ L=Y MM<V_P!EC\N>
M%4V+&ZXPRA?E"G@#CI576OA[X6\2:I9ZEJ_AK1]5U&SV_9KR]L(IIH-K!EV.
MRDKA@&&#P0#7SSJEG)X-NM#NG\*7W_"QI?&<4=UXB^R']]93WY4YNSQ)$;9@
MHA#$IM'R+LR/J:A:Q4_/\;)_K^8GH^3R_5K]#!\1> O#/B^[L[K7O#FDZW<V
M>?LTVHV,5P\&65CL9U)7E%/'=0>PJU+X5T6;7!K4FCV$FLB#[*-1:V0W'DDD
M^7YF-VS)/RYQR:\CM_".@7'QZTU_!FCV.E3:";FZ\2ZMI\"Q&YDGB(CLY749
ME<EQ.P8DIY<9XWBL#PWI-E9^&OA[XWM[.%/&6K^($34-14 7-RL\DJ3P2/U=
M$7.$)(7R4P!M%):\J[_FW;[GW[=QR=E)]E?Y)7/<O#G@3PUX/6Z70/#VE:(M
MT=UP--LHK<3$=WV*-W4]:KZ+\,_!_AMI&TGPIHFEM),ERYLM.AA+2INV2':H
MRR[FPW4;CCK7FMOX1\/W'Q\TU_!NCV.E2Z";BY\2ZMI\"Q&YDGB(CLY749E<
MEQ.P8DIY<9XWBJ7@GPG%\)_$EFWB#P/H+W6L^(]0^Q^)[!HY;U'N;BXGB$P:
M%&4&,[,H[X. <#D-:\K[_P">G_ _ )+27E^5FV_EU]3V>T\*Z+87AN[71["V
MNO.DN?/AM45_-D $DFX#.Y@ &;J<#-5M2\!>&=:T@Z5J'AW2;[2S.UT;&YL8
MI(#,SEVDV,I7>79F+8R2Q/4UNDA02>!7AVC_ !@US7O&)T2QU73=0L]4L+ZY
MT[4HO#=_:PP-"T>PB:67R[Q"LGWH6097(X;C.4E%/R7Y%13>W?\ ,]AM/#>D
MZ?'IZ6NEV5LFG(8[)8;=$%LA&"L8 ^0$ #"XXK#L?!/@7P;K-O?6>@>'M"U:
M^G>.&Y@LX+>>XF=6=U5@H9G90[$#)(#'UK$^ 5YX@U?X$^#KW5]6AU+6;S1K
M:<7SV\G)>!2#*&E9I&R<LVY=WHM>26=YXTU;P9\*;BYUK3M2UV;QM=I;WEU9
MS>7$BPZDA,BF=FDV@':H=. JY&-U;S@XU'![WM^-B8V::[)O[E<][LOA;X,T
MU]2>T\(Z#:OJ<;17S0Z9"ANT9BS++A?G!8DD-G))-7_$'A#2?%36?]J6<=VM
MJ9-B2#*,LD;1R1NIX=&1B"K @\<9 KR*^^-OB*R:VT&1;,>(?[8O--N-3M-#
MO;ZV\NWCCE,B6<#M+N99HUP9,*=QW' 4][X:DG^*GPQNK3Q1I,ED=1CNM.N[
M>:UEMA-%N>+S5BE&]%D0!PK<J' ).,UD]876JMI\U=#C;FU=M6G\G9_D:.G_
M  R\+:.FGQ:7H5AI%K8W9OXK33;=+:$S["GF,B !F"L<9'!P>H&-C5O#^EZ\
MH74]-L]141R0@7<"2C9(NV1?F!X9>".A'!KPSPGJUY\0%^'?@W4W:XO_  _/
M-=>(&8??DT]_(A+#MYLYCG7U$=7/!'CWQ1K&H> ]#T"V\.Z)IVH:;?ZG?;[&
M:01K!>11^7 BS(%+B5\LQ.#@X/W3;2DU%.][V\TEO^#^XB_+J]&K7\G?;\5]
MYZOX?^'OA7PG)')H?AG1]&DB$@1M/L(H"@DV>8 448W>7'GUV+GH*&^'GA5_
M$$FNMX9T=M;D97?4C81?:69=NUC)MW$C:N#GC:/2O*/ _C7QAHMC*^KZK8:W
M]M\;S:,O^ARQ&&'SY58*6G?@!5VKT4 @[L\;NJ?%B^A_X3:!K_3])GTG7X=(
MTZ1M*N=1><-9V]PRBV@D$DTG[V7 0C"KD@[3F8OF2DNB7_MK_P#;D6XVE*':
M_P"<E_[:SN]1T'PO-IX\-7^G:0]AJ)E8:/<01&*Z)8R2GR2,.=S%VX/)R>M7
M= \-Z1X4TU-.T32[+1]/1F=;33[=((E9B68A$ &222>.2:\7\(^.+WQ_XN^'
ME_J,:)?6U]KFGRO':36BRF$>6)!!,3)%N !V.25)(R>M=#\9/ KZQK6F>(KG
MPQI_C[1M/M9H+KPYJ2QN5#$,;BV64&-I@JE"K[<JQPZ\AE>V^SZ_*Z_KIU$M
M;KJOSV?]=>AV-E\+?!FFOJ3VGA'0;5]3C:*^:'3(4-VC,699<+\X+$DALY))
MK<DT>PENI;I[*W>YF@%M),T2EWB!)$9;&2N68[>G)]:\7L?'E^OQ O==TS5[
M6X^'\'@RWUJUTJ"PD5FA)F*[#YP57(0<^7]W"X&-U2ZQ\8O%'P[T73=?\5QZ
M1JFFZIIEU?16>BVTL,UK)#:O=>69'E<3*41E\P+'A@IVX;"NVEGTO\M9*WSL
MQZ\UNKM\](O\+H],M/#GA+P/:V(M=+T7P_;0C[!:"&WAMD032+^YCP !YDFS
MY!]YL<$XIMCX9\'^"SI]O9Z3H>A&8R65G#!;0V^\R#S)(8P ,[A%O*KU\O)'
MRUY%\;-=\4^%_A7:^(O%$ECK:6^M:+>1Z7X;TR5)U(OHF:,.\[^<<;0"%CY!
M..<+9\>ZKXC\1Z;\)-3M;O03JFH>)UGM)K=9+FRAA?3[PKE@ZF<JA)RIC#GI
MM'-6HMIM[\W+]]O\WY"5F]-N5R^Y/_)>>IZKHOPU\(^&[74+;2/"NBZ7;Z@G
MEWD-EIT,*7*X(VR!5 <89N&S]X^M,T/PIX-^'UU#!HVCZ%X:N=0_T>*.QM8;
M1[G8'D\M0H!?:/,; S@;CZUP5O\ %+Q/=FT\.Q_V0OBB;Q!<Z&^IM:2_8E6&
MW-R9A;^=O)*;5\OS?O$G=@8.#JGCK4+[QYX6M=<2VFU3PQXEO+6YN-.B:.&Z
M']B37"ND;.[(=LP!4LV"#R014WT<KZ6O\M/\U_5Q:RNEKK;YWM^:_K0]?U+P
MWX1&L2SW^EZ*-5UR,V$DES;P^?J$:H6,))&Z50JD[#D *3C J]X;\)Z)X.L#
M8Z!HVGZ'9,YD-MIMJEO&6/5MJ #)]:\'N/%/BS5/$7P<\3>()=%DTK4)+K5(
MK/3+:6.>USI=S(L9=Y7$_P C8+!8_F7[N&XTO"'QQ\5:YHXUB735GL+S0[C5
MHMOA_4+*/3Y%B$L44EQ/\ER&!(W1B/E,@$-\I/\ =*7-]E:_CI^#\@B_:-*.
MM]O/;_-'ML.AZ;;ZO<ZK%I]K%JEU$D$]\D*B>6-"Q1'?&YE4LV 3@;CCK5#0
M_ ?AGPOJ%W?Z-X=TG2+Z\S]IN;&QBAEGRQ8[V506^8D\]R36'X-U#Q%K/PM3
M4_$\VF2:G?V'VORM*MI(88%>$,(\O(Y<@D_/\H/'RCOX/\'/$M_\.?@#IW@>
MPF<:U=:?IH\-M(3(VS4(QAN>H@E%RQ&>(XU]:;C)2E'JK+U;OI^'I^J4E)1E
MT=WZ)6U_'U/HJ3X7^#9M$;1I/"6A/I#7'VLZ>VFPFW,YY,OE[=N__:QFM-/"
M^C1^'1H"Z18KH0@^RC2UMD%KY.,>7Y6-NS'&W&,5\W_#/Q=<_"WX=^#/ WA[
M="\MSKNR^N-'O-9\NWM=0>/!AMB)&=C*GS,P PQ.20#TD_QX\5WUU;:9;:0^
MC:O;Z4NHWD-UX:U*_P#M#-//%&B)#M:W5_L[/NER0)%&TD-A225[;?G:_P#E
MZ]BX\SM+^M[?FSUZS^'/A/3]'O-(M?"^BVVE7L?DW5C#I\*03IR=KH%VL/F;
M@C'S'UJ_-X9T>X\/G09=)L9=#,'V4Z8]LAMC#C'E^41MVXXVXQBO&;WQ1XLO
M?&FN7EW-:V^B?\(1'J<GAG4+&5FCD<3[HY&\\+OW+ACLY4;< C=3;KXG^,X;
M/6?[!B\.V&F>'?"FGZZUO=64\C7#21SLUNA691$H6W 5R'QNY5L4NDG+IO\
M?)?^VON)?%&,>NWS47_[<OZV]DM_".A6=K-;0:+IT%M/:I8RPQVD:I);H&"0
ML ,&-0[@*> &.!R:J:Y\.?"?B>>RFUCPQHVK36*A+62^T^*9K=000(RRG: 5
M4\8Y ]*\[\3?$KQEJ,/BV]\*-H-A:>'-+BO&AUJTFG>\F>W^T; \<T8B0)M7
M=M<DD\#;@]K?>,WM?A;!XCN;VSTFZGL(9Q<7%M)/"DTJKM A1@\F78 1JVYB
M0 <FAMW;>ZM^MOR8E9\J6TMOPO\ FCIY]+L[J^M;V:T@EO+4.+>XDB5I(0X
M<(Q&5R ,XZX%5M3\,:/K5PMQJ&DV-_.L1@$MU;)(PC+*Y3+ G:61&QTRBGL*
M^??$/Q2\9>)O!^HPV.K6^EZEI7BS1;!K]M!O=/-S!<7%JP4VTTRRQ_ZTJX+,
M'4$#;N^7V/XB^+-3\"^&+#5U2VNXH+ZTBU1C&RA;:218Y98QO^79O#\EL*K#
MGK5<NBEYV^]+_P"2U&]OZZ?\,=!>>&](U":ZENM*LKF6ZCCAN'FMT=IDC9FC
M1R1\RJS,0#P"Q(ZT7WAO2-2:_:\TJRNFO[=;2[,]NCFYA7=MBDR/G0;WPIR!
MO;U->+6/Q_U^_P!4U_3DTZP6YNM0M8O"S;'*W=K)<O;22R_/\Y0P2S'9M_=M
M'WR:CO/VA/$%A+H-O+IM@;BSU6>T\5;4?%I;+=K:QRQ#?\N\S13?-N'EK)WP
M1*]ZR77_ (%_NOKV&WRW;Z?TOOMIWZ'K-O\ ##P;9Z-=Z1!X2T.'2;M56YL(
M]-A6"8*Q90\87:P#,Q&1U)/>K>F^!_#FBVL5KI_A_2[&VBG6YCAMK*.-$F50
MJR!54 ,%  ;J  *\FD^/FLZ7YVJ:AI]F= U"TU2;0S"C"::6VF"01NQ<AC.A
M+KM X%:WPP^+/B#QGJ.A:+J-E86^MVT%]_PDJVZ.([>:"80(L(+DJLK;I%W;
MOD0]SFFKRL^KU\]+_E;\NY+]V_;;R_IW^>IZI)IEG)J$=^]I ]]'$T"731J9
M5C8J60-C(4E5)'0E1Z54L?"FB:7;:;;V>CZ?:6^FLSV,4%JB):LRLK&( 80D
M.X.W&0Q'<UYSK7Q:UG2_&&H^$TM[!M>DUFP@TM&1]LFGSH9))G&[)9%M[[H0
M,QIQSSS_ (5^('B?4=2\(:%X<M?#NBV^J77B">]>6QFD5$M-16/,<:S)\\GF
M,6);&YMV.-A<4VE;^M+_ *_?<;WMU_K_ "/6]/\ A]X6TGQ!<Z[9>&M'L]<N
M0XGU.WL(DN9=^-^Z4+N;.U<Y/.T>E)H/P[\*>%9+Z31?#&C:1)?+LNVL-/B@
M-PN6.)"JC<,LQYS]X^M>2Z#XX\8^&QXKNM1U73]9C/CBTT:&)K*:/R(9I+6-
M]I,[8 64E5  #9)SG ZG7OBC>:?<>.;8WMAI3:/>V=G83R:=<7[2--!'*5-O
M"XDF<EV"I'@].N#4_8C+HTOQ47;_ ,F0)WE*/:_X-J_X,ZB/P;X)T"UM=%30
M] TZVO(GT^WT];2"))XSNE>!(\ ,O#N4 QPQ(ZFKGB6TTZWM;JY=]+T[4+R%
M=-COM0@1U8NQ$4+ LID4N^!'N&2Q P37B=O\0-5\;ZUX%N)[>.XU?2O%&IV
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M!7NH]=/QL_U3_P"&/0M8^'/A/Q!#I\.J^%]&U.+3E"64=YI\,JVJC&!&&4[
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MLK>YLXVC9+>:)716C8-&0I&,JRJP/8J".E>)Z+\=M7GUS4;,W5CK=K)X?O\
M6]/O(/#]]IL(-N\8"AYY&6Z1A,A$D14?*3T=<6+?XE_$.&WMK>6'P_J.LZQX
M5N?$&EV]I9SQ)!/#Y'^CRLTS&4-]I0!U$9!4G;R *\_G_P"E?_(R^[S06=TE
MO_\ L_YK^D>N>(_">B>,;%;'7]&T_7+)9!*MOJ5JEQ&''1@K@C(R>?>J6H?#
MGPGJVAQ:+>^%]&O-'BE,\>GW&GPO;I(227$97:&)9CG&<D^M<]\,_BB?BAK&
MIW&EK _AFVLK%HK@*WFO=3Q>>Z$YQM6*2WXQG+MSQBN<U+XS7^G_ !,T[3+>
M^L]7T.\U5]*DAMM O4-LXAD8_P#$P+FWE=7B96C501NQG*G*DN5\LM/Z_P"&
M!/F7,ME_E?\ S/1+GP_X4TR&*PN--T:TBU%(M,CM9((D6Y2)7:.W"D?.$42%
M4YP Q  S6E<^'M*O6OGN-,LYVOX5MKMI($8W$2[ML<F1\ZC>^%.0-S>IKP"7
MQ3XL\::E\$O$NI2Z*NAZYKGVVUL+6VECNK17TV\>)7E:5EF.T_-A(\'ID5O^
M!?''B+Q-8Z#H?AB+0/#DQTV;4[F6XT^6XMU7[3)%''%"D\9R2K,S%SC@8.[*
MN2=^66[O^"N_U"453:MV3_\ )FE^AZUX9\(Z%X+T]K'P]HNGZ%9-(96MM,M8
M[>,N0 6*H ,X &?85-)X=TJ6SU&T?3+-[34BYO8&MT*71=0KF5<8?<H"G=G(
M&*\[\!_%S4?&'B'P[8S65K:QWNDZC<W83<Q6ZM+R*V81MG!C):0C(R1MY'.<
M;PM\4_&?C;5OAY:V']A6,&M:+<:SJ<T]I-,0(I[=/+@43+MW+,WS,6VD X;&
MTM)R:7>_W*]__27]Q":2;72WWNUOS/6I_#.CW45[%-I-C+'>JJ7226R,)U48
M4."/F ' !SBEO/#>DZA]O-UI=E<G4(5MKSSK='^TQ+NVQR9'SJ-[X4Y W-ZF
MO)?"WQ3\97UQX?U/4QH9T/5_$5]H*V-K:S+<Q+%)<I%/YS3%6)^S#<GEC[^0
MW&#FV'Q5^(NJR>'986\,06_B#Q!J.@VT<EC<.]H+9KHK<.PG EREHP,0"<N#
MOP,%<KDOZ_KJBOA?X_)7_P G]WFK^S^&O".A>"[&2R\/Z+IVA6<DAE>WTVTC
MMXV<@ L50 $X &>O J'3_ ?AG2=>N=<L?#NDV6MW6[S]2M[&*.YESC.Z0+N;
M.!G)["O(&^/&OS0Z'I"QVMMK]S=:O;W6H6^A7NIV^VPNA;LR6MN_F#S&=&&Z
M3"#(+,<9T-/^)'Q \5:EI^G6%II/ANZ;1)=3NCK6FW,C^8EPT*A8?-B9$D"B
M0;SN4$ @D\)NWO/S^Y)M_@F-Q<;Q?].]OS9ZU#X;TBWCL(XM+LHX]/D::S5+
M= +:1E96>,8^1BKN"1@X=AW-:5>%^'?''B?QQ\2/A=JMIJ5MIF@Z[X1N=6N-
M'>VDD^8O8DC>)E4L/-(5BAV@OPV[CW2KE!P^+S_!M?H(*^,?VP/^3POV6_\
ML)WG_H5O7V=7QC^V!_R>%^RW_P!A.\_]"MZ@:/LZBBB@1XU^V5_R:O\ %#_L
M!7'_ *#1^QK_ ,FK_"__ + 5O_Z#1^V5_P FK_%#_L!7'_H-'[&O_)J_PO\
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M#([XDAB:1XEQG"E6E<AEPV2.>!BQX7\(V'@^UFM[";4ITE<.S:GJMU?OD*%
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MHIR<D8P"!D5YYI_Q.\9ZSXAT" Z?I^@V7]@?VWK%O?V4\EV&678T$*F2/9N
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MKJ'A2^CT>/[9X6M6LM'F:21FM(6C6,J,M\WR*!ELD<\\G/6T4[N]^O\ P_\
MF_O9-DE;^OZT1Q]U\)?"]UIEG8_8;BUBL[J>\MYK'4+BVN(99I&DF*SQR+(
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M@K*V,AQ!*@?H,;LXYQC)J;1/ ^A>&]0%YI>FQ6,ZV$&EJ(2RHMM"7:*-4SM
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MG!8<X(W'.U13N_Z^?^;^]BLM_P"NG^2^Y!1112&%%%% !1110 4444 %%%%
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M""A,SJ3G!V#'\6>*[7XA_M[>$? /C;6-&DM[.:RT1[>/49KC5HK:\9I55O\
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M%MM]*N)HMT :82+('PP;,:L%'+%:ARY(\Z[7_"Z_/1^=NI:CSRY7UT^_1_\
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MZ$GS1U[?\'_V[\>S)KK]EOPI>:Q/J3ZAK GF\7P^-&59HMHO8XQ&L8_=9\G
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MNP'8"O3***.EA>85\8_M@?\ )X7[+?\ V$[S_P!"MZ^SJ^,?VP/^3POV6_\
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M=^( \1+X5TBXT6TL5T9;4/#($579Q*W[P!!N.,-@8"<Y]YHJ^9WYNO\ P_\
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M42Q[[:64@P;@JDJPD7(R "37TA127NM-=+?@4VY:/^MO\CP/Q-^RLGB#P_\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^,?VP/\
MD\+]EO\ ["=Y_P"A6]?9U?&/[8'_ ">%^RW_ -A.\_\ 0K>@:/LZBBB@1XU^
MV5_R:O\ %#_L!7'_ *#1^QK_ ,FK_"__ + 5O_Z#1^V5_P FK_%#_L!7'_H-
M'[&O_)J_PO\ ^P%;_P#H- ^A[+1110(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OC']L#_ )/"_9;_ .PG>?\ H5O7
MV=7QC^V!_P GA?LM_P#83O/_ $*WH&C[.HHHH$>-?ME?\FK_ !0_[ 5Q_P"@
MT?L:_P#)J_PO_P"P%;_^@T?ME?\ )J_Q0_[ 5Q_Z#1^QK_R:O\+_ /L!6_\
MZ#0/H>RT444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KXQ_; _P"3POV6_P#L)WG_ *%;U]G5\8_M@?\ )X7[+?\
MV$[S_P!"MZ!H^SJ***!'C7[97_)J_P 4/^P%<?\ H-'[&O\ R:O\+_\ L!6_
M_H-'[97_ ":O\4/^P%<?^@T?L:_\FK_"_P#[ 5O_ .@T#Z'LM%%% @HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OC']L#_ )/"_9;_ .PG>?\ H5O7V=7QC^V!_P GA?LM_P#83O/_ $*W
MH&C[.HHHH$>-?ME?\FK_ !0_[ 5Q_P"@T?L:_P#)J_PO_P"P%;_^@T?ME?\
M)J_Q0_[ 5Q_Z#1^QK_R:O\+_ /L!6_\ Z#0/H>RT444""BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OC']L#_ )/"_9;_ .PG>?\
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M"/&OVRO^35_BA_V KC_T&C]C7_DU?X7_ /8"M_\ T&C]LK_DU?XH?]@*X_\
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M?%/2I-7@\77.D^'-.UNPO+G3XX?L3W-R8)<I$!OBC ,@W988PS'K7T_'\(?
MD>GW%BG@KPZEE<0Q6TULNE0".2*)B\4;+LP51B653PI.1@UKR>$]#FU.[U*3
M1M/?4;RV%E<W;6L9EFMP21"[XRR L3M)QR>.:>FG]75K+TUUNM1W_3\U?\G]
MY\L_":2]_P"&WKJ&_P#&L7CJ>/X>Q'^T%@@B=-UXK;&$ "=]PP =K#.>IO\
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M;[2+W[>FEP"?[0 5$WF;=V_!(W9S@GFK7_"O?"W_  E!\2_\(UH__"1[=O\
M;'V"+[7CT\[;OQ^-7&2B[VTNW;_P'3SVM??44DVGWLE?_P "^[XD^VAT%%%%
M0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KXQ_; _Y/"_9;_["=Y_Z%;U]G5\8_M@?\GA?LM_]A.\
M_P#0K>@:/LZBBB@1YW^T5X-OOB%\!_'WAO3(O/U+4M%NH+2+./,F,;&-<^[
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M\=H_X=I_L^?]";<_^#F\_P#CM :'NG_"W/ O_0Z>'O\ P:P?_%T?\+<\"_\
M0Z>'O_!K!_\ %UX7_P .T_V?/^A-N?\ P<WG_P =H_X=I_L^?]";<_\ @YO/
M_CM :'NG_"W/ O\ T.GA[_P:P?\ Q='_  MSP+_T.GA[_P &L'_Q=>%_\.T_
MV?/^A-N?_!S>?_':/^':?[/G_0FW/_@YO/\ X[0&A[I_PMSP+_T.GA[_ ,&L
M'_Q='_"W/ O_ $.GA[_P:P?_ !=>%_\ #M/]GS_H3;G_ ,'-Y_\ ':/^':?[
M/G_0FW/_ (.;S_X[0&A[I_PMSP+_ -#IX>_\&L'_ ,71_P +<\"_]#IX>_\
M!K!_\77A?_#M/]GS_H3;G_P<WG_QVC_AVG^SY_T)MS_X.;S_ ..T!H>Z?\+<
M\"_]#IX>_P#!K!_\71_PMSP+_P!#IX>_\&L'_P 77A?_  [3_9\_Z$VY_P#!
MS>?_ !VC_AVG^SY_T)MS_P"#F\_^.T!H>Z?\+<\"_P#0Z>'O_!K!_P#%T?\
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M\=H_X=I_L^?]";<_^#F\_P#CM :'NG_"W/ O_0Z>'O\ P:P?_%T?\+<\"_\
M0Z>'O_!K!_\ %UX7_P .T_V?/^A-N?\ P<WG_P =H_X=I_L^?]";<_\ @YO/
M_CM :'NG_"W/ O\ T.GA[_P:P?\ Q='_  MSP+_T.GA[_P &L'_Q=>%_\.T_
MV?/^A-N?_!S>?_':/^':?[/G_0FW/_@YO/\ X[0&A[I_PMSP+_T.GA[_ ,&L
M'_Q='_"W/ O_ $.GA[_P:P?_ !=>%_\ #M/]GS_H3;G_ ,'-Y_\ ':/^':?[
M/G_0FW/_ (.;S_X[0&A[I_PMSP+_ -#IX>_\&L'_ ,71_P +<\"_]#IX>_\
M!K!_\77A?_#M/]GS_H3;G_P<WG_QVC_AVG^SY_T)MS_X.;S_ ..T!H>Z?\+<
M\"_]#IX>_P#!K!_\71_PMSP+_P!#IX>_\&L'_P 77A?_  [3_9\_Z$VY_P#!
MS>?_ !VC_AVG^SY_T)MS_P"#F\_^.T!H>Z?\+<\"_P#0Z>'O_!K!_P#%T?\
M"W/ O_0Z>'O_  :P?_%UX7_P[3_9\_Z$VY_\'-Y_\=H_X=I_L^?]";<_^#F\
M_P#CM :'NG_"W/ O_0Z>'O\ P:P?_%T?\+<\"_\ 0Z>'O_!K!_\ %UX7_P .
MT_V?/^A-N?\ P<WG_P =H_X=I_L^?]";<_\ @YO/_CM :'NG_"W/ O\ T.GA
M[_P:P?\ Q='_  MSP+_T.GA[_P &L'_Q=>%_\.T_V?/^A-N?_!S>?_':/^':
M?[/G_0FW/_@YO/\ X[0&A[I_PMSP+_T.GA[_ ,&L'_Q='_"W/ O_ $.GA[_P
M:P?_ !=>%_\ #M/]GS_H3;G_ ,'-Y_\ ':/^':?[/G_0FW/_ (.;S_X[0&A[
MI_PMSP+_ -#IX>_\&L'_ ,71_P +<\"_]#IX>_\ !K!_\77A?_#M/]GS_H3;
MG_P<WG_QVC_AVG^SY_T)MS_X.;S_ ..T!H>Z?\+<\"_]#IX>_P#!K!_\71_P
MMSP+_P!#IX>_\&L'_P 77A?_  [3_9\_Z$VY_P#!S>?_ !VC_AVG^SY_T)MS
M_P"#F\_^.T!H>Z?\+<\"_P#0Z>'O_!K!_P#%T?\ "W/ O_0Z>'O_  :P?_%U
MX7_P[3_9\_Z$VY_\'-Y_\=H_X=I_L^?]";<_^#F\_P#CM :'NG_"W/ O_0Z>
M'O\ P:P?_%T?\+<\"_\ 0Z>'O_!K!_\ %UX7_P .T_V?/^A-N?\ P<WG_P =
MH_X=I_L^?]";<_\ @YO/_CM :'NG_"W/ O\ T.GA[_P:P?\ Q='_  MSP+_T
M.GA[_P &L'_Q=>%_\.T_V?/^A-N?_!S>?_':/^':?[/G_0FW/_@YO/\ X[0&
MA[I_PMSP+_T.GA[_ ,&L'_Q='_"W/ O_ $.GA[_P:P?_ !=>%_\ #M/]GS_H
M3;G_ ,'-Y_\ ':/^':?[/G_0FW/_ (.;S_X[0&A[I_PMSP+_ -#IX>_\&L'_
M ,71_P +<\"_]#IX>_\ !K!_\77A?_#M/]GS_H3;G_P<WG_QVC_AVG^SY_T)
MMS_X.;S_ ..T!H>Z?\+<\"_]#IX>_P#!K!_\71_PMSP+_P!#IX>_\&L'_P 7
M7A?_  [3_9\_Z$VY_P#!S>?_ !VC_AVG^SY_T)MS_P"#F\_^.T!H>Z?\+<\"
M_P#0Z>'O_!K!_P#%T?\ "W/ O_0Z>'O_  :P?_%UX7_P[3_9\_Z$VY_\'-Y_
M\=H_X=I_L^?]";<_^#F\_P#CM :'NG_"W/ O_0Z>'O\ P:P?_%U\=?%;XA:+
M^T)^WA\%M#\!7<?B-/!;7.HZOJ5BXEM(4)0LHD7@E?+521QNE1<YR!ZC_P .
MT_V?/^A-N?\ P<WG_P =KV'X0_ 7P%\!](FT[P/X<MM$BG.9YE9I9YR"2-\K
MEG8#)P"<#/ % 'H%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
